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AIMS 
 
1) to develop a tandem mass spectrometric method for the simultaneous 
 measurement  of homocysteine, cysteine and methionine in human plasma 
 and urine, suitable both for research into their interrelationships and also for 
 application in the routine clinical laboratory 
 
2) to develop a tandem mass spectrometric method for the simultaneous 
 measurement  of ADMA, SDMA, MMA and arginine in human plasma and 
 urine, suitable both for research into their interrelationships and also for 
 application in the routine clinical laboratory 
 
3) to examine pre-analytical variables (eg sample type, patient demographics) 
 which  may determine the reliability of the above analyses and/or the 
 interpretation of the results obtained 
 
4) to test the hypothesis that an increase in plasma homocysteine leads to an  increase 
 in plasma ADMA 
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ABSTRACT 
Homocysteine is an amino acid formed by the metabolism of methionine. Increased plasma 
homocysteine concentrations are associated with cardiovascular disease, and it has been 
suggested that homocysteine lowering therapy may reduce cardiovascular risk. Plasma 
homocysteine measurements are frequently requested by clinicians investigating patients 
with vascular disease. A mechanism for homocysteine causing vascular disease has not yet 
been proven, but one possibility is that an elevated plasma homocysteine concentration may 
lead to the accumulation of asymmetric dimethylarginine (ADMA), a naturally occurring 
amino acid that inhibits nitric oxide synthase, resulting in impaired nitric oxide production, 
and therefore vascular dysfuntion. 
 
The aim of this project was to develop analytical methods suitable for the measurement of 
homocysteine and related metabolites in a routine clinical laboratory, and two methods 
have been established; i) for homocysteine, cysteine and methionine and ii) for asymmetric 
dimethylarginine, symmetric dimethylarginine (SDMA, a sterioisomer of ADMA), 
monomethylarginine (MMA) and arginine. A novel feature of the method for ADMA is 
that the use of unique daughter ions allows the determination of both ADMA and SDMA 
without the need to separate the isomers chromatographically. In addition, the synthesis and 
application of isotopically labelled SDMA, for use as an internal standard, is described for 
the first time. 
 
When the methods were applied to the analysis of routine clinical samples no association 
was detected between plasma total homocysteine and plasma ADMA concentrations. 
Measurements were also performed on samples from patients enrolled in a clinical trial 
investigating the progression of vascular dysfuntion, as measured by carotid-femoral pulse 
wave velocity (CF-PWV), in chronic kidney disease. Again no association could be found 
between plasma total homocysteine and plasma ADMA concentrations. In addition plasma 
total homocysteine was not a determinant of CF-PWV. 
 
These findings do not support the hypothesis that hyperhomocysteinaemia causes vascular 
disease by increasing ADMA concentrations.
 1 
1. Introduction 
 
1.1. Cardiovascular disease 
 
1.1.1. Cardiovascular disease and mortality 
 
Diseases of the heart and circulatory system (cardiovascular disease, CVD) are a major 
health care issue, accounting for approximately 35% of deaths in the United Kingdom in 
20061 (figure1.1). CVD is one of the major forms of premature death (death before age 75); 
in 2006 22% of premature deaths in women and 30% in men were due to CVD. The cost to 
the United Kingdom health care system in 2006, due to CVD, was  approximately £14.4 
billion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory disease: 13.5%
Injuries and poisonings: 4%
All other causes: 20.5%
Coronary heart disease: 16.5%Stroke: 9.5%
Other CVD: 8.5%
Lung cancer: 6%
Colo-rectal cancer: 3%
Other cancer: 18.5%
Figure 1.1. Causes of mortality in the United Kingdom, 2006. 
The figures are for men and women combined, using data taken 
from CHD UK Mortality. British Heart Foundation Statistics 
Database1. 
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1.1.2. The Pathogenesis of Atherosclerosis 
 
Atherosclerosis is now regarded as an inflammatory disease, the mechanisms of which have 
been reviewed2. In the response-to-injury hypothesis of atherosclerosis endothelial 
dysfunction is caused by damage to the vasculature, causes of which may include 
hypertension, damage by free radicals or oxidised LDL, diabetes mellitus, or infections (eg 
herpes virus). The resulting endothelial dysfunction leads to compensatory responses that 
alter the normal haemostatic properties of the endothelium, with changes in its permeability 
and increased adhesiveness for leukocytes and platelets2. The endothelium also develops 
procoagulant instead of anticoagulant properties with the formation and release of 
cytokines and growth factors2. If the initial injury is not repaired the inflammatory response 
can continue with a subsequent migration of smooth-muscle cells into the site of 
inflammation and an intermediate lesion forms, macrophages and lymphocytes then begin 
to emigrate from the blood into the lesion with further release of cytokines and growth 
factors2. As the lesion grows restructuring occurs so that it becomes covered by a fibrous 
cap covering a core of lipid and necrotic tissue, intruding into the vessel lumen and altering 
the flow of blood; thinning of the fibrous cap can lead to rupture of the lesion and 
thrombosis2. 
 
Traditional risk factors for the development of atherosclerosis include age, gender, 
hypertension, dyslipidaemia, hyperglycaemia and smoking, however there is a large 
proportion of CVD that can not be explained by these risk factors alone3, in particular they 
do not adequately account for  the substantial increase in cardiovascular events and 
mortality associated with chronic kidney disease4. Considerable research has therefore 
focused on identifying and evaluating novel cardiovascular risk factors5 (table 1.1). 
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Emerging risk factors for cardiovascular disease. 
C-reactive protein Interleukins 
Serum amyloid A Vascular and cellular adhesion molecules 
Soluble CD40 ligand Leukocyte count 
Fibrinogen Plasminogen activator inhibitor 1 
D-Dimer Tissue plasminogen activator 
Factors V, VII, VIII Small dense LDL 
LDL and HDL subtypes Apolipoproteins A1 and B 
Homocysteine Lipoprotein associated phospholipase A2 
Microalbuminuria Creatinine (glomerular filtration rate) 
Cystatin C Infectious agents 
ApoE genotype Fibrinopeptide A 
Remnant lipoproteins von Willebrand factor antigen 
Table 1.1. Emerging risk factors for cardiovascular disease. 
Adapted from Myers et al5. 
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1.2. Homocysteine 
 
1.2.1. The Biochemistry of Homocysteine 
 
Homocysteine is a thiol containing amino acid which exists as two enantiomers (D- & L-). 
Amino acid metabolism in humans is restricted to L- isomers and D- isomers are not 
metabolised: throughout this thesis the L-isomer is implied for all amino acids. 
Homocysteine is not obtained from the diet but is derived from the metabolism of 
methionine. Homocysteine lies at a metabolic branch-point: it may be further metabolised 
to cystathionine and then cysteine (transsulphuration) which requires vitamin B6 as a 
cofactor, or be remethylated to methionine, either by the vitamin B12 dependent enzyme 
methionine synthase, or by betaine-homocysteine methyltransferase. The structures of 
homocysteine, cysteine and methionine are shown in figure 1.2. and the formation and 
metabolism of homocysteine in figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.2. Structures of homocysteine, cysteine and methionine. 
homocysteine H CH2 CH2 SHC
COOH
NH2
cysteine H CH2 SHC
COOH
NH2
methionine H CH2 CH2 SC
COOH
NH2
CH3
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In plasma cysteine and homocysteine exist in a variety of forms, as reduced thiols, as 
disulphides, and as mixed disulphides. They are also found bound to protein. 
Approximately 4% of cysteine is in the reduced form, while 32% exists as a variety of 
disulphides and the remaining 64% is protein bound. In the case of homocysteine 
approximately 2% is reduced, 16% is in the form of disulphides and 82% is protein bound6. 
The predominant disulphides are cystine (formed from two cysteines), homocystine 
(formed from two homocysteines) and cysteine-homocysteine mixed disulphide. 
 
1.2.2. Classic Homocystinuria 
 
Homocystinuria was first described in 1963 in two sisters, aged 4 and 6, who presented 
with severe mental retardation and a history of seizures7. Both children had fine, sparse 
blonde hair and blue eyes, did not resemble other members of their family, and examination 
METHIONINE
S-adenosylmethionine
S-adenosylhomocysteine
HOMOCYSTEINE
protein glutathione taurine SO42-
cystathionine
CYSTEINE
B6
B6
cystathionine-b-synthase
5-methyltetra-
hydrofolate
tetrahydrofolate
5,10 methylene-
tetrahydrofolate
B12
methionine
synthase
5,10-methylenetetra-
hydrofolate reductase
transfer of 
methyl group
betaine
dimethylglycine
betaine:homocysteine
methyltransferase
urinary excretion
Figure 1.3. The metabolism of homocysteine. Homocysteine is formed by the transfer of a methyl group 
from methionine. It may further metabolised to cysteine in vitamin B6 dependent reactions 
(transsulphuration) or reconverted to methionine (remethylation) by a) betaine:homocysteine methyl 
transferase or b) the vitamin B12 dependant enzyme methionine synthase. 
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of both children's eyes showed that the lenses were “dislocated backwards and slightly 
upwards”7 Homocystine and methionine were shown to be increased in plasma, with a low-
normal cystine concentration, and these finding, together with the appearance of the 
children, led the authors to initially propose that "the pathogenesis of the disease was due to 
a cystine deficiency resulting from a metabolic block in the breakdown of methionine and 
cystine"7. At presentation the younger sibling was on the 3rd percentile for height and 25th 
percentile for weight, and treatment with oral cystine supplementation was initiated to see if 
it would induce a growth spurt and encourage improvement in hair growth, but with no 
effect. The lack of response following cystine treatment combined with further studies 
involving the measurement of urine homocystine and methionine following a methionine 
load led to the supposition that the disease was most likely be a result of defective cellular 
transport of methionine. 
 
In 1964 Mudd et al demonstrated reduced activity of cystathionine synthase activity in liver 
tissue obtained at biopsy of an 8 year old homocystinuric female8 and suggested this 
enzymic block could explain increased plasma concentrations of both homocystine and 
methionine. 
 
Post-mortem examinations of a male child who died at 7½ weeks revealed increased 
plasma and urine homocystine with low concentrations of methionine and normal tissue 
activity of cystathionine synthase and betaine-homocysteine methyltransferase, but reduced 
activity of methionine synthase9. At autopsy extensive microscopic lesions were observed 
throughout the arterial tree10, bearing a close similarity to those that had been noted in 
homocystinuria due to cystathionine synthase deficiency. This similarity, together with the 
only common biochemical finding of increased homocystine concentrations, led McCully 
to propose that increased plasma homocystine is directly responsible for the development of 
vascular disease10. 
 
In 1985 a questionnaire-based survey of physicians involved in the identification and care 
of 629 patients with homocystinuria, 472 of whom were identified on the basis of clinical 
features, the remaining being identified through screening programmes or investigated due 
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to having an affected sibling, showed that the age of onset of disease and the severity of 
clinical manifestations varied widely amongst affected individuals11. Of the individuals 
who had been identified clinically, common features were ectopia lentis (86%), mental 
retardation (56%) Marfanoid characteristics (37%) and early thromboembolic disorders 
(16%). The age at which therapy commenced varied (with age at presentation) and in those 
individuals where treatment was not initiated early the chance of a thromboembolic event 
was 25% by age 16 and 50% by age 29. Patients were classified as to their response to 
vitamin B6 therapy (ie by a lowering of plasma homocysteine): 36.7% being responsive, 
36.7% being non-responsive, 10.7% showing an intermediate response and the remaining 
15.9% not being classified due to insufficient information. Treatment by vitamin B6, in 
responsive individuals, resulted in a statistically significant reduction in the number of 
thromboembolic events but the authors stated that given the relatively small number of 
events that had been observed this finding should be considered suggestive rather than 
definitive11. 
 
A similar multicentre study carried out in 2001 examined data concerning 158 
homocystinuric patients who had been treated and followed for a mean of 17.9 years 
(resulting in 2822 patient years)12. Where patients had shown a lack of response to vitamin 
B6 therapy (a positive response being defined as lowering plasma homocysteine to less 
than 20 µmol/L) dietary restriction of methionine and/or the use of betaine had been 
employed. Based on the findings of the 1985 survey 112 vascular events were expected had 
the patients not been treated; a total of 17 occurred in 12 patients. The difference between 
predicted and observed events was statistically highly significant (p<0.001) and the study 
concluded that "long-term treatment to lower the markedly elevated plasma levels of 
homocysteine seen in homocystinuria due to cystathionine-β-synthase deficiency is 
effective in reducing the potentially life-threatening vascular risk".  
The frequent occurrence of severe thromboembolic disease at an early age in 
homocystinuria, and the findings that this seems to be lessened by the reduction of plasma 
homocysteine by vitamin treatment has led to the 'homocysteine theory of atherogenesis': 
homocysteine is in itself atherogenic and increased plasma concentrations may represent a 
risk factor for vascular disease in the general population. 
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1.2.3. Hyperhomocysteinaemia in the General Population 
 
Homocystinuria has an estimated worldwide incidence of 1 in 335,00013. The incidence 
varies with the population studied, ranging from 1 in 65,000 in Ireland, where a national 
screening programme has been in place since the late 1960s, to 1 in 900,000 in Japan13. 
Although homocystinuria is a rare disorder there is a large number of other causes of mild 
to severe hyperhomocysteinaemia, including polymorphisms in genes encoding for 
methylenetetrahydrofolate reductase (MTHFR)14, which forms part of the homocysteine 
remethylation cycle, various diseases and lifestyle factors15,16 and also a number of 
common therapeutic drugs17 (table 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determinant Effect 
Inherited  
homozygosity for CBS defects ++++ 
heterozygosity for CBS defects ++ 
homozygosity for MTHFR defects ++++ 
heterozygosity for MTHFR defects ++ 
Clinical conditions  
folate deficiency +++ 
vitamin B12 deficiency ++++ 
vitamin B6 deficiency ++ 
renal failure +++ 
hyperproliferative disorders ++ 
hypothyroidism ++ 
Lifestyle factors  
smoking + 
coffee consumption + 
alcohol consumption, moderate/excessive -/+ 
Drugs  
antiepileptics ++ 
cholestyramine ++ 
fibrates ++ 
L-dopa ++ 
metformin ++ 
methotrexate ++ 
nicotinic acid ++ 
nitrous oxide +++ 
Table 1.2. Determinants of hyperhomocysteinaemia. + is an increase in plasma 
homocysteine within the reference range (5-15 µmol/L), ++ is mild to moderate 
hyperhomocysteinaemia (15-30 µmol/L), +++ is intermediate hyperhomocysteinaemia 
(30-100 µmol/L)  and ++++ is severe hyperhomocysteinaemia (>100 µmol/L)15,16,17. 
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1.2.4. Epidemiological Evidence for Homocysteine as a Vascular Risk Factor 
 
1.2.4.1. Case Controlled and Prospective Studies 
 
The results of 27 studies examining the relationship between vascular disease and 
homocysteine were subject to meta-analysis in 1995 by Boushey et al18. The studies had 
been carried out at various times during the period 1974-1994. Three were prospective 
studies, five cross-sectional, and nineteen case-controlled studies and had examined 
cardiovascular disease, cerebrovascular disease, peripheral vascular or a combination of 
these. The studies varied considerably in the number of cases and controls, age of subjects, 
preparation of subjects (fasting, non-fasting, post-methionine load) and analyte measured 
(homocystine, cysteine-homocysteine mixed disulphide, total homocysteine), but all were 
considered to have provided good quality data18. Fourteen out of seventeen studies 
supported homocysteine as being a risk factor for cardiovascular disease with an overall 
odds ratio of 1.7 (95% confidence interval 1.5 - 1.9). Nine out of eleven studies showed an 
association between homocysteine and cerebrovascular disease, overall odds ratio 2.5 (95% 
confidence interval 2.0 - 3.0) and all nine studies investigating peripheral vascular disease 
showed a positive association with elevated plasma homocysteine concentrations, overall 
odds ratio 6.8 (95% confidence interval 2.9 - 15.8). 
 
The largest case controlled study performed so far is that of the European Concerted Action 
Project (reported in 1997), a multicentre study carried out in a total of 19 centres in 9 
European countries19. This included a total of 750 cases of vascular disease (cardiac, 
cerebral and vascular) and 800 controls. All samples were taken from subjects in the fasting 
state and also 6 hrs post methionine load (100 mg/kg body weight) and were all analysed at 
only one centre. Positive associations were found between plasma homocysteine and all 
three forms of vascular disease investigated, with the relative risk for vascular disease being 
given as 2.2 (95% confidence interval 1.6 - 2.9). The risk conferred by homocysteine was 
independent of other risk factors, but interactions between smoking and also hypertension 
were noted, with a multiplicative effect upon those risks. 
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Two further meta-analyses, both published in 2002, were both less supportive of there 
being an association between plasma homocysteine and vascular disease20,21, one 
concluding that "elevated homocysteine is at most a modest independent predictor of 
ischaemic heart disease and stroke risk in healthy populations"21. Pertinent details of these 
two studies are summarised in table 1.3. The study of Ford et al noted that case controlled 
studies provided a stronger degree of association between plasma homocysteine and 
vascular disease as compared with cohort and nested cohort studies. The authors could give 
no explanation for this observation but did note a number of difficulties in combining the 
data from individual reports. Results had been given in various ways, different reference 
ranges and cut-off values had been used, the boundary values used for data analysis (eg 
quartiles) were not always stated, odds ratios had not always been calculated in the original 
papers and had to be calculated by the reviewing authors. In addition, details about sample 
collection procedures were often lacking as was information regarding the methods used for 
homocysteine measurement and control procedures to ensure accuracy of the analysis. An 
examination of the analytical performance of laboratories participating in a quality 
assurance programme in 199922 (comparable to the date at which the meta-analyses were 
published) concluded that only 9 of the 34 participating laboratories achieved the minimum 
imprecision goal, the between laboratory imprecision for HPLC analysis was 8.7% and that 
there was a need for improvement in the imprecision of analysis. The lack of precision 
demonstrated by this scheme could represent a major confounder in meta-analyses. 
 
In the meta-analysis performed by the Homocysteine Studies Collaboration (HSC) the 
difficulties in amalgamating data had been circumvented by asking the original 
investigators to provide information and data on each participant but no consideration was 
given as to the possible effects that might arise through the use of different methods of  
homocysteine measurement. Although this study concluded that an increased plasma 
homocysteine was at best a modest risk factor for vascular disease it also stated that "the 
implications for public health of decreasing the population mean levels of homocysteine 
could still be substantial"21. 
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In both meta-analyses certain groups of patients had been excluded, in particular those with 
diabetes, renal impairment, and systemic lupus erythematosus (SLE), in an effort to reduce 
confounding factors, but as these populations show a high incidence of vascular disease a 
particular focus on these groups may be warranted. 
 
 
 Ford et al20 The Homocysteine Studies Collaboration21 
Search period 1966 - 1999 1966 - 1999 
Publications 
reviewed (n)  
57 30 
Study divisions cohort (3) 
nested case controlled (12) 
case controlled (42) 
retrospective (18) 
prospective (12) 
Conditions examined coronary heart disease and cerebrovascular 
disease 
ischaemic heart disease and cerebrovascular 
disease 
Information given 
regarding number of 
subjects 
CHD 5518 cases 
11068 controls 
CVD 1817 cases 
4787 controls 
Total population 16786 
Ischaemic heart disease events 5073 
Stroke events 1113 
Homocysteine 
measurements 
Studies either reported fasting, or post 
methionine load, homocysteine concentration 
Studies reporting free homocysteine 
measurements, and those performed post 
methionine load, were excluded 
Clinical criteria for 
excluding studies 
Special populations excluded including 
patients with cardiovascular disease, diabetes, 
systemic lupus erythematosus and those 
receiving dialysis 
Special populations excluded including patients 
with pre-existing cardiovascular disease, 
diabetes, renal impairment, systemic lupus 
erythematosus 
Quality of analysis Individual studies scored for quality and 
results inspected accordingly. 
Investigation of publication bias suggested 
that negative studies had not been selectively 
omitted 
No report on quality of individual studies or 
investigation of possible selection bias 
Results Odds ratios reported as increased risk 
associated with a 5 µmol/L increment in 
plasma homocysteine 
 
For CHD: 
cohort 1.06 (0.99 - 1.13) 
nested cohort 1.23 (1.07 - 1.41) 
case controlled 1.70 (1.50 - 1.93) 
 
For CVD: 
cohort 1.10 (0.94 - 1.28) 
nested cohort 1.58 (1.35 - 1.85) 
case controlled 2.16 (1.65 - 2.82) 
Reported as reduced risk for homocysteine 
concentrations in lowest quartile 
 
For IHD: 0.89 (0.83 - 0.96) 
 
For CVD: 0.81 (0.69 - 0.95) 
 
Stronger associations were observed in 
retrospective studies of homocysteine measured 
after onset of disease compared with 
prospective studies where individuals has no 
history of vascular disease when blood was 
collected 
Conclusions "prospective studies offer weaker support 
than case-control studies for an association 
between homocysteine and cardiovascular 
disease" 
"elevated homocysteine is at most a modest 
independent predictor of IHD and stroke risk in 
healthy populations" 
Table 1.3. Summary details of two meta-analyses 
investigating homocysteine as a vascular risk factor20,21. 
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1.2.4.2. Evidence From Studies on MTHFR Polymorphisms 
 
MTHFR catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, which then acts as a substrate for methionine synthase in the 
remethylation of homocysteine. A number of single nucleotide polymorphisms of the genes 
encoding for MTHFR have been identified including a C to T change at position 677 
(C667T) and an A to C change at position 1298 (A1298C)23.  The C667T polymorphism is 
relatively common: 47% homozygous CC, 43% heterozygotes CT, 10% homozygous TT24. 
C667T polymorphisms have been shown to result in reduced enzyme activity14 and 
increased plasma homocysteine25. The variant MTHFR resulting from the C667T 
polymorphism is often referred to as thermolabile MTHFR as a result of the way in which 
it was originally identified: variant MTHFR retaining 7 - 17% activity following heating at 
46 OC for five minutes as compared with 'normal' MTHFR which retains 20 - 50% activity 
after heating14. 
 
A large number of studies have been carried out to investigate if there is an association 
between the presence of the C677T polymorphism (and therefore elevated plasma 
homocysteine) and vascular disease. In these genetic based studies it is assumed that the 
distribution of genes is effectively random and independent of other cardiovascular risk 
factors (smoking, increased blood pressure, increased lipids) that may be confounding 
factors in other types of study29. Individual studies have been subject to a number of meta-
analyses24, 25, 26, 27, 28, 29, 30, details of which are given in table 1.4. The majority of studies 
show a positive (though sometimes small ) association between genotype and the form of 
vascular disease examined. One notable feature is the differences that occur when data is 
stratified according to geographical region, in particular North America consistently shows 
no association between genotype and vascular disease. It has been suggested that the 
differences may due to a publication bias30, with some geographical regions tending to 
report only strongly positive studies. An alternative explanation may lie in the fact that 
individuals with the TT genotype only demonstrate hyperhomocysteinaemia when folate 
deficient. In a study performed by Jacques et al31 subjects with the TT genotype and folate 
lower than the study median value had significantly higher plasma homocysteine 
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concentrations than subjects with similarly low folate but with the 'normal' CC genotype 
(p<0.05). There was no difference in plasma homocysteine between subjects with TT 
genotype and those with CC genotype when folate concentrations lay above the median 
value. In addition mandatory fortification of grain products with folic acid was instigated in 
North America, in order to reduce the incidence of neural tube defects, in 199632 and was 
essentially complete by 1997. Jacques et al32 assessed the effects of this fortification by 
comparing results from samples taken before fortification, with those taken after, for 350 
subjects enrolled in the Framingham Offspring Study cohort. Of the 350 subjects, 248 were 
not taking vitamin supplements, and for these the incidence of folate deficiency (defined as 
folate < 7 nmol/L) was decreased from 22.0 to 1.7% following fortification and the 
prevalence of high homocysteine ( defined as > 13 µmol/L) was reduced from 18.7 to 
9.8%. It may be that the lack of association between the C677T mutation and vascular 
disease in studies of North American populations would support the fact that the mutation 
only causes hyperhomocysteinaemia in the presence of folate deficiency and that this has 
largely been eliminated in this geographical region. 
 
Reference Number 
of 
studies 
Disease 
investigated 
Geographical 
Region 
Number of 
cases/controls 
Odds ratio 95% confidence 
interval 
Studies showing a positive association with genotype for at least one group 
72 not stratified 12193 11945 IHD    1.21 1.06 - 1.39 
 
IHD, DVT, 
stroke  3439 5063 DVT   1.29 1.08 - 1.54 
Wald et al 
(2002)24 
   1217 not given stroke  1.31* 0.80 - 2.15 
40 CHD Europe (22) 6207 8343 1.14 1.01 - 1.28 
  N. America (10) 3146 2532 0.87* 0.73 - 1.05 
Klerk et al 
(2002)26 
  Overall 11162 12758 1.16 1.05 - 1.28 
53 Europe (30) 5300 7382 1.15 1.02 - 1.30 
 
Venous 
thrombosis N. America (11) 1738 2108 1.03* 0.82 - 1.29 
Den Heijer et 
al (2005)27 
  Other (12) 1326 2978 1.60 1.27 - 2.02 
   Overall 8364 12468 1.20 1.08 - 1.32 
Cronin et al 
(2005)28 
32 ischaemic 
stroke 
not stratified 6110 8760 1.37 1.15 - 1.64 
80 CHD Europe (41) 17275 21313 1.08* 0.99 - 1.18 
  N. America (15) 3714 3969 0.93* 0.80 - 1.10 
Lewis et al 
(2005)30 
  Middle East (5) 971 1316 2.61 1.81 - 3.75 
   Asia (16 2755 4735 1.23 0.94 - 1.62 
   Australia (3) 1285 480 1.04* 0.73 - 1.49 
   Overall 26000 31813 1.14 1.05 - 1.24 
Studies showing no association with genotype 
Brattström et 
al (1998)25 
23 CVD not stratified 5869 6644 1.12 0.92 - 1.37 
Kelly et al 
(2002)29 
19 ischaemic 
stroke 
not stratified 2788 3962 1.23 0.96 - 1.58 
Table 1.4. Summary details of meta-analyses investigating MTHFR genotype as a vascular risk factor. 
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1.2.4.3. Intervention Studies 
 
A number of intervention trials to assess whether homocysteine lowering therapy decreases 
the risk of vascular disease have now been reported33, 34 ,35 ,36, 37, 38 and the salient features of 
these are given in table 2.4. All these studies concluded that treatment had no effect on 
vascular outcomes; these findings have generally met with disappointment and suggestions 
that increased plasma homocysteine is a marker of vascular disease and not causal39. There 
are, however, a number of criticisms in these studies both in terms of the conclusions drawn 
and study design. 
 
For the VISP trial, after the initial findings had been published33 the results were subject to 
further, sub-group analysis. After removal of subjects with impaired B12 absorption and/or 
significant renal impairment a 21% reduction in vascular events was noted in subjects 
receiving high-dose therapy as compared with those in the low-dose therapy group40. 
 
In the HOPE-2 trial a subgroup analysis showed that fewer patients receiving treatment had 
a stroke compared to those in the placebo group (relative risk, 0.75; 95% confidence 
interval, 0.59 - 0.97). It should be noted that in this trial not all participants had 
measurements of homocysteine and folate performed, but only a random selection: 60% at 
baseline, 21% at two years and 19% at five years (for both treated and placebo groups), ie 
at follow-up, data was incomplete for approximately 80% of participants. 
 
Inclusion criteria for five of the six studies in table 1.5 was the existence of established 
vascular disease, and it is possible that homocysteine lowering therapy at this stage may not 
reverse any damage already caused to the vascular system. In view of this, whilst these 
trials may have shown there was no benefit in secondary prevention of vascular disease, 
care must be taken inferring that homocysteine lowering therapy would have no benefit in 
primary prevention. 
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41
 
Trial and 
period of 
study 
No. of 
subjects 
Inclusion criteria Treatment 
groups 
Effect on 
plasma 
homocysteine 
concentration 
(µmol/L) 
Follow-
up 
period 
Results 
VISP33
 
1996 -2003 
3680 Nondisabling 
ischaemic stroke, 
age ≥ 35 years + 
plasma 
homocysteine in 
top quartile of 
North American 
population 
(threshold 
changed during 
the study) 
High dose 
B6, B12 
& folate 
vs low 
dose 
2.3 decline from 
baseline of 13.4 
in high-dose 
group 
2 years No effect on recurrent 
cerebral infarction, CHD or 
death. 
HOPE-235 
2000 - 2005 
5522 Age ≥ 55 years + 
vascular disease or 
diabetes along 
with other risk 
factors 
Folate, 
B6, B12. 
 
Placebo 
12.2 → 9.7 
 
 
12.2 → 12.9 
5 years No effect on the combined 
endpoint of cardiovascular 
death, myocardial infarction 
and stroke 
NORVIT34 
1998 - 2004 
3749 Acute myocardial 
infarction ≤ 7 days 
Folate, 
B12, B6 
 
Folate, 
B12 
 
B6 
Placebo 
13.1 → 9.5 
 
 
12.9 → 9.8 
 
 
13.3 → 13.3 
13.2 → 13.6 
3.5 
years 
No effect on the combined 
endpoint of myocardial 
infarction, stroke and 
sudden death. Increased risk 
in the folate + B12 + B6 
group 
HOST36 
2001 - 2006 
2056 End stage renal 
disease or 
creatinine 
clearance ≤ 30 
mL/min 
+ homocysteine 
≥ 15 µmol/L 
Folate, 
B12, B6 
 
Placebo 
21.5 → 15.3 
 
 
21.4 → 20.6 
 
5 years No effect on all cause 
mortality, MI or stroke. 
WAFACS38 
1998 - 2005 
5442 Women > 40 
years or post-
menopausal, 
cardiovascular 
disease or three 
risk factors 
Folate, 
B12, B6 
 
Placebo 
12.1 → 9.8 
 
 
12.5 → 11.8 
 
7.3 
years 
No effect on the combined 
endpoint of myocardial 
infarction, stroke, coronary 
revascularisation, 
cardiovascular death. 
WENBIT37 
1999 - 2006 
3096 Coronary 
angiography for 
suspected 
coronary disease 
or aortic stenosis 
Folate, 
B12, B6 
Folate, 
B12 
B6 
Placebo 
10.8 → 7.6 in 
first two groups 
with folate and 
B12 
No change in 
B6 or placebo 
groups 
38 
months 
No effect on composite 
endpoint of total mortality, 
nonfatal myocardial 
infarction, hospitalisation 
for unstable angina, or 
nonfatal thromboembolic 
stroke 
Table 1.5. Major clinical trials investigating the effect of homocysteine lowering therapy on vascular 
outcomes. Data adapted from Joseph et al41 in addition to individual references. 
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Four of the six studies were conducted (almost) exclusively in North America and Canada, 
where food fortification by folate is mandatory, and it could therefore be argued that the 
participants in the placebo groups were already receiving a degree of vitamin 
supplementation, and that the trials should be viewed in terms of the potential benefits due 
to additional supplementation rather than to supplementation per se. 
 
The majority of participants in the trials were taking a variety of medications, with 
polypharmacy being common table 1.6. In some trials 12-29% of participants were also 
taking multivitamins in addition to those being administered as part of the trial. There were 
no differences with regard to medication or vitamin usage between the active groups and 
control groups in any of the trials. Given that many of the participants were being treated 
for vascular disease with these therapeutic agents the trials would largely only be able to 
detect the additional benefit of homocysteine lowering therapy. A more serious concern is 
that some of these agents could mask the (possible) toxic effects of homocysteine, or at 
least reduce the power of the studies to detect them. So far there is no proven mechanism 
for the (possible) atherogenic effects of homocysteine (which will be discussed in detail 
below) but it has been demonstrated that homocysteine a) has a procoagulant effect42, 
which could possibly be reduced by aspirin therapy and b) reduces the production of nitric 
oxide, which could possibly be countered by statin therapy; many statins having been 
shown to increase nitric oxide production43. These issues were not addressed in the studies 
and caution should therefore be exercised in drawing conclusions beyond the lack of effect 
noted in the targeted population. 
 
 VISP HOPE-2 NORVIT HOST WAFACS WENBIT 
ACE inhibitors  66.0 31.0 40.5 25.1 32.2 
aspirin or antiplatelet agents  79.2 88.8 42.5 50.0 90.2 
beta blockers  46.4 91.0 58.0 26.8 78.2 
calcium channel blockers  37.0  58.0  22.4 
diuretics  26.3 17.8   10.0 
lipid lowering drugs  60.1 81.0 49.0 34.1 88.4 
multivitamins 22.5 11.6 28.8  22.9  
 
 
Table 1.6. Medication usage of participants in homocysteine lowering trials. The table shows medications 
being taken by participants, in addition to any homocysteine lowering treatment. Medications other than 
those listed, including calcium channel blockers, ACE inhibitors and oral hypoglycaemic agents, were also 
used to different extents in different trials. there was no significant difference in medication usage of 
participants in the active groups compared to the placebo groups. 
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1.2.4.4. Summary of Evidence for Homocysteine as a Vascular Risk Factor 
 
Overall there is a large body of evidence showing that homocysteine is associated with 
vascular disease but there is still substantial controversy as to whether it is merely a marker 
of disease or causative. Although intervention trials have demonstrated little benefit in 
lowering homocysteine with vitamin therapy the results of such trials must be interpreted 
with caution and further work is required to see if such treatment might have a role in 
primary care or for selected targeted populations (eg chronic kidney disease, SLE). Even if 
homocysteine proves to be only a marker of disease, further research to uncover why it is 
increased in various forms of vascular pathology may be of value. 
 
 
1.2.5. Possible Mechanisms for the Atherogenic Effect of Homocysteine 
 
A number of mechanisms for an atherogenic effect by homocysteine have been proposed 
though has yet been proven. These mechanisms have been reviewed44,45,46 and include 
effects on coagulation, generation and damage by free radicals, promotion of inflammation, 
decreasing nitric oxide production and binding to proteins with a subsequent alteration of 
their function. 
 
A number of studies have suggested that homocysteine may have a pro-coagulant effect by 
increasing platelet adhesion, inhibiting protein C activation and activating factor V44,45. 
Many of these studies have been criticised as they used extremely high, non-physiological 
concentrations of homocysteine and not all have been reproducible44,45. A study by 
Mohan et al42 investigated the effects of homocysteine on platelet function at physiological 
concentrations and concluded that homocysteine causes platelet activation and 
hypercoagulabilty, with the effects becoming apparent at approximately 50 µmol/L (a 
concentration corresponding to moderate hyperhomocysteinaemia). In a further study on 
platelet function Signorello et al47 also concluded that homocysteine stimulates platelet 
aggregation, and that this was due to dysregulation of nitric oxide production by 
homocysteine. The decrease in nitric oxide production occurred in a dose dependent 
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manner with homocysteine concentrations in the range 10 - 100 µmol/L. An important 
feature of this study was that the effect was unique to homocysteine and that similar 
experiments with methionine and cysteine produced no effect upon platelets. Homocysteine 
at physiological concentrations has also been shown to induce the expression of 
thrombokinase by monocytes in a dose dependent manner48 potentially leading to a pro-
coagulant state. 
 
Homocysteine can readily auto-oxidise to form both homocystine and mixed disulphides 
and in doing so generates reactive oxygen species such as superoxide anion radical (O2•-) 
and hydrogen peroxide (H2O2) which may then attack cell membranes, lipoproteins, and 
platelets49,50, however a particular weakness in this being a mechanism for homocysteine 
causing vascular disease is that cysteine may also undergo similar oxidation reactions, is in 
much higher concentration than homocysteine in plasma (approximately 20-30 fold51) but 
has not been associated with vascular disease51. 
 
Homocysteine forms stable disulphide bonds with protein cysteine residues and shows a 
greater tendency to do so than other thiols such as cysteine and glutathione46. It has been 
shown, both in vitro and in vivo, that this 'homocysteinylation' of proteins may lead to an 
impairment of protein function46 with the suggestion that this may account for the possible 
atherogenic effects of homocysteine. 
 
In cultured human aortic endothelial cells homocysteine has been shown to upregulate the 
production of interleukin-8 and monocyte chemoattractant protein-1 and may therefore 
contribute towards the initiation and progression of vascular disease by promoting 
leukocyte recruitment52. 
 
It has been shown that homocysteine may decrease the production of nitric oxide in the 
endothelium by increasing the concentration of asymmetric dimethylarginine (ADMA), a 
nitric oxide synthase inhibitor. This potentially leads to an increase in vascular stiffness, 
rendering the vasculature more susceptible to damage. This will be discussed in detail 
below. 
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1.2.6. Methods for the Analysis of Plasma Homocysteine 
 
1.2.6.1 General Considerations 
 
The first cases of homocystinuria were identified using simple screening methods: analysis 
of urine using the reaction of homocysteine with sodium nitroprusside to form a coloured 
complex (a test more commonly used for identifying cystinuria) and also by using thin-
layer chromatography. Quantitative analysis was provided by amino acid analysers (using 
ion-exchange chromatography and post-column derivatisation with ninhydrin) which had 
only been recently developed7. 
 
Since that time the increasing interest in homocysteine as a possible cardiovascular risk 
factor has necessitated the development of highly specific and precise quantitative methods 
with high-throughput capacity, this, together with the identification of thiol 
selective/specific reagents, capillary electrophoresis, automated immunoassay techniques 
and bench-top mass spectrometers, has led to the existence and publication of a vast 
number of methods for homocysteine analysis. Homocysteine methods have been reviewed 
extensively53, 54,  55, 56, 57, 58, 59, 60 and interest in method development continues.  
 
The majority of methods measure total homocysteine by utilising a reduction step to release 
homocysteine bound to proteins and from disulphides and a number of different reducing 
agents have been employed53. Dithiothreitol (DTT) and mercaptoethanol have been used 
most commonly but are not suitable for use with methods making use of thiol specific 
derivatising reagents since they react with and consume reagent53. Sodium borohydride has 
been used but the evolution of gas during the reduction process has been problematic in 
automating methods53. Tributyl-n-phosphine is an effective reducing agent, used in a 
number of HPLC assays, but due to being poorly soluble in aqueous solution it is necessary 
to dissolve it in a carrier solution such as dimethylformamide before use53. Tris(2-
carboxyethyl)phosphine (TCEP) is more soluble in water, and does not consume 
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derivatising agent53, but having been introduced comparatively recently it has only been 
used in a limited number of applications53. 
 
1.2.6.2. Radioenzymic assays 
 
Methods for the measurement of homocysteine in plasma and urine have been 
described61,62. These make use of S-adenosyl-L-homocysteine hydrolase to form 
radiolabelled S-adenosyl homocysteine (SAH) from homocysteine and 14C labelled 
adenosine. The adenosylhomocysteine is isolated by using HPLC and collecting fractions 
eluted from the column and then quantitated using scintillation counting. The sensitivity of 
the method was such that it allowed the determination of free homocysteine (by first 
removing plasma proteins by acid precipitation) as well as total homocysteine and was used 
to investigate the extent of protein binding by homocysteine. It was though extremely 
labour intensive and this, in addition to the special requirements necessary for handling 
radioisotopes, meant that it was unsuitable for processing large sample numbers or for use 
in a routine clinical setting. 
 
1.2.6.3. Amino Acid Analysers 
 
Ion-exchange chromatography with post-column derivatisation by ninhydrin is a technique 
commonly employed by dedicated amino acid analysers used for identifying and 
monitoring patients with inborn errors of amino acid metabolism. Briddon63 demonstrated 
that the use of a reduction step by DTT prior to sample analysis by Biochrom 20 amino 
acid analyser (Pharmacia Biotech) enabled the determination of total cysteine and 
homocysteine without substantially increasing analysis time or compromising the quality of 
analysis of other amino acids. Although this is useful for laboratories equipped with amino 
acid analysers such equipment is not common, generally being found only in centres 
offering a  specialised amino acid referral service. 
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1.2.6.4. HPLC 
 
Since homocysteine shows little native absorbance the majority of HPLC methods employ 
pre-column derivatisation for analysis. Traditional derivatising agents such as OPA react 
with all primary amino acids and so necessitate complex chromatography capable of 
separating the derivatised homocysteine from the other derivatised amino acids57, and this 
has led to the development of thiol selective/specific reagents64, 65. A number of methods 
have been described making use of derivatisation with monobromobimane66, 67, 68, 69, a 
compound with little native fluorescence that reacts quickly with, and shows a high degree 
of selectivity, although not specificity, for thiols. Monobromobimane and thiols derivatised 
with it form fluorescent breakdown products upon storage which can complicate 
chromatographic separation of the compounds of interest54. The derivatising agent that has 
proved most popular is 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBD-F), a reagent 
which shows no native fluorescence, exhibits a high degree of specificity towards thiols57, 
and has led to the development of a number of highly sensitive methods70, 71, 72 73. The 
breakdown products of SBD-F and its derivatives, formed upon storage, are non-
fluorescent which results in chromatograms with well-resolved analyte peaks free from 
interfering reagent peaks57. The main disadvantage of SBD-F is considered to be the 
relatively long reaction time for full derivatisation of thiols (1 hour at 60OC)57.  HPLC with 
electrochemical detection has been used for the routine analysis of biological thiols74, 75, 76, 
and has the major advantage that derivatisation of thiols is not necessary. The methods 
described show high specificity and sensitivity but precision is poorer than those methods 
employing fluorometric detection54. 
 
1.2.6.5. Gas Chromatography Mass Spectrometry. 
 
Methods utilising GS-MS have been developed77, 78, 79 but have not found widespread use, 
in part because the methods are considered cumbersome54. With GC-MS it is possible to 
use an isotopically labelled form of homocystine as internal standard, resulting in methods 
with high precision and accuracy. 
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1.2.6.6. Capillary Electrophoresis. 
 
A number of methods for homocysteine utilising capillary electrophoresis have been 
published80,81,82 and these methods generally have very short run times. Although 
photometric detection of thiols, after derivatisation with reagents such as 5,5'-dithio-bis-2-
nitrobenzoic acid (Ellman's reagent), is possible, in order to gain sufficient sensitivity and 
precision for the determination of homocysteine in biological fluids, either electrochemical 
detection is required or laser induced fluorescent detection following thiol derivatisation 
with reagents such as fluorescein isothiocyanate (FITC) or SBD-F60. Capillary 
electrophoresis equipment is not commonly found in routine clinical laboratories and these 
methods have not found widespread adoption. 
 
 
1.2.6.7. Immunoassay 
 
A number of commercially available immunoassays utilising enzyme-linked immunoassay 
(EIA)83, chemiluminescence immunoassay (ICL)84 or fluorescence polarisation 
immunoassay (FPIA)85 for plasma homocysteine measurements are available. All the 
immunoassays developed so far share a common feature in that, following a reduction step, 
homocysteine is converted by S-adenosyl-L-homocysteine hydrolase to S-
adenosylhomocysteine, which then reacts with an anti-SAH antibody. An EIA is available 
from Axis Biochemicals, ICL is used on the Immulite 2000 analyser (DPC) and FPIA was 
used on the IMx® analyser (Abbot laboratories). Although support for the latter instrument 
has now been withdrawn (2009) the FPIA is still available for use on the Architect® and 
AxSYM® analysers (Abbott Laboratories).  ICL and FPIA provide automated means for 
determining plasma homocysteine with little manual intervention but they are considerably 
more expensive in terms of reagent cost per sample as compared to other methods (HPLC, 
MS/MS). 
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1.2.6.8. Enzymatic Analysis 
 
Plasma homocysteine can be analysed by making use of enzymatic analysis. In a method 
described by Tan et al86, following reduction step using DTT, a recombinantly produced 
homocysteine α, γ-lyase87 is used to covert homocysteine to α-ketobutyrate, ammonia and 
H2S.  The H2S then reacts with N,N-dibutylphenylene diamine to form a highly fluorescent 
product. The procedure was performed in microtiter plates, required only five microlitres of 
sample and compared well with an HPLC method utilising SBD-F derivatisation and 
fluorescent detection. The authors reported that cysteine showed a small degree of cross 
reactivity in the analysis but claimed that with the assay conditions used there was almost 
no interference by plasma cysteine when measuring homocysteine. An enzymatic cycling 
assay has been described and evaluated88, 89. In this method homocysteine reacts with S-
adenosylmethionine (SAM) in the presence of a homocysteine S-methyltransferase to form 
methionine and S-adenosylhomocysteine (SAH); it should be noted that the SAH is formed 
by the loss of a methyl group from SAM and does not contain any part of the original 
homocysteine molecule. SAH is then hydrolysed into adenosine and homocysteine by SAH 
hydrolase. The adenosine is hydrolysed into inosine and ammonia, the latter then reacts 
with glutamate dehydrogenase, with an associated conversion of NADH to NAD and the 
reaction monitored by the decrease in absorbance at 340 nm. The homocysteine newly 
formed by the hydrolysis of SAH cycles back into the reaction providing a substantial 
amplification of the detection signal. This method is available commercially from Diazyme 
Laboratories (California, USA) and may be implemented on a number clinical chemistry 
analysers including the Roche Hitachi, Dade Dimension® and Beckman Synchron CX. 
Another commercially available cycling enzymatic method for plasma homocysteine, the 
performance characteristics of which have been evaluated90, 91, is that offered by Carolina 
Liquid Chemistries (Winston-Salem, North Carolina, USA). This uses cystathionine-β-
synthase to convert homocysteine and serine to cystathionine, the latter is then converted by 
cystathionine-β-lyase to homocysteine, pyruvate and ammonia. The pyruvate then reacts 
with lactate dehydrogenase with an associated conversion of NADH to NAD and the 
reaction monitored by the decrease in absorbance at 340 nm. Applications of this method  
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are available for automated instruments including those produced by Dade, Beckman, 
Roche, Bayer and Olympus. 
 
1.2.6.9. Tandem MS 
 
In 1999 the first paper to describe the use of liquid chromatography tandem mass 
spectrometry (LC-MS/MS) for the measurement of plasma and urine homocysteine was 
published by Magera et al92.  It employed very simple sample preparation (reduction using 
DTT for 15 min followed by protein precipitation using acetonitrile/formic 
acid/trifluoroacetic acid) and also used isotopically labelled homocystine for internal 
standardisation. The analysis time by the mass spectrometer was fast at 3 min per sample. 
The precision and recovery studies performed were not very thorough, both being 
performed using bovine calf serum (diluted 1:1 with distilled water) which had been spiked 
with homocysteine standard; only six replicates of each preparation were analysed to assess 
precision. Human plasma and urine were not used in these experiments. Nevertheless, 
results from MS/MS analysis compared favourably with those obtained by an HPLC assay 
(using derivatisation with monobromobimine and fluorescent detection) and with those 
obtained using FPIA on an Abbott IMx analyser. Since that initial paper a number of other 
similar methods have been published with adaptations to allow for the simultaneous 
determination of other compounds such as cysteine, methionine, folate and methylmalonic 
acid and with application to other matrices such as dried blood spots and intracellular 
fluid93, 94, 95, 96, 97, 98, 99, 100, 101, 102. 
Tandem mass spectrometry is often referred to as being an expensive technique, at least in 
terms of capital outlay, but as the cost of mass spectrometry analysers has fallen in the last 
few years such equipment is being found more commonly in large routine clinical 
laboratories and where this equipment is already in place its use provides a very economical 
means of homocysteine analysis as regards consumables. Even though isotopically labelled 
internal standards may seem expensive, a small quantity is sufficient for many analyses (eg 
0.1g homocysteine-d8 costs approximately £600 [2010 prices], but is sufficient for in 
excess of one million analyses). The use of isotopically labelled internal standards makes 
MS/MS a candidate reference method for homocysteine analysis100, this with the potential 
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for multi-analyte determination, simple sample preparation and reasonably high sample 
throughput makes it a good choice for plasma homocysteine measurements in laboratories 
already employing tandem mass spectrometry. 
 
 
 
 
1.3. Methylated Arginines 
 
1.3.1. The Biochemistry and Metabolism of Methylated Arginines 
 
Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and 
monomethylarginine (MMA) are naturally occurring amino acids that circulate in plasma 
and are excreted in the urine. They are formed by the continual enzymatic methylation of 
arginine residues within proteins by protein methyl transferases (PRMT)103 and their 
structures are shown, together with that of arginine, in figure 1.4.  
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Figure 1.4. The structures of arginine and methylated arginines. 
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A number of PRMTs have been identified and fall into two classes. PRMT 1 form MMA 
and ADMA, whilst PRMT 2 form MMA and SDMA103. Upon proteolysis these methylated 
arginines are released into cells and subsequently into the circulation103 from which they 
may then be actively transported into other cells by a y+ cationic amino acid transporter 
protein104.  Approximately 300 µmol ADMA is generated per day by humans105, around 
90% of which is metabolised by the enzyme dimethylarginine dimethylaminohydrolase 
(DDAH)106, of which there are two isoforms (DDAH 1 and DDAH 2), and the remainder is 
excreted unchanged via the kidney. MMA is also metabolised by DDAH whereas SDMA is 
not107, and it is thought that the only route of elimination of the latter is via the kidney. 
 
 
1.3.2. Methylated Arginines, DDAH, and Nitric Oxide 
 
ADMA and MMA are natural inhibitors of nitric oxide synthases (NOS) with ADMA being 
a more potent inhibitor of endothelial NOS (eNOS) and neuronal NOS (nNOS) than of 
inducible NOS (iNOS)108. SDMA has been shown to have no effect upon these enzymes109. 
NOS act upon arginine to produce nitric oxide (NO) and citrulline. The resultant NO 
induces vascular relaxation and also inhibits platelet adhesion and smooth muscle 
proliferation110.  
 
DDAH and NOS isoforms show distinct, and related, patterns of expression in different 
tissues111. DDAH 1 predominates in tissues that express nNOS (brain, kidney) whilst 
DDAH 2 predominates in endothelial cells and highly vascularised tissues that express 
eNOS (heart, placenta, kidney) and in immune tissues that express iNOS (spleen, thymus, 
bone marrow)111,112. Distribution of NOS and DDAH isoforms in the kidney is 
complicated, eNOS having been demonstrated in microvascular endothelial cells and the 
ascending loop of Henle, nNOS in the Bowman's capsule and collecting ducts and iNOS in 
the proximal tubule, ascending loop of Henle and distal convoluted tubules whilst DDAH 1 
has been identified in the proximal convoluted tubule and DDAH 2 in the ascending loop of 
Henle and distal convoluted tubule108. 
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In a study designed to investigate DDAH isoform expression on plasma ADMA 
concentrations, rats were administered an RNA inhibitor specific for either DDAH 1 or 
DDAH 2113.  In a control group, DDAH 1 in the kidney and liver were shown to be two and 
seven fold higher, respectively, than DDAH 2 whereas DDAH 2 was five fold higher than 
DDAH 1 in mesenteric resistance vessels. Following inhibition of  DDAH 1, a 35-50% 
decrease in its expression was observed in kidney and liver (with no significant change in 
DDAH 2) after 72 hours, with an associated 25% increase in plasma ADMA. Selective 
inhibition of DDAH 2 resulted in a 40-85% decrease in its expression (with no change in 
DDAH 1) but in this case no increase in plasma ADMA was observed. The authors 
concluded that plasma ADMA concentrations are regulated by the DDAH 1 isoforms 
whereas intracellular ADMA concentrations (and therefore production of NO) is primarily 
regulated by the DDAH 2 isoform. This conclusion is consistent with another study in 
which the liver has been shown to be a major organ for the elimination of circulating 
ADMA114. 
 
In vitro studies have shown that DDAH 2 (but not DDAH 1) expression is up regulated by 
NO, which possibly provides a positive feedback loop that serves to maintain endothelial 
NO concentration115. Other studies have shown that nitrosylation of DDAH 1 by NO leads 
to a reduction in its activity (DDAH 2 was not investigated)116. 
 
The growing body of evidence regarding the relationships between NO, ADMA and 
DDAH have now led to the suggestion that ADMA is a regulator of NO production, 
controlled by DDAH activity, and that pathological decreases in DDAH activity may lead 
to an increased ADMA concentration, a decreased production of NO, and thereby a pro-
atherogenic state108.  Although SDMA has no direct inhibitory effect upon nitric oxide 
synthase it has been suggested that it may compete with arginine for entry into cells, and 
therefore increased plasma SDMA concentrations may limit production of nitric oxide by 
limiting the availability of arginine117 (figure 1.5). 
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1.3.3. Inhibition of DDAH 
 
The active site of DDAH consists of a catalytic triad (cys 249, his 162, glu 114)107 and it 
has been shown by Stühlinger et al that homocysteine may bind to this site with a 
subsequent loss of enzyme activity118.  In the experiments they described: i) cultured bovine 
aortic endothelial cells were incubated with methionine or homocysteine (at physiological 
concentrations) and resulted in a dose dependent increase in ADMA production which was 
attenuated by the addition of the antioxidant pyrrrollidine dithiocarbamate (PDTC). ii) the 
activity of recombinantly produced DDAH was decreased following incubation with 
homocysteine, but not by methionine or cysteine, and the reduction in activity associated 
with homocysteine was attenuated in the presence of both PDTC and DTT. iii) DDAH was 
incubated with biotinylated homocysteine, applied to a streptavidin coated polystyrene 
plate and after washing DDAH was detected using a primary anti-DDAH antibody and 
peroxidase labelled secondary antibody; homocysteine was to have bound significantly to 
DDAH but similar experiments with biotinylated methionine and cysteine showed that their 
was no binding by these two amino acids. The essential points of these experiments were 
that they demonstrated that physiological concentrations of homocysteine resulted in an 
increased production of ADMA but that no effect was observed with cysteine. 
Figure 1.5. The effects of ADMA and SDMA on nitric oxide production. ADMA directly 
inhibits nitric oxide synthase and NO production. It has been suggested that SDMA may 
compete with arginine for entry into cells117 and thereby also decrease NO synthesis.  
SDMA (plasma)
ADMAarginine
nitric oxide
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DDAH
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A reduction in DDAH activity with increased production of ADMA has also been shown in 
cells cultured with oxidised LDL (but no effect with native LDL)119, cells cultured with 
cigarette smoke extract120, in cells cultured with 25.5 mmol/l glucose (the effects of which 
could be reversed by the antioxidant polyethylene glycol-conjugated superoxide 
dismutase)121, and in rats with streptozotocin induced diabetes mellitus121. 
 
1.3.4. ADMA and Clinical Studies 
 
A small number of studies have been performed examining the effects of ADMA infusion 
in humans105,122,123,124,125 and these have been reviewed126. The reported effects include 
decreases in forearm blood flow, renal plasma flow, cardiac output and heart rate and 
increases in systemic vascular resistance and mean arterial blood pressure; the results of 
these studies are summarised in table 1.6. 
 
Reference Subjects 
(n) 
Application Dose ADMA 
plasma 
concentration  
Effect 
Vallance et al 
(1992) 
5 i.a. bolus 8 µmol not reported Decrease in forearm blood 
flow by 28% 
Achan et al 
(2003) 
6 i.v. 3.0 mg/kg 2.6 µmol/L 
(30 min post 
injection) 
Decrease in heart rate by 9% 
and cardiac output by 15%. 
Increase in mean arterial 
blood pressure by 6% and 
systemic vascular resistance 
by 24% 
Kielstein et al 
(2004) 
6 i.v infusion 
over 40 min 
0.5 - 10.0 
mg/kg 
4.2 - 42.1 
µmol/L 
Dose-dependent decrease in 
effective renal plasma flow 
of up to 11% 
Kielstein et al 
(2004) 
7 i.v infusion 
over 40 min 
4.0 mg/kg 23.0 µmol/L Decrease in cardiac output by 
14%, increase in systemic 
vascular resistance by 11% 
Kielstein et al 
(2004) 
12 i.v infusion 
over 40 min 
0.8 mg/kg not reported Decrease in effective renal 
plasma flow by 10%. 
Increase in filtration fraction 
by 17% 
Kielstein et al 
(2005) 
7 i.v infusion 
over 40 min 
0.1 mg/kg not reported Increase in pulmonary 
vascular resistance by 38% 
 
Table 1.7. Summary of  studies investigating the phyiological effects of ADMA infusion. 
Adapted from Kielstein et al126. 
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A major criticism of these studies is that following infusion, plasma ADMA concentrations, 
where they have been measured, are often much greater than those found in health or 
disease states (typical 'healthy values  0.4 - 0.6 µmol/L, pathological values 2.6 - 5.3 
mmol/L)127 and that they are not therefore representative of the effects of plasma ADMA 
found at physiological concentration. It has been suggested that the infusion studies are still 
valid, since they possibly represent the intracellular concentration of ADMA, which may be 
considerably higher than plasma127. This argument though would not seem to be valid: in 
studies using cultured bovine aortic endothelial cells, incubation with 10 µmol/L ADMA 
(in the presence of 100 µmol/L arginine) resulted in intracellular ADMA concentrations 
increasing from 2.7 µmol/L to 23.5 µmol/L over a twenty minute period128. It might be 
expected, therefore, that in the infusion studies, most of which administered ADMA over a 
40 minute period,  there might also be a substantial increase in intracellular ADMA 
concentrations as well as plasma concentrations and that these are not representative of 
those occurring naturally. Unfortunately it is not possible to address this point further as 
intracellular concentrations of ADMA were not determined in any of the studies. 
 
Increased plasma ADMA concentrations have been shown to be associated with impaired 
glycaemic control. Abbasi et et al demonstrated that ADMA is significantly increased in 
patients with type 2 diabetes mellitus (mean ADMA: controls (n=18), 0.69 ± 0.04 µmol/L, 
type 2 diabetics (n = 16), 1.59 ± 0.22 µmol/L)129 whilst Anderson et al investigated 355 
patients with normal glycaemic control (but undergoing investigation for coronary artery 
disease), 239 patients with impaired fasting glucose and 256 patients with overt diabetes 
and found that ADMA increased with loss of glycaemic control130. Stühlinger et al 
determined the insulin sensitivity status of 64 non-diabetic, healthy volunteers and found 
that ADMA concentrations were significantly higher in those individuals classed as insulin 
resistant compared to those with normal insulin sensitivity. Furthermore, for patients with 
insulin resistance, treatment with rosiglitazone to increase insulin sensitivity decreased the 
plasma ADMA concentration131.  
 
A prospective study of 1874 patients with coronary artery disease and a median follow up 
of 2.6 years showed that ADMA and B natriuretic peptide were the strongest predictors of 
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death from cardiovascular cause or non-fatal myocardial infarction, independent of 
traditional cardiovascular risk factors132.  A one year follow up of patients with advanced 
peripheral artery disease showed that plasma ADMA concentrations predicted major 
adverse cardiovascular events133. In a multicenter study ADMA and traditional 
cardiovascular risk factors were determined in 131 patients with coronary heart disease 
(CHD) and 131 controls (matched for age, sex and BMI), and the researchers concluded 
that ADMA was an independent risk factor for CHD134. In a further prospective study 2543 
individuals with and 695 without coronary artery disease were investigated with a median 
follow up of 5.5 years. Plasma ADMA concentrations were found to be a predictor of all-
cause and cardiovascular mortality in individuals with coronary artery disease and, other 
than showing a strong association with plasma homocysteine and glomerular filtration rate, 
was independent of established risk factors135. 
 
A study of 225 patients with end-stage renal disease (ESRD), receiving haemodialysis three 
times per week, has shown that plasma ADMA is strong, independent predictor of  overall 
mortality and cardiovascular events136. In addition ADMA has been shown to 
independently predict progression to ESRD and mortality in patients with chronic kidney 
disease137 and the higher the baseline ADMA concentration the faster the progression138. 
 
Clinical studies in which both plasma ADMA and plasma homocysteine have been 
measured are conflicting regarding the association between the two. Positive associations 
have been reported in patients with Alzheimer's disease139, patients being investigated for 
chest pain140 and patients having suffered a stroke141 whereas  other studies involving 
patients with ESRD136 and patients undergoing percutaneous coronary intervention142 have 
shown no association between the two. 
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1.3.5. Methods for the Measurement of ADMA 
 
The measurement of dimethylated arginines in plasma presents a particularly difficult 
analytical challenge and a number of reviews of methods for their determination have been 
published143,144,145,146. A summary of methods including sample preparation and internal 
standard used is given in table 1.7. 
 
Being structural isomers, ADMA and SDMA are difficult to separate chromatographically 
and also produce very similar fragmentation patterns with tandem mass spectrometry. The 
majority of published methods employ HPLC and, as ADMA and SDMA are both present 
in plasma at low concentration (approximately 1 µmol/L) and show little native absorbance, 
these methods have required the use of pre-column derivatisation. No specific 
derivatisation reagent for ADMA or SDMA has been reported and so derivatisation is 
usually performed with general amino acid derivatising reagents, OPA having been the 
most popular choice147,148,149,150,151, although naphthalene-2,3-dicarboxaldehyde (NDA)152, 
6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AccQ-FluorTM)153 and ninhydrin154 
have also been used.  These methods generally have long run times and require gradient 
elution to separate ADMA from SDMA and from other derivatised amino acids; complete 
resolution of ADMA, SDMA and/or internal standard has not always been achieved. 
 
The similarity in the fragmentation patterns of ADMA and SDMA produced by tandem 
mass spectrometry has meant that the majority of methods developed using this technique 
have also relied upon chromatographic separation of the two isomers, prior to mass 
spectrometric analysis, usually by HPLC155,156,157,158, although GC159,160 has been described. 
In GC methods, derivatisation of the amino acids is used primarily to increase their 
volatility, whereas with HPLC methods derivatisation, most commonly with OPA, is 
frequently used to facilitate the chromatographic separation of the two isomers, which is 
again not always completely achieved. A few tandem mass spectrometric methods have 
been described which have identified and made use of specific fragments for ADMA (and 
sometimes SDMA) without derivatisation161,162,163, and also following butylation164,165, of 
the amino acids.  
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Reference Technique Analytes Measured Sample Preparation Internal Standard Comments 
Petterson et al 
(1997)147 
HPLC ADMA, SDMA cation exchange SPE, OPA 
derivatisation 
none Gradient elution, 70 min run time, ADMA and SDMA 
barely separated, requires 1.5 ml plasma 
Chen et al 
(1997)148 
HPLC ADMA protein precipitation (SSA), 
centrifugation, OPA 
derivatisation 
none Gradient elution, 35 min run time,  SDMA not 
investigated, no evidence that SDMA is separated 
from, and does not interfere with ADMA 
Teerlink et al 
(2002)149 
HPLC ADMA, SDMA, arg, 
Harg 
cation exchange SPE, OPA 
derivatisation 
MMA Isocratic, 20 min run time, ADMA and SDMA just 
separated 
Marra et al 
(2003)152 
HPLC ADMA, SDMA, arg cation exchange SPE, NDA 
derivatisation 
Nω-propyl-L-
arginine 
Isocratic, 30 min run time, excellent separation of 
ADMA and SDMA 
Zhang et al 
(2004)150 
HPLC ADMA, SDMA, arg, 
MMA, citrulline, 
ornithine, agmatine, 
hydroxy-L-arginine 
protein precipitation (ethanol), 
centrifugation, lyophilisation, 
OPA derivatisation 
Harg Gradient elution, 40 min run time, ADMA and SDMA 
just separated 
Heresztyn 
et al (2004)153 
HPLC ADMA, SDMA, arg protein precipitation (SSA), 
cation exchange SPE, 
derivatisation with AccQ-FluorTM 
MMA Two extractions required 1) for ADMA & SDMA, 2) 
for arg. Gradient elution, run time approximately 40 
min. Excellent separation of ADMA and SDMA but 
poor separation of internal standard  from Harg. 
Sotgia et al 
(2008)154 
HPLC ADMA protein precipitation 
(acetonitrile), centrifugation,  
ninhydrin derivatisation, 
incubation with H2SO4 at 100 OC 
Harg Isocratic with 12 min run time. SDMA did not 
derivatise using the procedure described and was not 
detected. Good separation of ADMA form other peaks 
but poor separation of internal standard (Harg). 
Blackwell 
et al (2009)151  
HPLC ADMA, SDMA, arg, 
Harg 
cation exchange SPE, OPA 
derivatisation 
monoethylarginine Isocratic, 35 min run time, good separation of ADMA 
and SDMA. 
Tsikas et al 
(2003)159 
GC-MS/MS ADMA ultrafiltration, methylation 
(MeOH), derivatisation with 
PFPA/ethyl acetate 
ADMA methylated 
with CD3OD 
Approximately 15 min run time. sample and internal 
standard are not treated identically (separate 
methylation procedures). 
Albsmeier 
et al (2004)160 
GC-MS ADMA protein precipitation (acetone), 
derivatisation with 
PFPA/methanol 
ADMA-d6  * Approximately 9 min run time. Method applied to cell 
cultures as well as plasma. 
Huang et al 
(2003)155 
LC-MS, APCI ADMA, SDMA. arg protein precipitation (SSA), 
centrifugation 
Harg isocratic, run time 5 minutes.  Poor separation of 
ADMA and SDMA. Method applied to urine 
measurements but not plasma. 
Table 1.8. Methods for the analysis of plasma ADMA, 
 continued on following page 
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Reference Technique Analytes Measured Sample Preparation Internal Standard Comments 
Martens-
Lobenhoffer 
et al (2004)156 
LC-MS, ESI ADMA, SDMA, arg protein precipitation 
(acetonitrile), OPA derivatisation 
ADMA-d6 *, Harg, 
13C6-arg 
Gradient elution, 20 min run time. ADMA and SDMA 
fairly well separated. 
Martens-
Lobenhoffer 
et al (2006)158 
LC-MS, ESI ADMA, SDMA, arg protein precipitation 
(acetonitrile), OPA derivatisation  
ADMA-d6 *, 
homoarginine, 13C6-
arginine 
Gradient elution, 20 min run time. . ADMA and 
SDMA separated to baseline. 
Vishwanathan 
et al (2000)161 
LC-MS/MS, ESI ADMA, SDMA, MMA, 
arg 
protein precipitation 
(acetonitrile/TCA) 
13C6-arg Isocratic, 15 minute run time. Specific fragments used 
for monitoring ADMA (203 → 158) and SDMA (203 
→ 172). 
Kirchherr et al 
(2005)157 
LC-MS/MS, ESI ADMA, SDMA protein precipitation 
(acetonitrile/methanol), 
centrifugation 
leucine-d3 Gradient elution, 6 min run time. ADMA and SDMA 
separated to baseline. 
Schwedhelm 
et al (2005)164 
LC-MS/MS, ESI ADMA, SDMA, arg protein precipitation (acetone), 
derivatisation with butanol/HCl 
arginine-d7, ADMA-
d6 * 
Gradient elution,  run time 4 min. Specific fragments 
used: ADMA (259 → 214), SDMA (259 → 228). 
Martens-
Lobenhoffer 
et al (2006)162 
LC-MS/MS, ESI ADMA, SDMA, arg protein precipitation 
(acetonitrile/TFA/propionic 
acid), centrifugation 
ADMA-d6 * 
13C6-arginine 
Isocratic, run time 6 min. Specific fragments used for 
monitoring ADMA (203 → 46) and SDMA (203 → 
172). 
Schwedhelm 
et al (2007)165 
LC-MS/MS, ESI ADMA, SDMA. arg Protein precipitation (methanol), 
derivatisation with butanol/HCl, 
performed in microtitre plates. 
arginine-d7, ADMA-
d6 * 
Isocratic, run time 1.6 min. Specific fragments used 
for monitoring ADMA (259 → 214) and SDMA (259 
→ 228). 
Bishop et al 
(2007)163 
LC-MS/MS, ESI ADMA, arg ultrafiltration lysine-d4,  15N2-
arginine 
Gradient elution, run time 2 min. ADMA determined 
by specific fragment (203 → 46). 
Caussé et al 
(2000)166 
CE ADMA, arg dilution of sample in water 
(1/1000), FITC derivatisation 
Harg Run time approximately 11 min. ADMA and internal 
standard not completely resolved. 
Table 1.8. Methods for the analysis of plasma ADMA 
continued from previous page 
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A method using capillary electrophoresis with laser-induced fluorescence has been 
published166, samples being derivatised with fluoresceine isothiocyanate after precipitation 
of proteins with sulphosalicylic acid. The paper initially describes experiments with 
ADMA, SDMA and arginine, claiming good separation of the two dimethylarginines. 
Subsequent experiments and method evaluation were performed with modifications to the 
procedure in order to reduce analysis time; SDMA not being analysed. Inspection of the 
electropherograms published would suggest that with these modifications resolution of 
ADMA from the internal standard (Harg) was not complete. 
 
An ELISA for plasma ADMA is commercially available (DLD Diagnostika GmbH, 
Hamburg, Germany). In this method plasma ADMA is first acylated and then competes 
with ADMA bound to a microtitre plate for a limited number of rabbit anti-ADMA 
antiserum binding sites. After equilibrium has been achieved the plate is washed and the 
antibody-ADMA complex bound to the plate reacted with a second, peroxidase labelled, 
antibody (goat anti-rabbit). Quantitation is performed  using 3,3',5,5'-tetramethylbenzidine 
as peroxidase substrate. Evaluations of this method are conflicting. Valtonen et al167 
compared it with  an HPLC method and reported that there was no correlation between the 
two, whilst Širok et al168 in a similar comparison of ELISA with HPLC found a strong 
correlation between the two methods and claimed that the “HPLC method for ADMA 
determination can be replaced by ELISA which gives comparable results”. It is likely that 
the latter group did not correctly interpret their data as one of the figures they presented 
shows that the values they obtained using ELISA were approximately double that found by 
HPLC (the regression equation given: ELISA ADMA = 2.303 x HPLC ADMA - 0.1622). 
In another comparison study results obtained by  ELISA were approximately twice that 
obtained using LC-MS169, the authors also noted that the results of the ELISA method 
seemed to be strongly influenced by differences in sample matrix. 
 
In addition to the discrepancy in results obtained when using ELISA, it has also been 
reported that there is considerable variation in plasma ADMA concentrations obtained 
using different methods in general. In reviewing 41 published studies Horowitz and 
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Heresztyn145 noted that the mean plasma ADMA concentration of normal subjects ranged 
from 0.30 - 4.02 µmol/L, but also stated that "the majority of MS-based assays suggest the 
mean value for ADMA in 'normal' plasma lies within the range 0.36 - 0.60 mmol/L". 
 
The variation in results obtained using different methods has been attributed in part to poor 
chromatographic separation by some methods of ADMA and SDMA, and also due to the 
use of different sample preparation techniques coupled with a lack of appropriate internal 
standardisation143. Sample preparation techniques have included ultrafiltration, cation 
exchange solid phase extraction and protein precipitation using a variety of different agents 
including sulphosalicylic acid, acetonitrile, ethanol and acetone. The identification of 
suitable internal standards has been particularly problematic and some methods have not 
made use of internal standardisation. A number of methods have made use of either 
monomethylarginine or homoarginine, both of which are not ideal since they occur 
endogenously in plasma at variable concentration.  Isotopically labelled ADMA has only 
become available relatively recently (2007), but some groups have synthesised their own 
based on a method described by Pundak and Wilchek170 and subsequently modified by 
Albsmeier et al160. Isotopically labelled lysine and leucine have also been used as internal 
standards for the measurement of ADMA. Isotopically labelled SDMA is still not 
commercially available and its synthesis has not been described in methods for 
dimethylarginine determination. Chemical differences between an internal standard and an 
analyte may result in different behaviour between the two with regard to extraction, 
precipitation and derivatisation procedures and this is of particular importance when sample 
and standard matrix do not match. In addition analyte and internal standard may not ionise 
to the same extent in the mass spectrometer.  
 
There is currently no agreed reference method for the measurement of dimethylated 
arginines, reference materials for their standardisation or quality assurance programmes and 
until these are established it is unlikely that agreement of plasma ADMA results produced 
by the various methods will be reached. 
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1.4. Arterial Stiffness 
 
1.4.1. Overview 
 
Although the heart delivers blood to the circulatory system in a pulsatile fashion the elastic 
nature of the arteries dampens the pulse and this, combined with the high resistance of the 
smaller diameter peripheral blood vessels, results in an almost smooth continuous flow of 
blood through the tissue bed171.  
 
The pulse wave velocity (PWV) is mainly dependent upon the elasticity of the arterial wall 
and is described by the Moens-Korteweg equation172: 
   c0 = √(Eh/2Rρ) 
 
where c0 is the wave speed, E  is Young's modulus in the circumferential direction, h is the 
wall thickness, R is the vessel radius and ρ is the density of fluid. From this it may be seen 
that PWV is proportional to the square root of the Young's modulus of elasticity of the 
blood vessel and, put simplistically, the stiffer the blood vessel the faster the pulse wave 
travels.  The cellular and histological structure of arteries varies throughout the arterial tree, 
and also changes with age, the proximal arteries being more elastic than the distal173,174. 
 
In systole a pressure wave travels away from the heart through the arterial tree, this wave is 
reflected by bifurcation points creating a retrograde wave which travels back to the heart 
and, in young healthy individuals, reaches it in diastole. At any point in the arterial tree the 
blood pressure is due to the summation of pressures produced by the forward and reflected 
waves175. The fact that the retrograde wave reaches the heart in diastole is beneficial in that 
it enhances perfusion of the heart by the coronary arteries. In individuals with stiffer 
arteries the associated increase in pulse wave velocity results in the retrograde pulse wave 
reaching the heart in systole, rather than diastole, and increases the systolic pressure. The 
diastolic pressure is reduced resulting in impaired coronary perfusion171. 
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Arterial stiffness has been shown to increase with age176 and has also been shown to be a 
strong predictor, independent of other risk factors, for coronary events and stroke177,178,179 
and for mortality in both diabetes180 and end-stage renal failure181. 
 
1.4.2. Measurements of Arterial Stiffness 
 
Arterial stiffness can be measured regionally, systemically and locally182. In addition, 
analysis of the pulse waveform can be used to provide information about the nature of 
reflected waves. Carotid-femoral pulse wave velocity (CF-PWV), a non-invasive measure 
of regional arterial stiffness, has been described by a recent expert consensus document as 
being the 'gold standard' for determination of arterial stiffness183 and has been used for the 
majority of clinical studies. With this method the pulse waveform is determined 
transcutaneously at both the right common carotid artery and at the right femoral artery; the 
waveform being recorded using pressure, distension or Doppler measurements. The foot of 
each waveform, defined as being the end of diastole, is identified and the difference in time 
between the two (∆t) is calculated. The distance, D, between the two sites is measured over 
the body surface, usually with a tape measure, and the CF-PWV calculated as PWV = D/∆t 
(m/s). Some limitations to these measurements have been noted, the femoral waveform 
being sometimes difficult to record accurately in individuals with metabolic syndrome, 
diabetes and peripheral disease, and  the distance between carotid and femoral sites may be 
inaccurately measured in those with abdominal obesity182. 
 
Systemic measures of arterial stiffness rely on theoretical modelling of the arterial system, 
based on comparisons to electrical circuits containing elements of capacitance and 
resistance. The number of theoretical approximations they make have limited their 
usefulness in being applied to clinical settings183. 
 
Local arterial stiffness is determined by measuring the difference in blood vessel diameter 
between diastole and systole. Ultrasound devices are commonly used for measurements on 
superficial arteries, particularly the carotid artery; measurements on deep arteries such as 
the aorta have also been performed using magnetic resonance imaging182,183. These 
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techniques generally require video image analysis, which limits the precision of the 
measurements made.  High precision measurements of blood vessel diameter change can be 
made using echotracking devices. Local arterial stiffness measurements have the advantage 
in that they allow the determination of the Young's elastic modulus of the arterial wall but 
all the techniques suffer from the disadvantage in that they are more time consuming than 
measurements of pulse wave velocity and require a greater degree of technical expertise to 
perform183. In addition, although CF-PWV and locally determined carotid stiffness 
measurements general provide consistent information in healthy subjects, discrepancies 
have been noted for subjects with high blood pressure and/or diabetes184. Measurements of 
local arterial stiffness are therefore performed mostly for mechanistic rather than 
epidemiological studies. 
 
Analysis of the shape of the arterial pressure waveform allows determination of the 
augmentation index (AIx) a parameter giving information regarding the reflected pulse 
wave183. As mentioned previously, with increased arterial stiffness the reflected pulse wave 
reaches the heart in systole and adds to (augments) the systolic, rather than diastolic, 
pressure. The resulting arterial pressure wave form shows a point of inflection 
corresponding to the initial (forward) pressure wave and a peak corresponding to the sum of 
forward and retrograde pressure waves. The augmentation index, as a percentage, is 
calculated as the ratio of  pressure augmentation to pulse pressure (SP-DP). 
 
 
Ideally the arterial pressure waveform should be measured at the ascending aorta to truly 
represent the load imposed upon the left ventricle but, as this is difficult practically, 
measurements are usually made at the radial artery and a mathematical transform used to 
convert them to those that which would be seen at the aorta183. Measurements can be made 
at the common carotid artery, being close to the aorta a mathematical transform does not 
need to be applied to the waveform obtained, but a higher degree of technical expertise is 
required for its measurement as compared to measurement at the radial artery. The AIx has 
been shown to be of all-cause and cardiovascular mortality in end stage renal disease185 and 
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a predictor of cardiovascular events in patients undergoing percutaneous coronary 
interventions186. 
 
 
1.4.3. Homocysteine, and Arterial Stiffness 
 
Conflicting results have been demonstrated by studies investigating whether vascular 
dysfunction, as determined by arterial stiffness measurements, is associated with plasma 
homocysteine concentrations187,188,189,190,191,192 (table 1.8) however, these studies differed 
widely in the age of participants and the measures of arterial stiffness used. Also it should 
be noted that in all but one study191, plasma homocysteine concentrations were only mildly 
elevated. 
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Reference  Patient category and sample 
numbers 
Measures 
of arterial 
stiffness 
Age (years) Homocysteine (µmol/L) Conclusions 
Bortolotto 
et al 1999187 
Hypertensive patients with and 
without clinical vascular disease, 
n = 236 
CF-PWV 58 ± 13 no vascular disease: 13.6 ± 4.9, vascular 
disease present: 15.9 ± 5.3  
CF-PWV positively correlated with 
plasma homocysteine  
Woodside 
et al 2004188 
Young healthy adults, males = 
251, females = 238 
CF-PWV, 
CR-PWV, 
CT-PWV 
males: 22.4 ± 1.6, 
females 22.8 ± 1.7 
males: geometric mean = 9.47 ± 1.43, 
females: geometric mean = 9.10 ± 1.43 
no correlation between plasma 
homocysteine and any measure of 
PWV 
Tso et al 
2006189 
Chinese females with systemic 
lupus erythematosus, n = 58 
ba-PWV 40 ± 15 13.19 ±  6.10 ba-PWV positively correlated with 
plasma homocysteine for total patient 
group. When the group was subdivided 
according to the presence of 
anticardiolipin antibodies a positive 
correlation was observed for the 
antibody positive group but not the 
antibody negative group.  
Levy et al 
2007190 
Members of the Framingham 
Study offspring Cohort. 
Individuals were excluded on the 
basis of prior myocardial 
infarction or heart failure. Males: 
n = 856, females n = 1106. 
CF-PWV, 
CR-PWV 
males: 60.5 ± 9.8, 
females 61.1 ± 9.5 
Males: median = 8.5, IQR = 7.2 - 10.0, 
Females: median = 7.1, IQR = 5.9 - 8.8 
Males: CF-PWV, but not CR-PWV 
positively correlated with plasma 
homocysteine (p = 0.036). For females 
there was no correlation between 
plasma homocysteine and either CF-
PWV or CR-PWV). 
Ertek et al 
2009191 
Peritoneal dialysis patients, n = 60 CF-PWV 46.2 ± 13.2 27.2 ± 15.7 No association found between plasma 
homocysteine  and CF-PWV. 
Vyssoulis 
et al 2010192 
Normotensive controls, n = 31. 
Patients with isolated office 
hypertension, n = 480 and patients 
with essential arterial 
hypertension, n = 1188. 
CF-PWV  
AIx 
Normotensives: 45.8 ± 
1.0, 
isolated office 
hypertension: 
52.4 ± 0.6, 
arterial hypertension:  
52.4 ± 0.3 
Normotensives: 9.3 ± 0.2, 
isolated office hypertension: 10.5 ± 0.2,  
arterial hypertension:  11.7 ± 0.1 
CF-PWV correlated positively with 
plasma homocysteine when all three 
groups were combined and for each of 
the three groups separately. 
AIx correlated positively with plasma 
homocysteine when all three groups 
were combined, for the patients with 
isolated office hypertension and for 
patients with arterial hypertension but 
for normotensive controls. 
Table 1.9. Studies investigating  homocysteine and measures of arterial stiffness. 
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2. Experimental 
 
2.1. Materials 
 
Homocysteine method 
Dithiothrietol, D,L-homocystine, D,L-cystine, D,L methionine and HPLC grade acetonitrile 
were obtained from Sigma-Aldrich (Gillingham, Dorset, UK). D,L-homocystine-d8 and 
D,L-methionine-d3 were purchased from Promochem (Welwyn Garden City, Hertfordshire, 
UK). D,L-cystine-d4 was obtained from CK Gas Products (Wokingham, Berkshire, UK). 
Autonorm Human Liquid Control, level one, was purchased from Bio-Stat Ltd (Stockport, 
Cheshire, UK). Chromatography column: 3.3cm, 4.6mm id Supelcosil LC-CN column 
(Sigma-Aldrich, Gillingham, Dorset, UK). 
 
ADMA method 
Arginine, NG, NG-dimethylarginine hydrochloride, NG, NG´-dimethyl-L-arginine di(p-
hydroxyazobenzene-p´-sulfonate) salt, NG-methyl-L-arginine acetate salt, copper carbonate, 
cyanogen bromide activated Sepharose, dimethylamine, dimethylsulphate, 1,2-dimethyl-2-
thiopseudourea hydroiodide, 1,3-dimethyl-2-thiourea, N,N´-dimethylurea and Supelclean 
LC-SCX solid phase extraction tubes were purchased from Sigma-Aldrich (Dorset, UK). 
Formic acid and 0.1 M  HCl were obtained from VWR (Leicestershire, UK). Ammonia 
solution (35%) and HPLC grade methanol were purchased from Fisher Scientific 
(Leicestershire, UK). L-arginine-d7:HCl and L-ornithine-d2:2HCl were supplied by CK Gas 
Products LTD (Hampshire, UK). 
 
 
2.2. Reagents and Methods for Homocysteine Experiments 
 
Standards 
Plasma and urine standards were prepared by spiking commercially available controls with 
stock standard (500 µL stock standard to a final volume of 10 mL of control). AutonormTM 
Human Liquid Control, level one was used for preparing plasma standards and Lyphocheck 
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Quantitative Urine Control for preparing urine standards.  The added concentrations were 0, 
100, 200, 400 and 800 µmol/L for cysteine and 0, 10, 20, 40 and 80 µmol/L for 
homocysteine and methionine.  The actual concentrations of the working standards were 
determined by analysing each standard five times and calculating the endogenous 
concentration of the analytes by the standard additions principle.  Standards were frozen at 
-20 OC until use.   
 
Internal standard 
The internal standard was prepared by dissolving cystine-d4, homocystine-d8 and 
methionine-d3 in 20 mmol/L HCl, resulting in final concentrations of 1 mmol/L, 50 µmol/L 
and 100 µmol/L respectively, this was stored frozen at -20oC until use. The reducing agent, 
dithiothreitol (200 mmol/L) in 0.1 mol/L NaOH, was prepared just before use. The protein 
precipitating agent was prepared by the addition of 100 µL formic acid and 50 µL 
trifluoroacetic acid to 100 mL of acetonitrile. 
 
Sample preparation 
Samples were prepared by adding 50 µL of sample to 50 µL of internal standard, followed 
by 50 µL of reducing agent and, after mixing, these were left to stand at room temperature 
for 15 minutes. Protein precipitating agent (500 µL) was then added and, after mixing, the 
samples were centrifuged at 9000g for two minutes at which point the supernatant was 
removed and transferred to autosampler vials. 
 
Mass spectrometric analysis 
Ten microlitres of prepared sample was injected for analysis. The mobile phase consisted of 
acetonitrile:water (50:50 vol/vol) containing 0.1% formic acid and was pumped at a flow 
rate of 500 µL/min. The total analysis time was two minutes. The gas settings used with the 
mass spectrometer were, curtain gas (air) 40 psi, ion source gas 1 (nitrogen) 40 psi, ion 
source gas 2 (nitrogen) 60 psi and collision gas (nitrogen) 3 psi. The electrospray voltage 
was set to +5000 V and the nebuliser temperature to 500OC.  The parent/daughter 
transitions used to monitor each analyte and the associated potential settings are given in 
table 2.1; a dwell time of 100 ms was used for each transition. 
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Plasma methionine  
This was determined using an in-house HPLC method193. Plasma proteins were precipitated 
with ethanol (twice) and amino acids were then derivatised with PITC. The derivatives 
were separated on a C18 column using gradient elution and the derivatised amino acids 
detected by absorbance at 254 nm. Norleucine was used as internal standard.   
 
Urine cystine 
The method used for the determination of urine cystine was that used routinely in the 
Clinical Chemistry and Immunology Department at the Royal Sussex County Hospital, 
Brighton. Four mL of water (blank), standard (420 µmol/L cystine) or urine was added to 
1 g Amberlite IR-120(H) resin and mixed by inversion for five minutes, after which the 
liquid was removed from the resin and discarded. The resin was washed by adding four mL 
deionised water and mixing by inversion for five minutes. The water was removed and 
discarded. Three mL 3 mol/L ammonium hydroxide was added to the resin, and after 
mixing by inversion for a further five minutes, 1 mL of the ammonia solution was removed, 
transferred to a 1 mL plastic microcuvette and 500 µL of sodium cyanide (5% wt/vol) 
added. After fifteen minutes the absorbance of each solution was measured at 520 nm 
(abs1), 50 µL of sodium nitroprusside was added (5% wt/vol) and the absorbance at 
520 nm measured exactly 10 seconds later (abs2). The change in absorbance ∆abs (= abs2-
abs1) was calculated for each solution and the concentration calculated according to the 
following formula: 
 
 
Parent 
ion 
(m/z) 
Daughter 
ion 
(m/z) 
Declustering 
potential 
(V) 
Focusing 
potential 
(V) 
Entrance 
potential 
(V) 
Collision 
energy 
 (V) 
Collision cell 
entrance 
potential (V) 
Collision cell 
exit potential 
(V) 
homocysteine 136.0 90.1 26 50 7.5 17 6 4 
homocysteine-d4 140.1 94.1 26 50 7.5 17 6 4 
cysteine 122.0 76.0 11 360 7.5 19 6 4 
cysteine-d2 126.0 80.0 11 360 7.5 19 6 4 
methionine 150.0 103.8 11 360 6 15 6 16 
methionine-d3 153.0 107.1 11 360 6 15 6 16 
Table 2.1. Mass spectrometer settings for the analysis of homocysteine, cysteine and methionine. 
x  concentration of standard 
(∆abs standard - ∆abs blank) 
(∆abs sample - ∆abs blank) concentration in sample   = 
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2.3. Reagents and Methods for Methylated Arginine Experiments 
 
Stock standards. 
ADMA (10 mmol/L): 27.5 mg ADMA.2HCl dissolved in 10 mL 0.1 mol/L HCl. 
SDMA (10 mmol/L): 22.8 mg SDMA.di(p-hydroxyazobenzene-p'-sulphonate) salt 
dissolved in 3 mL 0.1 mol/L HCl. 
MMA (10 mmol/L): 24.8 mg MMA acetate dissolved in 10 mL 0.1 mol/L HCl. 
arginine (100 mmol/L): 870 mg arginine dissolved in 50 mL 0.1 mol/L HCl. 
 
Working Standards. 
For routine sample analysis four working standards were prepared by diluting stock 
solutions of ADMA, SDMA, MMA and arginine in 0.1 mol/L HCl and freezing portions of 
the standards at -20oC until used. 
 
The concentration of the working standards were: 
standard A 0.5 µmol/L ADMA, SDMA and MMA, 20 µmol/L arginine 
standard B 1.0 µmo/L ADMA, SDMA and MMA, 40 µmol/L arginine 
standard C 2.0 µmol/L ADMA, SDMA and MMA, 80 µmol/L arginine 
standard D 5.0 µmol/L ADMA, SDMA and MMA, 200 µmol/L arginine 
 
These values were considered suitable for analysis of plasma samples but the literature 
suggested that the concentration of ADMA and SDMA in urine would be considerably 
higher and so in all subsequent analyses urine samples were pre-diluted 1 in 10 in deionised 
water. 
 
Derivatising Agents. 
a) Borate buffer, 200 mmol/L: 2.473 g boric acid was dissolved in approximately 
180 mL deionised water and 5 mol/L sodium hydroxide then added to adjust the pH 
to 9.5.  The solution was made up to a final volume of 200 mL with deionised 
water.  
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b) OPA (35 mmol/L) / mercaptoethanol (75 mmol/L): 25 mg OPA was dissolved in 
500 µL methanol. Borate buffer, 4.5 ml, was then added followed by 26 µL 
mercaptoethanol. 
 
c) OPA  (35 mmol/L) / mercaptopropionylglycine (75 mmol/L): 25 mg OPA and 
61.2 mg mercaptopropionyl glycine were dissolved in 500 µl methanol and 4.5 ml 
borate buffer then added. 
 
d) OPA  (35 mmol/L) / 3-mercaptopropanol (75 mmol/L): 25 mg OPA was dissolved 
in 500 µl methanol. Borate buffer, 4.5 ml, was then added followed by 32.5 µL 
mercaptopropanol. 
 
e) OPA (35 mmol/L) / monothioglycerol (75 mmol/L): 25 mg OPA was dissolved in 
500 µL methanol. Borate buffer, 4.5 ml, was then added followed by 31 µL 
monothioglycerol. 
 
f) OPA (37 mmol/L) / 11-mercapto-1-undecanol (75 mmol/L): 27.5 mg OPA and 
80 mg 11-mercapto-1-undecanol were dissolved in 4 mL propan-2-ol and 1 mL 
acetonitrile and 200 µL triethylamine then added. 
 
g) NDA (37 mmol/L) / mercaptoethanol (75 mmol/L): 7.1 mg NDA was dissolved in 
1 mL acetonitrile. Triethylamine, 40 µL, and mercaptoethanol, 5 µL, were then 
added. 
 
NDA is very insoluble in aqueous solution and so the reagent preparation procedure that 
had been used for OPA reagents had to be modified. 
 
 
h) NDA (37 mmol/L) / monothioglycerol (75 mmol/L): 7.1 mg NDA was dissolved in 
1 mL acetonitrile. Triethylamine, 40 µL, and monothioglycerol, 5 µL, were then 
added. 
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i) PITC (40 mmol/L) : 5 µL PITC was added to 1 mL methanol and 40 µL 
triethylamine then added. 
 
PITC is very insoluble in aqueous solution and so the reagent preparation procedure that 
had been used for OPA reagents had to be modified. 
 
Derivatisation Procedures. 
i) For reagents a) - f) and i) derivatisation of amino acids was carried out by adding 
100 µL of derivatising reagent to 200 µL of standard. Derivatisation was allowed to 
proceed for at least five minutes before using the preparation. 
 
ii) For reagents g) & h) derivatisation of amino acids was carried out by adding 100 µL 
acetonitrile to 100 µL standard followed by 100 µL derivatising reagent. 
Derivatisation was allowed to proceed for at least five minutes before using the 
preparation. 
 
For the determination of MRM parameters 1 mL of derivatised standard was diluted in 
9 mL 50:50 MeOH : 0.1 % formic acid 
 
Synthesis of Isotopically Labelled ADMA, SDMA and MMA. 
Isotopically labelled ADMA, SDMA and MMA was not commercially available when this 
work began, although isotopically labelled arginine (as arg-d7) could be purchased 
commercially. Subsequently ADMA-d7 has become commercially available from 
Cambridge isotope laboratories. A method for the synthesis of isotopically labelled ADMA 
from labelled ornithine has been described by Albsmeier160, and this method was utilised 
here. Methods for the synthesis of SDMA194,  and MMA195,  had also been published and 
these were adapted to the synthesis of isotopically labelled internal standards. 
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An ornithine-d2 copper complex was used as the starting point for synthesis of all internal 
standards. The preparation of the complex was based upon that described by Albsmeier et 
al160. 
 
a) For each synthesis an ornithine-d2 copper complex was used as the starting point and this 
was prepared as follows: 20.6 mg ornithine-d2:2HCl was dissolved in 1 mL water. Small 
amounts of copper carbonate were added, with mixing, resulting in the development of a 
blue colour. Copper carbonate continued to be added until saturation was achieved and the 
intensity of the colour no longer increased. The ornithine-d2 copper complex preparation 
was centrifuged and the supernatant removed and stored at 4oC for later conversion into 
ADMA-d2, SDMA-d2 or MMA-d2. 
 
b) Synthesis of ADMA-d2: this was based upon the procedure described by Albsmeier et 
al160. In brief 0.5 g bromcyan-agarose was suspended in 10 mL of 1 mol/L HCl in methanol 
and mixed for 30 min. The bromcyan-agarose was then washed with 10 mL  of 1 mmol/L 
HCl and three times with 10 mL water. The ornithine-d2 complex prepared above (a) was 
added to the bromcyan-agarose and mixed overnight at 4oC. The mixture was then 
centrifuged, the supernatant removed and discarded and the bromcyan-agarose washed with 
10 mL 1 mol/L HCl and then three times with 10 mL water. The ornithine-d2 bromcyan-
agarose complex was suspended in 20 mL 20% dimethylamine and the mixture incubated 
at 50oC for 24 hr. The supernatant was then removed and dried under vacuum, reconstituted 
in methanol: water 50:50, centrifuged and the supernatant again dried under vacuum. The 
residue was dissolved in 10 mL 0.1 mol/L HCl to yield a stock solution. Analysis of the 
product by mass spectrometry confirmed the formation of ADMA-d2; no formation of 
ADMA, SDMA, MMA or arginine was detected. 
 
c) Synthesis of SDMA-d2: this was based upon a procedure described by Kakimoto and 
Akazawa194  for the synthesis of SDMA from ornithine. Dimethylsulphate (50 µL) was 
added to dimethylthiopseudourea (54 mg). The container was sealed and heated to 110oC 
for 30 min. The ornithine-d2 copper complex prepared above (a) was added along with 
100 µl 5M NaOH  and 9 ml water. The mixture was then incubated at 30oC for three days. 
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The mixture was centrifuged and the supernatant removed and dried under vacuum, 
reconstituted in methanol: water 50:50, centrifuged and the supernatant again dried under 
vacuum. The residue was dissolved in 10 ml 0.1 M HCl to yield a stock solution. Analysis 
of the product by mass spectrometry confirmed the formation of SDMA-d2; no formation of 
ADMA, SDMA, MMA or arginine was detected. 
 
d) synthesis of methylarginine-d2: this was based upon a procedure described by Corbin 
and Reporter195 for the synthesis of methylarginine from ornithine. To the ornithine-d2 
copper complex prepared above (a), 2 mL of 35% ammonia solution and 23.2 mg 1,2-
dimethyl-2-thiopseudourea was added. The mixture was then incubated at 25oC for 24 hr. 
The mixture was then centrifuged and the supernatant removed and dried under vacuum, 
reconstituted in methanol: water (50:50), centrifuged and the supernatant again dried under 
vacuum. The residue was dissolved in 10 mL 0.1 mol/L HCl to yield a stock solution. 
Analysis of the product by mass spectrometry confirmed the formation of MMA-d2; no 
formation of ADMA, SDMA, MMA or arginine was detected. 
 
Internal standard for routine use. 
For routine analysis of plasma and urine samples a working internal standard solution was 
prepared by diluting the stock internal standard in 0.1 mol/L HCl. to give final 
concentrations of 20 µmol/L for ADMA-d2, SDMA-d2 and MMA-d2 and 200 µmol/L for 
arginine-d7. 
 
Solid Phase Extraction 
The extraction procedure was carried out by using a ten column solid phase extraction 
(SPE) manifold connected to a water pump. Samples were initially acidified by the addition 
of 1 mL of 0.1 mol/L HCl to 50 µL of working internal standard solution and 200 µL of 
plasma or urine sample; urines having been pre-diluted with deionised water (1 part urine: 9 
parts water). Strong cation exchange solid phase extraction (SPE) columns were 
conditioned by washing with two reservoirs of methanol (approximately 1.2 mL each) 
followed by washing with two reservoirs of 0.1 mol/L HCl. The acidified samples were 
applied to the SPE columns and drawn through under reduced pressure with the flow rate 
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being maintained at approximately 1 mL/min. The SPE columns were then washed with 
two reservoirs of deionised water followed by two reservoirs of methanol. Analytes were 
then eluted from the SPE columns using 1 mL of ammonia/methanol (1 part 35% ammonia 
solution : 4 parts methanol), with this being drawn through the SPE columns under reduced 
pressure with the flow rate being maintained at approximately 1 mL/min. The eluates were 
dried under vacuum and then reconstituted in 1 mL of 0.1% formic acid. 
 
 
Mass spectrometric analysis 
Twenty microlitres of prepared sample was injected for analysis. The mobile phase 
consisted of 0.1% formic acid and was pumped at a flow rate of 500 µL/min. The total 
analysis time was three minutes. The gas settings used with the mass spectrometer were, 
curtain gas (air) 40 psi, ion source gas 1 (nitrogen) 10 psi, ion source gas 2 (nitrogen) 0 psi 
and collision gas (nitrogen) 4 psi. The electrospray voltage was set to +5000 V and the 
nebuliser temperature to 500OC. The parent/daughter transitions used to monitor each 
analyte and the associated potential settings are given in table 2.2; a dwell time of 500 ms 
was used for each transition. 
 
 
 
 
 
 
Parent 
ion 
(m/z) 
Daughter 
ion 
(m/z) 
Declustering 
potential 
(V) 
Focusing 
potential 
(V) 
Entrance 
potential 
(V) 
Collision 
energy 
 (V) 
Collision cell 
entrance 
potential (V) 
Collision cell 
exit potential 
(V) 
ADMA 203.0 46.3 26 360 8 37 13.6 0 
ADMA-d2 205.0 46.3 26 360 8 37 13.6 0 
SDMA 203.0 172.0 31 220 6.5 17 12.0 30 
SDMA-d2 205.0 174.0 31 220 6.5 17 12.0 30 
MMA 189.0 70.1 41 210 6.5 33 13.6 0 
MMA-d2 191.0 72.1 41 210 6.5 33 13.6 0 
arginine 175.1 70.1 31 60 8.5 31 12.0 2 
arginine-d7 182.1 77.1 31 60 8.5 31 12.0 2 
Table 2.2. Mass spectrometer settings for the analysis of arginine and methylated arginines. 
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2.4. The API Sciex 2000 Mass Spectrometer 
 
 
The mass spectrometer used throughout the course of these studies was a Perkin-Elmer 
Sciex API 2000 triple quadrupole mass spectrometer, fitted with an electrospray ion source 
and coupled to a Perkin-Elmer HPLC autosampler and micropump (series 2000), this is 
shown schematically in figure 2.1. 
 
Sample is injected by the autosampler into the mobile phase, pumped to the mass-
spectrometer and sprayed into the electrospray ion source where, with the application of a 
high voltage, small charged droplets are formed. As the droplets evaporate (assisted by the 
application of heat) ions are ejected and are attracted by an applied voltage into the first 
quadrupole of the mass spectrometer (Q1), (figure 2.2.a). In Q1 the trajectories of the ions 
are manipulated by the further application of electric fields, and only ions of a selected 
charge to mass ratio (m/z) pass straight through to the second quadrupole (collision cell, 
Q2) (figure 2.2.b). In Q2 the ions collide with gas molecules (nitrogen) which, in addition 
to the application of electrical energy by the quadrupole, results in fragmentation of the ion 
(figure 2.2.c). The ion fragments pass to the third quadrupole where a particular fragment is 
selected according to its mass to charge ratio and is allowed to pass through to the detector.  
Software provided with the mass-spectrometer (Analyst-NT software) allows processing of 
the signal generated, and quantitation of results. The software provides facilities (Autotune 
facility) for the automatic determination of the energies, and mass spectrometer settings, 
required to produce the individual fragments. 
 
 
 
 
 
 
HPLC system and 
autosampler. 
Electrospray 
ion source/ 
nebuliser 
Quadrupole 
one (Q1). 
Ion selection 
Quadrupole 
two (Q2). 
Collision cell. 
Quadrupole 
three (Q3). 
Ion selection 
Detector 
Figure 2.1.  Schematic diagram of the API 2000 mass spectrometer. Sample is injected by the autosampler into 
the mobile phase and pumped to the mass-spectrometer. Small charged droplets are formed by the 
electrospray-ion-source/nebuliser. Ions of interest are selected according to their mass/charge ratio by the first 
quadrupole and pass to the second quadrupole where they are fragmented. Specific ion fragments are selected 
by the third quadrupole, again based on their mas to charge ratio, and are allowed to pass to the detector. 
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formation 
Evaporation Ion 
ejection 
To mass 
analyser 
(Q1) 
Ion with selected m/z 
pass straight through 
Ions with incorrect m/z 
thrown off original path 
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Ion fragments pass to 
third quadrupole (Q3) 
Figure 2.2. Ionisation, mass selection and fragmentation within the mass spectrometer. a) Injected sample 
is pumped to the electrospray ion source where if forms a spray of small charged droplets, which 
evaporate and eject ions which are then drawn by an electric field into the first quadrupole of the mass 
spectrometer. b) The trajectories of the ions are manipulated with electric fields and only those of the 
selected mass to charge ratio pass straight through. c) energy from the collision cell (quadrupole 2) and 
collisions with nitrogen molecules energise the ions, rendering them unstable and causing fragmentation. 
a) 
b) 
c) 
hot gas 
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3. Development of a Tandem-Mass Spectrometric Method for the Determination 
 of Homocysteine, Cysteine and Methionine in Plasma and Urine. 
 
3.1. Background 
 
Plasma total homocysteine had been measured routinely in the Clinical Chemistry and 
Immunology Department at the Royal Sussex County Hospital since 1992, using an in-
house HPLC method based upon that of Ubbink71. The method was laborious and time 
consuming, 20 samples taking more than two hours to prepare and approximately five 
hours for HPLC analysis, and as routine requests for homocysteine analysis continued to 
increase so an alternative method of analysis was sought. The department had recently 
taken possession of a bench-top tandem mass spectrometer (Applied Biosciences API Sciex 
2000) and this, together with a publication describing the measurement of plasma total 
homocysteine by tandem mass spectrometry (Magera et al92), offered the possibility of 
developing a fast and simplified method for plasma homocysteine and related analytes. 
 
3.2. Method Development and Optimisation 
 
3.2.1. Determination of Fragmentation Patterns 
 
The parent/daughter transitions for cysteine, homocysteine and methionine, along with the 
optimal potential settings for each, were determined by infusing a 10 µmol/L solution of 
each analyte at a flow rate of 5 µL per minute and using the AutoTune algorithm provided 
with the system software. The fragmentation patterns obtained for homocysteine, cysteine 
and methionine are shown in figures 3.1, 3.2, and 3.3. 
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Figure 3.1. The mass spectrometric fragmentation pattern for homocysteine. This 
was determined by infusing a 10 µmol/L solution of homocysteine (containing 
0.1% formic acid) into the mass spectrometer at a flow rate of 10 µL/min and 
scanning on the third quadropole. Homocysteine was produced by reduction of  
homocystine with DTT. The fragments were identified automatically by the mass 
spectrometer software. 
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Figure 3.2. The mass spectrometric fragmentation pattern for cysteine. This was 
determined by infusing a 10 µmol/L solution of cysteine (containing 0.1% formic 
acid) into the mass spectrometer at a flow rate of 10 µL/min and scanning on the 
third quadropole. Cysteine was produced by reduction of cystine with DTT. The 
fragments were identified automatically by the mass spectrometer software. 
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Figure 3.3. The mass spectrometric fragmentation pattern for methionine. This 
was determined by infusing a 10 µmol/L solution of methionine (containing 
0.1% formic acid) into the mass spectrometer at a flow rate of 10 µL/min and 
scanning on the third quadropole. The fragments were identified automatically 
by the mass spectrometer software. 
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3.2.2. Nebuliser Optimisation. 
 
Optimal nebulizer conditions were determined by repeat injection of 10 µL of a 10 µmol/L 
solution of homocysteine and stepwise variation of individual gas flows. The results 
obtained for the optimisation of the heater gas (gas source 2) are shown in figure 3.4 as an 
example of this process. The optimum conditions found were: curtain gas (air) 40 psi, ion 
source gas 1 (nitrogen) to 40 psi, ion source gas 2 (nitrogen) 60 psi and collision gas 
(nitrogen) 3 psi. The electrospray voltage was set to 5000 V.   
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GS2 = 60 psi 
Figure 3.4. Optimisation of the heater gas. Ten microlitres of a 10 µmol/L solution of 
homocysteine was injected by the autosampler at 30 second intervals. The mass spectrometer 
was set to monitor the parent/daughter transition corresponding to homocysteine (m/z 136→90), 
and the pressure of the heater gas (GS2) was increased in 10 psi increments. The optimum gas 
pressure was determined as that which gave the greatest counts per second (height). 
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3.2.3. Temperature Optimisation and Effect on Suppression 
 
The extent to which the analyte signal might be suppressed by other plasma constituents, 
and how this was affected by nebulizer temperature, was determined by monitoring the 
signal generated by an internal standard in both an aqueous preparation and a plasma 
preparation. Initially three solutions were prepared.  Solution A consisted of 400 µL plasma 
and 200 µL reducing agent, solution B 400 µL internal standard and 200 µL reducing agent 
and solution C 400 µl deionised water and 200 µL reducing agent. After 15 minutes 2 mL 
of the protein precipitating agent was added to each, and  after centrifugation equal parts of 
A and B were mixed for the plasma preparation and equal parts of B and C mixed for the 
aqueous preparation.  The nebulizer temperature was set to 250 OC and the aqueous 
preparation injected five times, followed by five injections of the plasma preparation. The 
injection sequence was repeated with 50OC increments in nebulizer temperature over the 
range 250-500 OC, allowing twenty minutes between each series for temperature 
equilibration (figure 3.5). 
 
For cysteine-d2, the mean signal obtained in the plasma preparation was 90% of that 
obtained for the aqueous preparation.  For homocysteine-d4 and methionine-d3 it was 80%. 
There was no association between suppression and temperature (one-way ANOVA; 
cysteine p = 0.167, homocysteine p = 0.455, methionine p = 0.657). Increasing temperature 
produced an increase in absolute signal reaching a plateau at approximately 450OC. 
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3.3. Method Validation 
 
3.3.1. Linearity Studies 
 
Preliminary experiments to assess the linearity of the method were carried out using 
aqueous standards, the concentration of the highest standard (following reduction) being 
2000 µmol/L cysteine, 200 µmol/L homocysteine and 2000 µmol/L for methionine. 
Although the standard curves for homocysteine and methionine were linear for the 
concentration range examined a distinctly curved response was obtained for cysteine. The 
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Figure 3.5. The effect of temperature on nebulisation and suppression. A solution of 
internal standard was prepared in water and plasma, and then each preparation was 
analysed by the mass spectrometer five times at each temperature, the latter being 
increased from 250OC, in 50OC increments, with twenty minutes being allowed between 
temperature changes for thermal equilibrium to be reached. For clarity only the results 
for the aqueous preparation are shown. 
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cause of this alinearity was determined as being due to isobaric interference of the internal 
standard, cysteine-d2, by cysteine. Of the cystine isotopes available, cystine-d4, which on 
reduction yields cysteine-d2, had been chosen for use as one of the internal standards, partly 
on considerations of cost. A close examination of the molecular weight distribution for 
cysteine, taking into account the relative abundances of the naturally occurring isotopes, 
showed that whilst the predominant form of cysteine has a molecular weight of 121 
approximately 5% of naturally occurring cysteine has a molecular weight of 123, the same 
as the predominant form of the labelled internal standard. The relatively high proportion of 
cysteine with a molecular weight of 123 is due to the fact that sulphur naturally exists as 
two isotopes, 16S32 and 16S34, with relative abundances of 95.0% and 4.2% respectively. 
Cysteine, and other substances containing one sulphur atom, therefore also exists mainly in 
two molecular weight forms in approximately the same proportions.  This does not in itself 
cause problems with quantitation since standards and samples will both contain the same 
isotopic forms in the same relative proportions. Problems do arise though with internal 
standardisation as approximately five percent of cysteine has a molecular weight of 123, the 
same as the major form of cysteine-d2 and both of these ionise and fragment in the mass 
spectrometer to produce a daughter ion of the same mass, the minor cysteine component 
therefore produces an isobaric interference with the major cysteine-d2 component. This 
difficulty was overcome by using the higher molecular weight form of cysteine-d2 for 
internal standardisation. 
 
Further linearity studies were performed using aqueous, plasma and urine based standards. 
The plasma and urine standards were prepared by first producing a stock standard 
containing 20 mmol/L cystine (equivalent to 40 mmol/L cysteine after reduction), 
2 mmol/L homocystine (equivalent to 4 mmol/L homocysteine after reduction) and 
40 mmol/L methionine in 0.1 mol/L HCl.  Standards were prepared in HCl as cystine is 
poorly soluble in water. Intermediate standards were prepared by further dilution of stock 
standard in 0.1 mol/L HCl. Finally working standards were prepared by addition of 
intermediate standard (50 µL) to either pooled plasma (950 µL) or pooled urine (950 µL). 
All standards were analysed in triplicate, in random order, within one batch.  The linearity 
of the method was determined as being to at least 2000 µmol/L for cysteine, 200 µmol/L 
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for homocysteine and 2000 µmol/L for methionine for both plasma and urine. A 
chromatogram for a typical plasma sample is shown in 3.6 and the standard curves obtained 
for the aqueous, plasma and urine based standards are shown in figures 3.7, 3.8, and 3.9. 
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Figure 3.6. An example of a typical chromatogram of a plasma sample, 
analysed as described on p43. 
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Figure 3.8. Standard curves for cysteine. For plasma and urine standards, pooled 
plasma or urine was spiked with an aqueous standard (19 parts plasma or urine:1 part 
standard). All standards were analysed in triplicate, in random order. The results for 
each standard are plotted individually, but many points are coincidental. 
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Figure 3.7. Standard curves for homocysteine. For plasma and urine standards, pooled 
plasma or urine was spiked with an aqueous standard (19 parts plasma or urine:1 part 
standard). All standards were analysed in triplicate, in random order. The results for 
each standard are plotted individually, but many points are coincidental. 
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3.3.2. Precision 
 
Within-batch and between-batch precision was determined at three concentrations using 
pooled human plasma or pooled human urine (with stock standard added to the plasma or 
urine pool for the intermediate and high concentrations).  Twenty replicates were analysed 
in each case.  Results for within batch-precision and between batch-precision are shown in 
table 3.1. 
 
 
 
 
 
Figure 3.9. Standard curves for methionine. For plasma and urine standards, pooled 
plasma or urine was spiked with an aqueous standard (19 parts plasma or urine:1 part 
standard). All standards were analysed in triplicate, in random order. The results for 
each standard are plotted individually, but many points are coincidental. 
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Sample type Analyte Within-batch Between-batch 
 
 Mean 
(µmol/L) 
%CV Mean 
(µmol/L) 
%CV 
Plasma homocysteine 10.1 3.5 10.7 9.1 
  33.5 3.3 32.1 5.8 
  63.4 3.1 62.6 5.6 
      
 cysteine 310 4.9 323 10.5 
  538 3.9 653 14.1 
  835 4.0 1117 14.4 
      
 methionine 30.6 2.9 30.4 11.1 
  50.0 3.7 49.5 11.8 
  80.2 3.2 83.0 12.7 
      
Urine homocysteine 11.5 4.5 10.8 7.5 
  63.0 2.5 59.7 5.3 
  108.9 2.5 104.5 5.2 
      
 cysteine 319 4.2 313 7.7 
  832 3.8 802 3.0 
  1296 4.1 1260 7.0 
      
 methionine 6.5 5.2 6.7 14.8 
  60.0 3.4 54.5 4.6 
  107.7 3.1 99.6 5.8 
 
 
 
 
 
3.3.3. Recovery 
 
Samples for recovery studies were prepared by adding stock standard (at two different 
concentrations) or 0.1 mol/L HCl to twenty different plasma and twenty different urine 
samples (20 µL standard to 180 µL plasma, 50 µL standard to 950 µL urine).  Each 
preparation was analysed in duplicate.  The effects of using HCl as diluent rather than water 
was examined by using ten different plasma samples, splitting each into two portions, and 
adding 0.1 mol/L HCl to one portion and deionised water to the other (50 µL 0.1 mol/L 
HCl or water, 950 µL plasma). No statistically significant difference was observed in 
adding 0.1 mol/L HCl to samples as compared with deionised water (Student’s paired 
Table 3.1. Within- and between-batch precision for plasma and urine total 
homocysteine, total cysteine and methionine. Pooled plasma or urine was used for the 
low value samples. For intermediate and high values, pooled plasma or urine was spiked 
with an aqueous standard (1 part standard to 19 parts plasma or urine). Twenty 
replicates were analysed at each concentration. 
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t-test: p = 0.73 for cysteine, p = 0.48 for homocysteine and p = 0.15 for methionine). The 
results of the recovery experiment are shown in table 3.2.  The use of aqueous standards led 
to a lower mean recovery compared to using matrix-matched standards (by approximately 
5% for all analytes) and so for comparison studies and the routine analysis of samples 
matrix-matched standards were used. 
 
 
 
 
 
In a review of tandem mass spectrometric methods for the analysis of homocysteine58 the 
above results for recovery and precision compared well with other similar methods (table 
3.3). 
 
 
 
Sample 
type 
Analyte Added concentration 
(µmol/L) 
Aqueous standards Matrix matched standards 
   Mean recovery (%) %CV Mean recovery (%) %CV 
Plasma homocysteine  20 93.1 4.4 100.9 4.3 
   50 93.9 3.2 101.8 3.2 
       
 cysteine  200 94.6 10.1 97.0 10.1 
   500 97.6 6.1 100.1 6.0 
       
 methionine  20 94.7 8.6 102.7 8.6 
   50 93.4 4.4 101.1 4.4 
       
Urine homocysteine  20 94.2 4.1 97.5 4.1 
   50 90.6 4.9 93.7 5.0 
       
 cysteine  200 92.5 9.5 103.7 9.5 
   500 89.7 7.6 100.5 7.5 
       
 methionine  20 92.5 3.8 97.3 3.7 
   50 89.5 5.4 94.2 5.4 
       
Table 3.2. Recovery of homocysteine, cysteine and methionine from plasma and urine. Baseline 
samples were prepared by the addition of 0.1 mol/L HCl, spikes by the addition of standard in 0.1 
mol/L HCl (1 part HCl or standard to 19 parts sample). Homocystine and cystine were used for 
preparation of standards, with homocysteine and cysteine being subsequently generated by reduction 
of samples with DTT. Twenty samples were prepared at each concentration and were analysed in 
duplicate. The results were calculated using both aqueous and matrix matched standards. 
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3.3.4. Limits of Detection and Quantitation 
 
The limit of detection and limit of quantitation were determined by analysing ten sample 
blanks (water in place of sample). The signal (baseline) obtained from each analysis was 
integrated using Analyst-NT software to obtain a measure of noise. The  limit of detection 
was  then calculated as 3 x blank sd and the limit of quantitation as 10 x blank sd. The 
limits of detection for homocysteine, cysteine and methionine were 0.2 µmol/L, 0.5 µmol/L 
and 0.2 µmol/L respectively, while the limits of quantitation were 0.4 µmol/L, 0.9 µmol/L 
and 0.4 µmol/L respectively. 
 
 
Reference, year of 
publication 
Mean recovery 
(%) 
Mean between batch  
precision, %cv (number) 
Mean within batch 
precision, %cv (number) 
Hempen et al102, 2008 97.5 (4) 2.3 (20) 5.0 (12) 
Li et al, 2008196 98.6 3.2 4.0 
Huang et al99, 2007 102 4.9 (45) not given 
Rafi et al100, 2007 101.1 (12) 4.5 (9) 5.8 (27) 
Weaving et al197, 2006 101.4 (20) 3.3 (60) 6.8 (60) 
Kuhn et al98, 2005 94.7 not given not given 
Tuschl et al97, 2005 79.8 10.2 (10) 11.5 (5) 
Nelson et al96, 2005 not given 2.1 (2) 6.0 (6) 
Nelson et al94, 2003 not given 3.6 (60) not given 
McCann et al95, 2003 not given 6.0 (10) 10.3 (10) 
Magera et al92, 1999 96.0 4.3 (18) 4.1 (18) 
Table 3.3. Precision and recovery data for published methods for the analysis of plasma homocysteine by 
tandem mass spectrometry. Adapted from Rafii et al58. 
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3.3.5. Homocysteine method comparison. 
 
Comparison studies for plasma total homocysteine were performed on two different types 
of analyser.  The Drew Scientific Ltd DS 30 is an enclosed automated HPLC system (Drew 
Scientific Ltd, Barrow-in-Furness, UK) using pre-column derivatisation with ammonium 
7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBDF) and fluorescence detection. This 
analyser was chosen because it gave comparable results to our previously used in-house 
HPLC system. The IMx analyser (Abbott Diagnostics, Maidenhead, UK) uses an enzymic 
reaction to first convert homocysteine to adenosyl homocysteine which is then measured 
using fluorescence polarisation immunoassay. Both the commercial systems were 
calibrated and used to assay plasma samples according to the manufacturer’s instructions. 
The results of the comparisons are shown in figures 3.10. and 3.11.  
 
 
Figure 3.10. Comparison of plasma total homocysteine results 
obtained by mass spectrometry and by HPLC (Drew 30). 
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Plasma total homocysteine measured by tandem mass spectrometry produced results higher 
than those produced by either the Drew analyser or the Abbot IMx analyser. The respective 
Deming regression equations were: MS = 1.06 HPLC - 0.01, and MS = 1.10 IMx - 0.43. 
Others have also reported discrepant  results between methods and inspection of external  
quality assessment scheme reports for homocysteine shows that between-laboratory 
comparability is problematic. 
 
The inter-method differences may be due in part to the use of different calibration materials 
and procedures. The LC-MS/MS method employs matrix-matched homocystine standards 
whilst the Drew DS 30 uses an  aqueous homocysteine calibrant. 
 
For the IMx method calibration is not performed using homocysteine but 
adenosylhomocysteine is used instead. Plasma samples are initially treated enzymically to 
Figure 3.11. Comparison of plasma total homocysteine results 
obtained by mass spectrometry and by FPIA (Abbot IMx).  
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convert homocysteine to adenosylhomocysteine, but this step is not required for the 
calibrants. Not only are there issues regarding the material used for calibration but samples 
and standards are not subject to identical steps. 
 
Although the comparison studies were only performed using matrix matched standards for 
the MS assay the possible effects of having used aqueous standards may be modelled using 
the results of the recovery experiments detailed above. In these experiments the mean 
recovery of homocysteine added to plasma was 93.5% when aqueous standards were used 
for calibration and 101.4% when matrix matched standards were used. If these values are 
representative of the general behaviour of plasma samples with regard to the use of 
different calibration procedures in the MS assay, then they may be used to ‘recalculate’ the 
results obtained to give values that would be expected had aqueous standardisation been 
used. When this is performed there is much closer agreement between the MS method and 
both the Drew 30 and IMx methods, the Deming regression equations becoming:  
MS = 0.98 HPLC + 0.01, and MS = 1.02 IMx - 0.39 (figures 3.12 and 3.13).  
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Figure 3.12. Comparison of plasma total homocysteine results obtained by mass spectrometry to 
those obtained using HPLC (Drew 30), after adjusting for calibration effects. The results obtained 
by mass spectrometric analysis were recalculated, using results obtained from the recovery 
experiments, to simulate the effect of using aqueous standards instead of plasma based standards. 
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At the moment, a universally agreed  reference material for the calibration of plasma 
homocysteine  assays is not available 
 
3.3.6. Methionine method comparison. 
 
For comparison of plasma methionine, samples were analysed by an in-house HPLC based 
amino acid screening system. As all the samples available for analysis had methionine 
concentrations falling within a narrow range, the methionine concentration of some samples 
was increased by 50, 100, 150 or 200 µmol/L (five of each) by the addition of 50 µL 
standard to 950 µL sample. Methionine measurements by tandem mass-spectrometry was 
approximately 30% higher than measurements by HPLC, the Deming regression equation 
for the comparison being MS = 1.34 HPLC - 5.85. The results of the comparison are shown 
in figure 3.14.  
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Figure 3.13. Comparison of plasma total homocysteine results obtained by mass spectrometry to 
those obtained using FPIA (Abbot IMx), after adjusting for calibration effects. The results obtained 
by mass spectrometric analysis were recalculated, using results obtained from the recovery 
experiments, to simulate the effect of using aqueous standards instead of plasma based standards. 
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The HPLC method serves as a first-line screening test to detect abnormal amino acid 
patterns in sick neonates and not as a quantitative amino acid analyser. With this method, 
plasma proteins are first precipitated with ethanol and then the amino acids are derivatised 
with phenylisothiocyanate; nor-leucine is used as internal standard, which may behave very 
differently from methionine with regard to precipitation and derivatisation. The method is 
calibrated with an aqueous standard which may also behave differently to plasma samples. 
No recovery data was available for this method. A series of aqueous and plasma standards 
analysed by HPLC gave calibration curves with gradients in the ratio 1:1.43 
(plasma:aqueous). Therefore, it is likely that the HPLC method shows poor recovery for 
plasma methionine, and this could account for the difference in the measurements obtained 
by mass spectrometry. 
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Figure 3.14. Comparison of plasma methionine results obtained 
by mass spectrometry and by an in-house HPLC method193. 
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3.3.7. Cysteine method comparison. 
 
Urine cysteine comparisons were carried out using an in-house colorimetric assay based on 
the cyanide-nitroprusside reaction. Results are shown in figure 3.15. Urine cysteine 
measurements obtained by mass spectrometry were consistently lower than those obtained 
by the colorimetric assay, the Deming regression equation being: 
MS = 0.86 colorimetric - 69.3. 
 
Although useful for detecting and monitoring cystinuria, the cyanide-nitroprusside reaction 
is known to suffer from a number of interferences and is probably best regarded as a 
semiquantitative assay, and this may account for the lack of agreement between the two 
methods. Plasma cysteine was also measured by LC-MS/MS, but the results were not 
subjected to a comparative procedure since no routine method was available.  
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Figure 3.15. Comparison of urine cysteine results obtained by 
mass spectrometry and by an in-house colorimetric assay. 
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3.4. Conclusion 
 
A method for the simultaneous measurement of total homocysteine, total cysteine and 
methionine in plasma and urine has been described. Results obtained by mass spectrometry 
for plasma homocysteine compare with accredited commercially available kits (Drew DS 
30 HPLC and Abbott IMx immunoassay). The technique requires only 50 µL of plasma, is 
relatively fast and uses less expensive reagents than the commercial systems. The 
simultaneous assay of methionine helps distinguish cystathionine beta synthase deficiency 
from other causes of hyperhomocysteinaemia and the replacement of a routine assay for the 
determination of urinary cystine that utilizes sodium cyanide with a more specific and less 
hazardous method is an additional benefit. 
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4. Development of a Tandem-Mass Spectrometric Method for the 
 Determination of Arginine and Methylated Arginines in Plasma and Urine. 
 
4.1. Method Development 
 
4.1.1. Initial Considerations 
 
The aim was to develop a method that would ideally measure ADMA, SDMA, MMA and 
arginine simultaneously and which was sufficiently accurate and precise to allow for the 
reliable interpretation of the results in clinical practice. Consideration was also given to the 
routine working practises of the department in which the method was to be used. A method 
using an isocratic mobile phase would be more convenient over a method requiring 
gradient separation, as one of the two solvent lines of the HPLC system attached to the 
mass spectrometer was in regular use for other analyses, short run times would enable a 
greater sample throughput and the preparation of samples should be as quick, simple and 
robust as possible so that the method could be performed by a variety of staff with differing 
levels of skill. Methods for the analysis of dimethylarginines have been reviewed in section 
1.3.5 and many of these have made use of OPA derivatisation to facilitate the 
chromatographic separation of ADMA and SDMA but have disadvantages that include 
long run times and the need for gradient elution, nevertheless derivatisation by OPA was 
thought to be a useful starting point for the development of a tandem mass spectrometric 
method. 
 
4.1.2. The Use of O-phthaldialdehyde 
 
The fragmentation patterns of OPA-ADMA and OPA-SDMA were obtained by 
derivatising 1 mmol/L solutions of ADMA and SDMA (separately),  as described in section 
2.3 (figure 4.1). The derivatised amino acids were diluted 1/10 in 0.1% formic acid and 
then infused into the mass spectrometer at 5 µL/min. The infused solutions were initially 
scanned using only the first quadrupole of the mass spectrometer (Q1 scan) over the mass 
range 300 – 400 amu to ensure that the predicted product, m/z = 379, had indeed been 
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formed. This peak was observed in the Q1 scan but two others, with m/z = 319 and 
m/z = 334, were also seen. In comparing the Q1 scans obtained for OPA-ADMA and OPA-
SDMA to that obtained from infusing a blank solution consisting of OPA reagent diluted in 
0.1% formic acid, it was apparent that these additional peaks were not associated with 
contaminants in the reagents but were additional products being formed by the 
derivatisation of dimethylated arginines. The Autotune software facility (section 2.4.) was 
used for determining the fragmentation of each of the products. On examining the 
fragmentation patterns obtained it was noted that there appeared to be the production of 
three parent/daughter combination which were unique to ADMA (m/z: 378.9 → 230.1, 
378.9 → 257.2, and 378.9 → 290.2) and  also  two parent/daughter combinations which 
were unique to SDMA (m/z 378.9 → 205.2 and 378.9 → 244.2) . There were no unique 
daughter ions observed for the parent ions with m/z 319 and 334. 
 
 
 
 
 
 
 
 
4.1.3. Stability problems with OPA. 
 
Whilst carrying out the determination of the fragmentation patterns for the different OPA-
DMA derivatives it was observed that the relative proportions of the parent ions, for both 
ADMA and SDMA derivatives, changed with time. In particular the product with m/z 379 
decreased whilst the product with m/z 319 increased. The decrease in intensity of the first 
product was not surprising as OPA-amino acid derivatives are well known for being 
unstable198  
 
To examine the rate at which the concentrations of the various products changed, and 
whether this might be affected by the presence of the formic acid which had been added to 
+ R1 - NH2 + R2 - SH
CHO
CHO
SR2
NR1
Figure 4.1. The reaction of amino acids with o-phthaldialdehyde and a 
conjugating thiol. 
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promote ionisation, a 10 mmol/L ADMA standard was derivatised using 
OPA/mercaptoethanol as reagent (10 µL standard + 90 µL reagent). To this was then added 
either 900 µL 0.1% formic acid or 900 µl deionised water. The preparation was then 
quickly transferred to the mass spectrometer for analysis. Twenty microlitres of the 
preparation was injected into the mass spectrometer, using 0.1% formic acid as the carrier 
solution, pumped at 50 µL per minute. Scanning over the mass range 40 – 400 amu was 
performed using the first quadrupole of the mass spectrometer. Each scan cycle took 20 s 
and was repeated continuously for 5 minutes, at which time the sample was re-injected and 
the scanning process repeated.  A total of 12 consecutive injections for each preparation 
was performed. A nebuliser temperature of 500 oC was used, the other parameters being set 
to the equipment’s default conditions The data was analysed by extracting the total ion 
count for each mass from the sum of all the scans performed within one 5 minute injection 
cycle. In previous experiments the products which had formed from the reaction of OPA 
with either ADMA or with SDMA all had m/z greater than 300 amu. The reactants had not 
been examined below 300 amu to determine whether there were further 
products/breakdown products being formed with lower molecular weights, and therefore to 
determine whether this might be so, an extended scanning range, 40 – 400 amu, was chosen 
for this experiment. No peaks corresponding to product formation were seen other than 
those previously noted with m/z = 319, 334 and 379. The change of concentration of each 
product with time is figure 4.2. 
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Figure 4.2. Changes in ADMA-OPA products with time. A 10 mmol/L ADMA standard was 
derivatised with OPA/mercaptoethanol reagent (10 µL standard + 90 µL reagent) and  900 
µL of 0.1% formic acid was then added (a). Twenty microlitres of the  preparation was 
injected into, and analysed by, the mass spectrometer with repeat injections every five 
minutes for one hour. The experiment was then repeated, but the derivatised standard was 
diluted with deionised water instead of formic acid (b). 
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The ADMA standard used for this experiment was highly concentrated (10 mmol/L). The 
way in which it was derivatised and diluted resulted in a preparation with an OPA-ADMA 
concentration of 100 µmol/L, assuming that all the ADMA had indeed derivatised. The 
latter was a reasonable assumption in that the OPA was in large excess by comparison to 
ADMA. Although this concentration was much higher than that expected to be found in 
plasma samples (approximately 1 µmol/L) its use was required due to the fact that in a 
preliminary experiment, using a standard with an ADMA concentration of 1 mmol/L 
(resulting in a final concentration of  10 µmol/L for OPA-ADMA) the peaks observed had 
very low intensity. 
 
For both OPA-ADMA diluted in formic acid and also diluted in water the products with 
m/z = 379 and m/z = 334 decreased with time whilst the product with m/z = 319 increased. 
These changes were most rapid in the acid preparation, with the peak at 379 being virtually 
undetectable by 25 minutes. Although the changes were slower when the product was 
diluted with water instead of acid, at 60 minutes the peak at 379 had decreased by 30% of 
its initial intensity and this was considered to be extremely undesirable for developing a 
method for routine use in which even a moderately sized batch of samples (along with 
standards and controls) could take several hours for analysis. The instability of the products 
would not have been a problem had the mass spectrometer autosampler been able to mix 
sample with reagent just prior to injection, but this facility was not available on the system 
used.   
 
4.1.4. Other derivatising reagents and procedures 
 
Given that derivatisation with OPA led to the formation of products which could be 
identified by unique daughter ions, the possibility existed that the use of other means of 
derivatisation might also form products with unique daughter ions, but hopefully with 
increased stability. Derivatisation with OPA utilising a variety of different conjugating 
agents was examined and also derivatisation with  naphthalene-2,3-dicarboxaldehyde 
(NDA) (figure 4.3) and phenylisothiocyanate (PITC) (figure (4.4). 
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Until this point it had been assumed that ADMA and SDMA, without derivatisation, would 
not form unique daughter ions, since this had not been reported in the literature and 
published methods focussed upon chromatographic separation of the two isomers. As part 
of the work with differing methods of derivatisation, the fragmentation of ADMA and 
SDMA without derivatisation was also examined to test the validity of this assumption 
 
The majority of this work was carried out looking for the production of daughter ions with 
a mass greater than 55 (the default setting for the API 2000), the data in the literature 
suggested that useful fragments with a lower mass might also be formed199 and so an 
extended mass range was used when examining PITC derivatives, and the fragmentation of 
ADMA and SDMA without derivatisation. 
 
The findings of these experiments are shown in table 4.1. Unique daughter ions were 
observed for both ADMA and SDMA without derivatisation (figure 4.5), and also 
following derivatisation with PITC; no other derivatisation procedure resulted in the 
generation of unique daughter ions for both ADMA and SDMA. 
+ R1 - NH2 + R2 - SH 
CHO 
CHO 
SR2 
NR1 
Figure 4.3. The reaction of amino acids with  naphthalene-2,3-dicarboxaldehyde (NDA).  
C
COOH
R
H2N H
N C
COOH
R
H S
NH C HN C S
+
Figure 4.4. The reaction of amino acids with phenylisothiocyanate (PITC). 
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Derivatising Reagent Parent ion 
(m/z) 
Daughter 
ion (m/z) 
Observations Quantity of 
fragment  (% of 
most abundant 
fragment) 
378.9 230.1 unique for ADMA 12 
378.9 257.2 unique for ADMA 8 
378.9 290.2 unique for ADMA 9 
378.9 205.2 unique for SDMA 15 
OPA-mercaptoethanol a) 
 
378.9 244.2 unique for SDMA 15 
335.0 290.2 unique for ADMA 9 
335.0 105.0 unique for SDMA 6 
335.0 205.1 unique for SDMA 15 
OPA-mercaptoethanol a) 
 
335.0 244.0 unique for SDMA 14 
319.0 119.1 unique for ADMA 9 OPA-mercaptoethanol a) 
 319.0  no unique daughter for SDMA  
393.0 142.2 unique for ADMA 7 OPA-mercaptopropanol a) 
 393.0  no unique daughter for SDMA  
349.0 257.2 unique for ADMA 28 OPA-mercaptopropanol a) 
 349.0 111.0 unique for SDMA 13 
OPA-mercaptoundecanol a) 505.1  no unique daughter ions  
461.9 97.2 unique for ADMA 8 OPA-mercaptoundecanol a) 
 461.9 203.1 unique for ADMA 22 
 461.9  no unique daughter for SDMA  
408.9 258.3 unique for ADMA 12 
408.9 205.1 unique for SDMA 17 
OPA-monothioglycerol a) 
 
408.9 244.1 unique for SDMA 18 
     
365.0 205.2 unique for SDMA 18 
365.0 244.2 unique for SDMA 18 
365.0 290.1 unique for SDMA 13 
OPA-monothioglycerol a) 
 
365.0  no unique daughter for ADMA  
OPA-mercaptopropionylglycine a) 464.0  no unique daughter ions  
OPA-mercaptopropionylglycine a) 420.1  no unique daughter ions  
NDA-mercaptoethanol 369.0  no unique daughter ions  
NDA-monothioglycerol 421.9  no unique daughter ions  
PITC 338.0 46.1 unique for ADMA 47 
 338.0 158.1 unique for ADMA 18 
 338.0 171.9 unique for SDMA 20 
 338.0 175.0 unique for SDMA 38 
no derivatisation 203.0 46.3 unique for ADMA 25 
 203.0 133.0 unique for SDMA 22 
 203.0 172.0 unique for SDMA 48 
 
 
 
Table 4.1. Characteristics of selected daughter ions formed by tandem mass spectrometric 
fragmentation of ADMA and SDMA derivatives. Daughter ions that were produced with an 
abundancy less than 5% of the most intense fragment are not shown. 
 
a)
 reagents which formed more than one product with ADMA and SDMA. 
  
80 
 
4.2. Method Optimisation 
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Figure 4.5. The fragmentation patterns of underivatised ADMA and SDMA. a) 
The transition m/z: 203 → 46 is unique to ADMA. b) The transitions m/z: 
203 → 133 and 203 → 172 are unique to SDMA. 
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4.2.1. Nebuliser Optimisation. 
 
Optimal nebulizer conditions were determined by repeat injection of 10 µl of a 10 µM 
solution of ADMA and stepwise variation of individual gas flows and temperature. The 
optimum conditions found were: curtain gas (air) 40 psi, ion source gas 1 (nitrogen) 10 psi, 
ion source gas 2 (nitrogen) 0 psi, collision gas (nitrogen) 4 psi and temperature 500oC. 
 
 
4.2.2. Mobile phase optimisation. 
 
Organic solvents such as acetonitrile are often added to mobile phases in order to achieve 
chromatographic separation of analytes and to improve peak shape, the addition of such 
solvents can also improve the sensitivity of mass spectrometric methods by enhancing 
ionisation through increased droplet evaporation in the nebuliser. The effect of mobile 
phase composition upon ionisation was investigated by using the mass spectrometer HPLC 
system to mix varying proportions of a) 0.1% formic acid and b) 0.1% formic 
acid:acetonitrile (50:50) to produce mobile phases with varying concentrations of 
acetonitrile but constant concentration of formic acid. Repeat 20 µL injections of a 
standard, consisting of 5 µmol/L of ADMA, SDMA, MMA and arginine, were performed 
and the concentration of acetonitrile varied in 10% increments from 50% to 0% acetonitrile. 
Two injections were performed at each acetonitrile concentration before moving on to the 
next. Finally the sequence of injections was repeated in reverse order of acetonitrile 
concentration, so as to eliminate possible confounding effects such as a change of detector 
response with time or a change in the thermal state of the ionisation source. The results of 
this experiment are shown in figure 4.6. For all four analytes the most intense ionisation 
was obtained with a mobile phase consisting of 0.1% formic acid, ie with no acetonitrile 
present. Given the results obtained, concentrations of acetonitrile greater than 50% were not 
examined and a mobile phase consisting of 0.1% formic acid was chosen for routine use.  
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4.2.3. Sample preparation 
 
For the analysis of clinical samples tandem mass spectrometry exhibits a very high degree 
of selectivity in identifying analytes, but specificity cannot be guaranteed due to the 
possible presence of isobaric interferences. In addition, as discussed previously (see hcy X), 
the presence of substances other than the analytes of interest in the sample matrix can lead 
to undesirable signal suppression effects. Interferences and suppression effects may be 
reduced or eliminated by sample preparation techniques and/or the use of on-line 
chromatography. Suppression effects may also be reduced by sample dilution. There is a 
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Figure 4.6. The effect of acetonitrile on the ionisation of arginine and methylated 
arginines. The HPLC system attached to the mass spectrometer was used to mix 
various proportions of a) 0.1% formic acid and b) acetonitrile/0.1% formic acid. 
Acetonitrile proportions > 50% were not examined. 
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very large number of possible combinations of sample preparation techniques and 
chromatographic options which, combined with the selectivity conferred by the mass 
spectrometer, may produce a working method suitable for the routine analysis of clinical 
samples. Given these possible combinations, consideration must also be given to the 
importance of cost, sample preparation time and mass spectrometer analysis time. In the 
case of methylated arginines sample preparation by simple protein precipitation techniques 
were not considered an option as experience from developing the method for homocysteine 
analysis, together with considerations of reported concentrations of plasma ADMA 
(approximately ten-fold lower than plasma homocysteine) suggested that the resultant 
sample dilution would not produce a method with a sufficient signal to noise ratio with the 
equipment available for the accurate and precise determination of plasma methylated 
arginines. Due to their amphoteric nature amino acids are particularly difficult to extract 
from aqueous solutions (including plasma and urine) using simple liquid-liquid extraction 
techniques. Solid phase extraction is a possible alternative and in this case the amphoteric 
property of amino acids lends itself to solid phase extraction  using ion exchange columns. 
The possibility therefore existed that if solid phase extraction resulted in a sample 
preparation method with sufficient selectivity then it may be possible to avoid the use of 
on-line chromatography altogether. 
 
Strong cation SPE columns were obtained from Sigma-Aldrich and included guidelines for 
their use. These suggested that samples should be diluted in a suitable buffer to ensure that 
the analytes functional groups are ionised, and that the SPE columns should first be 
conditioned with either methanol or acetonitrile and then equilibrated with a solution 
similar to that in which the sample had been diluted. Solvents suitable for washing the 
columns post sample application included buffers and methanol, and a solution of 
ammonium hydroxide in methanol was a suitable solvent for the elution of basic 
compounds from the columns. In following the manufacturer’s general guidelines for 
method development, the extraction procedure detailed in section 2.3. p49, above, was 
employed.  
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4.2.4. Possible Interferences and Selectivity of Extraction Procedure. 
 
The following substances were ones which might possibly produce interferences in the 
method under development: homoarginine, acetyl glutamine, Nα-acetyl lysine and Nε-
acetyl lysine (molecular weight 188, isobaric with MMA), tryptophan (molecular weight 
202, isobaric with ADMA-d2 and SDMA-d2), and tyrosine (molecular weight 181, isobaric 
with arginine-d7). To investigate this possibility, 200 µmol/L solutions of each substance 
(obtained from Sigma-Aldrich) were prepared and analysed, but without the use of solid 
phase extraction. No interference was observed for tryptophan, homoarginine, acetyl 
glutamine, Nα-acetyl lysine or Nε-acetyl lysine but tyrosine did produce a fragment, m/z: 
182 > 77, isobaric with that used to determine arginine-d7 (data not shown). 
 
To determine the extent that this might interfere in the quantitation of arginine, tyrosine 
standards were added to pooled plasma (9 parts plasma to 1 part standard) to increase the 
endogenous tyrosine concentration by 200, 400, 600, 800 and 1000 µmol/L; this range of 
tyrosine concentrations greatly exceeds that found in healthy subjects (32 – 88 µmol/L)200 
and pathological conditions excluding tyrosinaemia. These preparations were prepared by 
solid phase extraction and analysed by mass spectrometry.  In addition an aqueous arginine 
standard, 100 µM, was also spiked with tyrosine and these preparations analysed both 
including and omitting the solid phase extraction procedure. The results are shown in figure 
4.6. If extraction is not used then tyrosine, through isobaric interference, increases the 
signal produced by arginine-d7, leading to a decrease in measured arginine concentrations.  
The solid phase extraction procedure completely removes this interference. 
 
To further investigate the specificity of the extraction step, two standards, (each consisting 
of a mixture of seven different amino acids), were prepared and analysed separately. 
Standard A consisted of proline, leucine, lysine, histidine, arginine, tyrosine and 
monomethylarginine. Standard B consisted of valine, ornithine, methionine, phenylalanine, 
citrulline, homoarginine and ADMA. These amino acids were chosen as they offered a 
range of structures and physical characteristics and are commonly found in plasma. The 
structures and properties of these amino acids are given in table 4.2. The concentration of 
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each amino acid was 500 µmol/L. Standards were diluted with 0.1 mol/L HCl (1 part 
standard: 5 parts HCl), and 1 mL of this was applied to the SPE columns, which were 
conditioned, washed and eluted as described in section 2.3. Each standard was collected 
upon passing through the SPE column, rather than allowing it to pass to waste, and the 
ammonia/methanol eluate was collected as normal. The approximate percentage of each 
amino acid retained by the column, and then recovered from it after washing and eluting are 
shown in table 4.3. 
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Figure 4.7. The effect of tyrosine on measured arginine, and its elimination by solid phase extraction. 
A series of aqueous standards were prepared, each containing 100 µmol/L arginine, but increasing 
concentrations of tyrosine. These were analysed using the methylated arginine method a) as normal, 
b) omitting the solid phase extraction stage. In addition a plasma sample was spiked with an aqueous 
tyrosine standard c) and also analysed (with SPE extraction). Tyrosine produces an isobaric 
interference with the internal standard arginine-d7, increasing its signal in the mass spectrometer and 
resulting in a decrease in measured arginine concentrations. The SPE columns used in this method do 
not retain tyrosine and eliminate its interference. 
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Although solid phase extraction with cation exchange columns might be expected to be 
extremely non-selective, the results of these experiments demonstrate that this is not so and 
that the converse is in fact true. Of the test substances examined only those that are very 
basic in nature are completely extracted and eluted from the SPE columns using the 
protocol described. Amino acids showing some degree of basicity, such as ornithine, lysine 
and histidine, are partially retained and eluted whereas all other amino acids examined 
show little extraction by the columns and do not appear in the final eluate. 
 
This experiment was repeated using weak cation exchange columns (also obtained from 
Sigma). With these columns no extraction of any of the amino acids examined was 
observed.  
 
4.2.5. Evaluation of Suppression effects. 
 
Experiments to investigate the extent of ion suppression were carried using the solid phase 
extraction procedure to prepare a) internal standards and b) plasma (without the addition of 
internal standard). The internal standard extract was reconstituted in carrier solution (0.1% 
formic acid) and this was then used to reconstitute the plasma extract. The internal standard 
extract and plasma extract were analysed ten times each and the signals for the internal 
standards obtained from the two different extracts compared. In the presence of extracted 
plasma, the signal from each of the internal standards was suppressed by approximately 
40%. The degree of suppression was higher than expected, especially given the degree of 
selectivity conferred by the solid phase extraction step demonstrated above but 
nevertheless, at this stage, it was considered to be acceptable for further method 
development. 
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ADMA201 fw = 202 
  
methionine  fw = 149 
pI = 5.7 
 
arginine fw = 174 
pI = 10.8 pK = 12.6 a) 
 
MMA  fw = 188 
 
citrulline fw = 175 
 
ornithine  fw = 132 
  pK = 10.8 a) 
 
histidine fw = 155 
pI = 7.6 pK = 6.0 
phenylalanine fw = 165 
pI = 5.9 
 
homoarginine fw = 188  
 
proline  fw = 115 
pI = 6.3 
 
 
 
leucine fw = 131 
pI = 6.0 
 
tyrosine  fw = 181 
pI = 5.6  pK = 10.1 a) 
 
lysine fw = 146 
pI = 9.5 pK = 10.3 a) 
 
valine  fw = 117 
pI = 6.0 
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Table 4.2. The structures and properties of amino acids used to test the retention 
characteristics of SPE columns201.  
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4.2.6. Linearity 
 
To assess linearity five aqueous standards were prepared (ADMA, SDMA: 5, 10, 15, 20 
and 25 µmol/L, methylarginine: 10, 20, 30, 40 and 50 µmol/L and arginine: 50, 100, 150, 
200, and 250 µmol/L). Each standard was analysed in triplicate in random order. Inspection 
of the standard curves obtained showed linearity for the range of standards (figure 4.7). The 
regression data for the standard curves is given in table 4.3.  
 
 
 
 % retained by SPE column % obtained after washing and eluting column 
ADMA  100  100 
arginine  75  75 
citrulline  20  0 
histidine  50  50 
homoarginine  100  90 
leucine  10  0 
lysine  40  30 
methionine  60  0 
MMA  90  90 
ornithine  60  50 
phenylalanine  30  0 
proline  5  0 
tyrosine  10  0 
valine  20  0 
Table 4.3.  The retention and elution behaviour of Supelclean LC-SCX 
strong cation exchange columns with selected amino acids. 
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 standards (n) slope sd slope intercept sd intercept standard error 
       
ADMA 15 0.1722 0.0019 0.0406 0.0312 0.0516 
SDMA 15 0.1955 0.0014 0.0670 0.0237 0.0391 
MMA 15 0.1823 0.0017 0.0639 0.0568 0.0938 
arg 15 0.0183 0.0001 0.0235 0.0230 0.0379 
Figure 4.8. Standard curves for ADMA, SDMA,  MMA and arginine. The results 
for each standard are plotted individually, but many points are coincidental. 
Table 4.4. Regression data for ADMA, SDMA, MMA and arginine standard curves. 
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4.2.7. Precision 
Within and between batch precision was assessed by analysing plasma and urine samples, 
at three different concentrations, ten times each. For low concentrations pooled plasma or 
pooled urine was used. For intermediate and high concentrations the low concentration 
pools were spiked with aqueous standard (pool:standard::19:1). 
Results are shown in table 4.4 In addition the results obtained for a normal plasma sample 
are shown in figure 4.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample type analyte Within-batch Between-batch 
 
 Mean 
(µmol/L) 
%CV Mean 
(µmol/L) 
%CV 
Plasma ADMA 0.497 1.7 0.499 4.1 
  1.411 2.1 1.486 2.6 
  5.637 0.9 5.693 1.8 
      
 SDMA 0.547 2.2 0.515 7.6 
  1.338 2.4 1.335 3.0 
  4.931 1.7 4.825 1.8 
      
 MMA 0.158 3.0 0.153 13.5 
  2.280 0.9 2.403 2.5 
  11.560 0.6 11.950 3.0 
      
 arginine 109 1.1 114 1.4 
  125 1.1 133 2.2 
  237 1.2 239 1.9 
      
Urine ADMA 86.2 2.0 85.6 2.1 
  102.4 2.0 102.2 2.6 
  185.7 2.0 182.9 2.2 
      
 SDMA 68.8 2.7 69.8 3.2 
  84.9 2.0 87.0 3.0 
  163.7 2.2 166.9 3.3 
      
 MMA 2.1 2.9 1.7 10.8 
  22.5 1.9 22.9 2.0 
  104.8 2.0 106.5 2.4 
      
 arginine 48.2 5.6 39.0 12.7 
  72.5 2.5 62.7 6.0 
  169.0 3.1 165.5 7.1 
Table 4.5. Within-batch and between-batch precision for plasma and urine ADMA, 
SDMA, MMA and arginine. Ten replicates were analysed at each concentration. 
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4.2.8. Recovery 
Recovery experiments were performed by spiking ten individual plasma and ten individual 
urine samples with  either 0.1 mol/L HCl or aqueous standard at two different 
concentrations (sample: standard::19:1). The results of this experiment are given in 
table 4.5. 
 
 
4.2.9. Limits of Detection and Quantitation 
The limit of detection and limit of quantitation were determined by analysing ten sample 
blanks (water in place of sample). The signal (baseline) obtained from each analysis was 
integrated using Analyst-NT software to obtain a measure of noise. The  limit of detection 
was  then calculated as 3 x blank sd and the limit of quantitation as 10 x blank sd. 
The limits of detection for ADMA, SDMA, MMA and arginine were 0.023 µmol/L, 
0.011 µmol/L, 0.009 µmol/L, and 0.258 µmol/L respectively, while the limits of 
quantitation were 0.077 µmol/L, 0.037 µmol/L, 0.030 µmol/L and 0.860 µmol/L 
respectively. 
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Figure 4.9. The mass-spectrogram of a typical plasma 
sample. For purposes of clarity the internal standards are 
not shown. 
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Sample type Analyte Added (µmol/L) Mean recovery (%) %CV 
Plasma ADMA 1 91.7 10.3 
  5 91.4 2.2 
 SDMA 1 91.7 11.8 
  5 91.4 4.0 
 MMA 2 90.3 5.8 
  10 91.6 1.5 
 arginine 20 98.2 23.2 
  100 90.5 4.3 
Urine ADMA 20 91.7 19.5 
  100 92.0 5.6 
 SDMA 20 98.0 23.2 
  100 93.5 5.9 
 MMA 20 98.3 6.1 
  100 98.3 4.6 
 arginine 20 89.4 14.3 
 
 100 92.6 4.3 
 
 
 
 
 
 
4.2.10. Plasma and urine results. 
 
To verify that the method would produce results similar to those described in the literature, 
lithium heparin plasma from nine healthy volunteers was analysed (table 4.6) and the 
results obtained were comparable to values reported in other studies (table 4.7). Five 
twenty-four hour urine collections, surplus samples from patients undergoing routine 
investigations, but with no indications of vascular disease, were also analysed (table 4.8). 
There is little data available for urine concentrations and outputs of arginine and methylated 
arginines, but in a study by Huang et al similar values were reported for ADMA and 
SDMA, however in that publication urinary arginine outputs were considerably higher than 
those found here (mean urinary arginine 114 ± 30 vs 12.7 ± 8.5 µmol/24hr). 
 
 
Table 4.6. Recovery of ADMA, SDMA, MMA and arginine from plasma and urine. Baseline 
samples were prepared by the addition of 0.1 mol/L HCl, spiked samples by the addition of 
standard in 0.1 mol/L HCl (1 part HCl or standard to 19 parts sample), Ten samples were 
prepared at each concentration. 
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 Age ADMA SDMA  MMA  arg  
 (years) (µmol/L) (µmol/L) (µmol/L) (µmol/L) 
 
24 0.512 0.472 0.182  132 
 18 0.177 0.448 0.201  249 
 24 0.265 0.504 0.157  167 
 20 0.290 0.414 0.332  316 
 24 0.387 0.371 0.158  125 
 20 0.484 0.523 0.167  125 
 18 0.443 0.547 0.195  150 
 19 0.627 0.456 0.190  133 
 21 0.372 0.499 0.176  64 
      
mean ± 1sd 20.9 ± 2.5 0.395 ± 0.139 0.470 ± 0.055 0.195 ± 0.054 162 ± 76 
Analyte Range of mean concentrations 
reported (µmol/L) 
Median of mean concentrations 
 reported (µmol/L) 
ADMA 0.30 - 2.60 1.04 
SDMA 0.34 - 3.0 0.73 
MMA 0.100 - 0.177 0.104 
arginine 50 - 236 110 
Age Urine volume ADMA SDMA MMA arg 
(years) (ml) (µmol//24hr) (µmol/24hr) (µmol/24hr) (µmol/24hr) 
59 1233 48.8 42.5 1.55  20.8 
25 2594 57.6 62.3 1.85  6.0 
41 2466 52.3 59.7 1.18  22.9 
52 2714 34.2 58.1 1.35  5.6 
35 2150 46.2 40.0 1.34  7.9 
      
mean ± 1sd  47.8 ± 8.7 52.5 ± 10.4 1.5 ± 0.3  12.7 ± 8.5 
Table 4.7. Concentrations of arginine and methylated arginines in 
plasma of nine healthy male volunteers. 
 
Table 4.9. Concentrations of arginine and methylated 
arginines in five 24 hour urine collections. 
Table 4.8. Concentrations of plasma ADMA, SDMA, MMA and arginine 
reported in published studies. Adapted from Zhang et al150 
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4.3. Investigation of sample stability 
 
To investigate the effects of delayed separation of plasma from red-cells upon 
homocysteine, cysteine, methionine, arginine and methylated arginine concentrations 7 mL 
of lithium heparin anticoagulated blood samples were collected from each of five 
volunteers, on five separate occasions. Approximately 1 mL of whole blood was removed 
from each tube immediately upon blood collection, centrifuged at 1000g for five minutes, 
the plasma was then removed from the red-cells and frozen at -20OC. The tubes were left to 
stand at room temperature (21OC), and at timed intervals (1, 2, 4, 8, and 24 hours) the tubes 
were mixed by inversion, a further 1 ml of blood removed, centrifuged and the plasma 
again removed and stored at -20OC until analysis. Samples were analysed for total 
homocysteine, total cysteine and methionine within one batch and also for arginine and the 
methylated arginines within one batch. All analyses were performed on the same day to 
avoid repeat freeze thawing of samples. For total cysteine and methionine no statistically 
significant difference was detected for samples separated 24 hours post blood collection as 
compared with immediate separation (Student's paired t-test: p = 0.250, and 0.157 
respectively). For total homocysteine plasma concentrations increased gradually over the 
24 hour period, consistent with previous observations that red-cells continue to produce 
homocysteine post blood collection53, however no statistically significant difference was 
detected for samples separated 2 hours post blood collection as compared with immediate 
separation (Student's paired t-test: p = 0.08). For ADMA, SDMA and MMA no statistically 
significant difference was detected for samples separated 8 hours post blood collection as 
compared with immediate separation (Student's paired t-test: p = 0.277, 0.667 and 0.096 
respectively) however significant differences were seen for samples separated 24 hours post 
collection with ADMA being on average 28% higher than samples separated immediately, 
SDMA 10% higher and MMA 47% higher. The concentration of arginine was significantly 
lower at each time interval compared to samples separated immediately (figure 4.9), with 
concentrations at 1 hour post separation being on average 17% lower than samples 
separated immediately and this is most probably due to transport of arginine into red-cells 
with subsequent metabolism to ornithine by red-cell arginase202. 
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In conclusion for arginine analysis plasma must be removed from red-cells immediately 
upon blood collection, for homocysteine analysis separation should take place within two 
hours whereas for ADMA, SDMA, MMA, cysteine and methionine lithium heparin 
anticoagulated whole blood samples are stable for at least 8 hours. 
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Figure 4.10. The effect of delayed separation on plasma arginine. Five lithium 
heparin anti-coagulated blood samples were stored at room temperature, and at 
timed intervals 1 mL of blood was removed, the plasma separated, and stored at -
20OC until analysis. The results shown are mean ± 1 sd. 
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4.4. Conclusion 
 
A method for the simultaneous analysis of asymmetric dimethylarginine, symmetric 
dimethylarginine, monomethylarginine and arginine in human plasma and urine, with short 
analysis time and isotopic internal standardisation for each analyte has been described. The 
method requires neither sample derivatisation nor the need for chromatographic separation 
of analytes. The method described shows good precision and accuracy and is suited for 
both research purposes and implementation in the busy, routine clinical laboratory. In 
addition the synthesis and utilisation of isotopically labelled symmetric dimethylarginine 
and monomethylarginine is described for the first time, avoiding the use of surrogates such 
as homoarginine for internal standardisation. 
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5. Homocysteine and Methylated Arginines in Clinical Samples 
 
 
5.1. Investigations With Routine Clinical Samples 
 
 
5.1.1. Sample Selection 
 
The methods for homocysteine and methylated arginines developed in Chapters 3 & 4 were 
applied to the analysis of routine plasma samples to determine whether plasma total 
homocysteine concentration is a determinant of plasma ADMA concentration, and in 
addition to explore what relationships might exist between total homocysteine, methylated 
arginines, patient demographics such as age and gender, and other routinely assessed 
biochemical parameters. Plasma arginine was not included part of these studies, as it could 
not be guaranteed that plasma had been separated from cells sufficiently promptly to allow 
for its reliable measurement. The samples analysed consisted of a random and essentially 
heterogeneous selection of 111 specimens that had been received by the laboratory for 
routine homocysteine analysis. The clinical details that had been given with these requests 
included cardiovascular disease, raised lipids, pulmonary embolism, secondary prevention, 
various miscellaneous comments unrelated to any form of vascular disease and were often 
missing. In addition 9 samples from patients with hypothyroidism (TSH > 5 mu/L) were 
included as well as 14 patients with a hyperthyroid pattern of results (TSH < 0.3 mu/L). All 
work was performed in accordance with local ethical guidelines. 
 
Patient samples had been collected by venepuncture into Greiner Vacuette tubes containing 
lithium heparin as anticoagulant. After centrifugation at 1000 g for 10 minutes plasma was 
removed from the samples and stored at -20 oC until being prepared for homocysteine 
analysis at which point they were refrozen, and again stored at -20 oC until being tested for 
methylated arginines and the remaining biochemical parameters:- sodium, potassium, 
creatinine, urea, total protein, albumin, cholesterol, uric acid, TSH and fT4. Serum B12 and 
folate were recorded where this had formed part of the original sample request but was not 
tested for otherwise, as serum samples, paired with the plasma samples, were generally 
unavailable and plasma samples were not considered suitable for folate measurements by 
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the manufacturer of the folate kit. All analytes other than homocysteine and methylated 
arginines were measured on a Roche Modular system, the methods used and associated 
reference ranges are given in table 5.1.  Samples were anonymised other than the recording 
of gender, age and clinical information.  
 
 
 
 
5.1.2. Preliminary Investigations, Calculations and Data Transformations 
 
5.1.2.1. Gender 
The combined data from groups all three groups was initially investigated to see if any 
variables showed differences between the genders. No assumptions were made about the 
underlying data structure and the non-parametric Mann-Whitney U test was used for the 
Analyte Method Reference range (at Royal Sussex 
County Hospital, Brighton) 
Na indirect ion-selective electrode 135 - 146 mmol/L 
K indirect ion-selective electrode 3.2 - 5.1 mmol/L 
creatinine colorimetric using alkaline picric acid (Jaffe 
reaction) 
Females: 44 - 80 µmol/L 
Males: 62 - 106 µmol/L 
urea enzymatic colorimetric 1.7 - 8.3 mmol/L 
total protein colorimetric using biuret 66 - 87 g/L 
albumin colorimetric using bromocresol green 34 - 48 g/L 
uric acid enzymatic colorimetric using uricase Females: 0.14 - 0.34 mmol/L 
Males: 0.20 - 0.42 mmol/L 
B12 immunoassay with electrochemiluminescent 
detection 
197 - 866 pg/mL 
folate competitive binding assay  with 
electrochemiluminescent detection 
4.6 - 18.7 ng/mL 
cholesterol enzymatic colorimetric using cholesterol oxidase < 5.0 mmol/l 
TSH immunoassay with electrochemiluminescent 
detection 
0.3 - 4.2 mU/L 
fT4 immunoassay with electrochemiluminescent 
detection 
12 - 22 pmol/L 
Table 5.1. Methods used, and reference ranges for, biochemical parameters measured in clinical studies. 
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analysis. The data set was well balanced in the proportions of males and females (males 
47.8%). All data analyses were performed using SPSS 15.0. 
 
Significant gender differences were found for age (p = 0.007), creatinine (p < 0.001), uric 
acid (p < 0.001) and urea (p < 0.001). Significant differences (p <= 0.05) were not found 
for any other variable. 
 
5.1.2.2. Age 
The median age for females in the combined group was 48.5 years while for males it was 
58.0 years. Inspection of the subgroups showed that this difference in age was most likely 
to be due to a selection bias (figure 5.1). Although the samples in the homocysteine group 
had mostly be selected at random, only a few samples had been available with hyperthyroid 
and hypothyroid results and these had been dominated by samples from comparatively 
young females (hyperthroid: median age = 45 yr, n = 11, hypothyroid: median age = 47 yr, 
n = 6) with only a few samples from comparatively older males (hyperthroid: median age 
64 yr, n = 3, hypothyroid: median age = 79 yr, n = 3). There was no statistically significant 
difference between genders for age when considering only the homocysteine sample group 
(p = 0.094).  
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Figure 5.1. The age distribution of patients by subgroup.  
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5.1.2.3. Plasma creatinine and uric acid. 
Both plasma creatinine and uric acid show a strong association with gender and most 
laboratories quote a gender related reference range for each of these analytes. In order to 
remove the gender association and simplify data analysis a transform was applied to both 
plasma creatinine and uric acid results to express them in terms of their difference from the 
mid-point of the reference range, in terms of standard deviations (figures 5.2. and 5.3). 
 
 
transformed result = plasma result - mid-point reference range 
      sd 
 
where sd   =  upper reference range limit - lower reference range limit 
        4 
 
 
For plasma creatinine (µmol/L):  
Females: reference range = 44 - 180, mid-point = 62, sd = 9 
Males: reference range = 62 - 106, mid-point = 84, sd = 11 
 
For plasma uric acid (mmol/L):  
Females: reference range = 0.14 - 0.34, mid-point = 0.24, sd = 0.050 
Males: reference range = 0.20 - 0.42, mid-point = 0.31, sd = 0.055 
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Figure 5.2. The elimination of gender associated differences in plasma creatinine by data transform. 
a) Plasma creatinine shows a significant difference between genders (Mann-Whitney U, p <0.001) 
b) there is no significant difference between genders after applying the data transform described in 
section 5.1.2.3 (Mann-Whitney U, p = 0.596).) 
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Figure 5.3. The elimination of gender associated differences in plasma uric acid by data transform. 
a) Plasma uric acid shows a significant difference between genders (Mann-Whitney U, p <0.001) b) 
there is no significant difference between genders after applying the data transform described in 
section 5.1.2.3 (Mann-Whitney U, p = 0.897).) 
n = 70, females 
n = 64, males 
n = 70, females 
n = 64, males 
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5.1.2.4. Urea 
The reference range for plasma urea (1.7 - 8.3 mmol/l) in use at RSCH is not stratified 
according to either age or gender however, examination of the data showed a significant 
correlation between urea and age (Spearman's rho <0.001) and linear regression analysis 
produced the following equations:  
 
  females, urea = 3.47 + 0.029 age 
  males, urea = 4.27 + 0.032 age 
 
The rate of increase of urea with age was approximately the same for both females and 
males at approximately 0.03 mmol/L/yr (figure 5.4). 
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Figure 5.4. Change of plasma urea with age. Urea was significantly 
associated with age for both females (Pearson correlation: r = 0.407, 
p < 0.001) and males (Pearson correlation: r = 0.265, p = 0.035) For 
both males and females plasma urea changes by approximately 
0.03 mmol/L/year. 
♦Females, urea = 3.47 + 0.029 age 
♦Males, urea = 4.27 + 0.032 age 
 
  
103 
 
 
To test whether the difference in plasma urea between the sexes that had been identified in 
the data was accounted for by the change of urea with age, in conjunction with the age 
selection bias noted above, an 'age adjusted urea' was calculated according to the following 
formula: 
  age adjusted urea = measured urea - 0.03 age. 
 
and this new variable, grouped by gender, was then subjected to the Mann-Whitney U test. 
A statistically significant difference between the sexes was detected for age adjusted urea 
and it was concluded that further analysis involving plasma urea may require separate 
analysis by gender. 
 
 
 
 
5.1.2.5. Tests for Normality 
All variables (except gender) were examined for normality using the Kolmogorov-Smirnov 
test and all passed this test with the exception of total homocysteine (p < 0.001), SDMA 
(p = 0.007),  albumin (p < 0.001) and TSH (p < 0.001).  A logarithmic transform was found 
to normalise both total homocysteine (p = 0.196) and also SDMA (p = 0.174) (figures 5.5. 
and 5.6). Albumin could not be normalised using simple transforms (logarithmic, power) 
and so relationships between albumin and other variables were examined 
nonparametrically. The lack of normality for TSH was attributed to the way in which 
samples had been selected, as TSH was found to conform to a normal distribution when the 
three subgroups were tested individually. 
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5.1.2.6. Biochemical results for sample groups and associations between variables 
 
The results of biochemical analyses for individual subgroups, and all groups combined, are 
shown in table 5.1, and the correlations between variables are shown in table 5.2. 
 
Figure 5.5. The effect of log transform on plasma total homocysteine results. a) Plasma homocysteine 
did not pass the Kolmogorov-Smirnov test for normality (p <0.001) but following a log 
transformation b) the results were effectively normalised (p = 0.196) 
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Figure 5.6. The effect of log transform on plasma SDMA results. a) Plasma SDMA did not pass the 
Kolmogorov-Smirnov test for normality (p <0.001) but following a log transformation b) the results 
were effectively normalised (p = 0.174) 
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  Routine 
homocysteine 
group 
Hypothyroid 
group 
Hyperthyroid 
group 
Combined 
group 
n  111 14 9 134 
% male  52.3 21.4 33.3 47.8 
Age mean 52.8 48.4 60.0 52.8 
(years) sd 15.55 17.67 20.98 16.20 
Na mean 143.0 141.9 140.3 142.7 
(mmol/L) sd 2.79 3.51 4.95 3.10 
K mean 4.27 4.34 4.22 4.28 
(mmol/L) sd 0.408 0.348 0.511 0.408 
creatinine mean 83.24 66.29 78.33 81.14 
(µmol/L) sd 19.54 16.264 25.426 20.195 
Tr creatinine a) mean 0.974 -0.11 1.22 0.866 
 sd 1.5044 -1.17 - 1.36 -1.12 - 2.78 1.5845 
urea (female) mean 4.99 4.90 4.38 4.92 
(mmol/L) sd 1.221 1.385 1.170 1.237 
urea (male) mean 6.09 4.13 7.30 6.06 
(mmol/L) sd 1.660 0.603 2.265 1.708 
total protein mean 76.5 76.2 72.4 76.2 
(g/L) sd 4.65 5.48 7.38 5.02 
albumin median 45.0 44.0 40.0 45.0 
(g/L) IQR 43.0 - 46.0 42.5 - 46.0 34.0 - 44.0 43.0 - 46.0 
uric acid mean 0.330 0.303 0.268 0.323 
(mmol/L) sd 0.0734 0.0911 0.0940 0.0780 
Tr uric acid b) mean 1.025 0.914 0.054 0.948 
 sd 1.2775 1.3667 1.3558 1.3046 
Table 5.2. The results of biochemical analyses for clinical samples. 
Continued on next page. 
a) Tr creatinine = transformed creatinine 
b)
 Tr uric acid = transformed uric acid 
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  Routine 
homocysteine 
group 
Hypothyroid 
group 
Hyperthyroid 
group 
Combined 
group 
n  111 14 9 134 
cholesterol mean 4.83 4.75 4.91 4.83 
(mmol/L) sd 1.224 1.015 1.484 1.214 
TSH median 1.81 0.01 12.60 1.76 
(mU/L) IQR 1.17 - 2.29 0.01 - 0.04 8.39 - 39.21 1.02 - 2.50 
log TSH median 0.258 -2.000 1.100 0.244 
 IQR 0.068 - 0.360 -2.000 - -1.398 0.914 - 1.590 0.008 - 0.398 
fT4 mean 15.88 23.36 10.44 16.29 
(pmol/L) sd 2.318 5.053 3.318 3.9129 
total homocysteine median 14.8 13.9 19.0 14.9 
(µmol/L) IQR 12.9 - 18.5 11.9 - 16.0 13.9 - 23.5 12.9 - 18.5 
log total homocysteine mean 1.197 1.153 1.251 1.196 
 sd 0.1626 0.1010 0.1281 0.1557 
ADMA mean 0.4987 0.5923 0.4707 0.5066 
(µmol/L) sd 0.08278 0.12119 0.07529 0.09141 
SDMA median 0.526 0.528 0.501 0.527 
(µmol/L) IQR 0.470 - 0.608 0.403 - 0.570 0.460 - 0.777 0.459 - 0.607 
log SDMA mean -0.2686 -0.297 -0.243 -0.2699 
 sd 0.10167 0.1032 0.1252 0.10324 
MMA mean 0.1252 0.1691 0.1134 0.1290 
(µmol/L) sd 0.03498 0.03856 0.03010 0.03755 
Table 5.2. The results of biochemical analyses for clinical samples. 
Continued from previous page. 
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    log thcy ADMA log SDMA MMA 
log thcy Correlation Coefficient  0.197 0.252 0.069 
  
Significance 
 0.023 * 0.003 ** 0.430 
ADMA Correlation Coefficient 0.197  0.315 0.518 
  
Significance 0.023 *  <0.001 ** <0.001 ** 
log SDMA Correlation Coefficient 0.252 0.315  0.225 
  
Significance 0.003 ** <0.001 **  0.009 ** 
MMA Correlation Coefficient 0.069 0.518 0.225  
  
Significance 0.430 <0.001 ** 0.009 **  
age Correlation Coefficient 0.206 0.190 0.494 0.112 
  
Significance 0.017 * 0.028 * <0.001 ** 0.199 
Na Correlation Coefficient 0.151 0.277 0.065 0.022 
  
Significance 0.082 0.001 ** 0.453 0.801 
K Correlation Coefficient -0.074 -0.089 0.042 0.045 
  
Significance 0.393 0.306 0.630 0.604 
Tr creat Correlation Coefficient 0.144 -0.010 0.559 0.043 
  
Significance 0.096 0.906 <0.001 ** 0.624 
urea Correlation Coefficient 0.276 0.205 0.550 0.199 
female Significance 0.021 * 0.089 <0.001 ** 0.098 
urea Correlation Coefficient 0.017 0.050 0.369 0.015 
male Significance 0.895 0.695 0.003 ** 0.904 
total protein Correlation Coefficient -0.027 -0.186 -0.153 -0.151 
  
Significance 0.757 0.031 * 0.078 0.081 
albumina) Correlation Coefficient a -0.113 -0.164 -0.046 -0.195 
  
Significance 0.195 0.059 0.601 0.024 * 
Tr uric acid Correlation Coefficient 0.178 0.278 0.360 0.111 
  
Significance 0.040 * 0.001 ** <0.001 ** 0.200 
cholesterol Correlation Coefficient 0.040 -0.131 0.051 -0.054 
  
Significance 0.650 0.132 0.556 0.538 
fT4 Correlation Coefficient -0.047 0.247 -0.247 0.195 
  
Significance 0.590 0.004 ** 0.004 ** 0.024 * 
log TSHa) Correlation Coefficient a 0.157 -0.180 0.248 -0.055 
  
Significance 0.070 0.037 * 0.004 ** 0.529 
 B12 Correlation Coefficient -0.181 -0.150 -0.114 -0.284 
 
Significance 0.472 0.553 0.654 0.253 
folate Correlation Coefficient -0.290 0.002 0.084 0.378 
 
Significance 0.244 0.993 0.741 0.122 
 
 
 
 
 
Table 5.3. Correlations between the results obtained for clinical samples. 
**  Correlation is significant at the 0.01 level (2-tailed). 
*    Correlation is significant at the 0.05 level (2-tailed). 
a
     Spearman correlation coefficient 
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5.1.3. ADMA and Homocysteine 
 
A plot of ADMA versus log total homocysteine is shown in figure 5.6. The data is highly 
scattered and the correlation coefficient small (Pearson = 0.197) but statistically significant 
(p = 0.023). The association between the two could be (i) a random statistical finding, (ii) 
might be due to a common association with another variable or (iii) might be real and 
possibly diminished by the effect of other variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculating partial correlation coefficients, allowing for control by other variables, revealed 
that the association between ADMA and total homocysteine was likely to be due, at least in 
part, to common associations with age and with Tr uric acid. When age and Tr uric acid 
were used together as control variables no statistically significant association was detected 
y = 0.1154x + 0.3686
0.0
0.2
0.4
0.6
0.8
1.0
0.50 0.75 1.00 1.25 1.50 1.75 2.00
log (plasma total homocysteine)
Figure 5.7. The association between plasma ADMA and log 
(plasma total homocysteine). ADMA and log total homocysteine 
showed a statistically significant association (Pearson correlation: 
r = 0.197, p =0.023). 
A
D
M
A
 
(µ
m
o
l/L
) 
n = 134 
  
109 
between ADMA and log total homocysteine table 5.3. It should be noted that age and Tr 
uric acid were not correlated (Pearson: p = 0.228). 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.4. Investigation of Data Using Linear Modelling 
 
Linear modelling techniques were  used to further investigate the extent to which variables 
were predictors of plasma ADMA, SDMA and MMA concentrations.  The variables 
included in the models were those which had shown a significant correlation with ADMA;  
creatinine was also included, although having shown no association with ADMA so far, as 
a measure of renal function. Two models were used, a standard multivariate least-squares 
model (in which all variables are included) and a step-wise least squares model (in which 
variables are entered one at a time, in order of strength of association, until either all 
variables are entered or there is no association with the remaining variables). The 
differences between the two techniques were minor and made no difference to the 
interpretation of the findings, only the results of the step-wise model will therefore be 
considered. The models were applied to the combined set of results and also to sub-groups 
by gender and/or thyroid status. Whilst analysing male and female sub-groups urea was 
included as a variable; no association was seen with ADMA. An association between urea 
and log SDMA was observed but as this was duplicated by a similar association between 
creatinine and log SDMA, the inclusion of urea was thought to be redundant and it was 
Control variable(s) partial correlation coefficient significance (p) 
none 0.197 0.023 
age 0.164 0.059 
Tr uric acid 0.156 0.073 
age and Tr uric acid 0.128 0.145 
Table 5.4. Correlation between ADMA and log total homocysteine 
controlling for other variables. Although a statistically significant association 
existed between ADMA and log homocysteine (p <= 0.05), this no longer 
remained significant when other variables were taken into account (p > 0.05) 
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therefore not considered further. The effects of the transforms on creatinine and uric acid 
were explored by analysing the results for males and females separately, first using the 
original variables and then using the corresponding transformed variables. Virtually 
identical results, for all variables in the model, were obtained. The largest difference 
observed was for the association between ADMA and creatinine for the male subgroup: the 
significance of the association was 0.425 when using creatinine, and 0.423 when using 
transformed creatinine and these findings validated the use of the transforms as a means of 
amalgamating the results for males and females into one group. The results of the 
regression modelling for all results combined, and selected sub-groups, are shown in table 
5.4. With the exception of fT4 the results are generally consistent regardless of the sub-
group; some (small) differences are seen but this is not surprising when performing 
multiple statistical tests (type I and type II statistical errors). fT4 shows a significant 
association with ADMA, and with MMA, in some groups but not others, and this is entirely 
explained by selection bias, the majority of samples with abnormal thyroid function results 
having been taken from females. Most importantly ADMA showed no association with 
homocysteine in any of the groups. Table 5.5 shows the way in which each variable was 
finally classified as being a predictor of ADMA, SDMA and MMA. 
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  All samples  Routine 
homocysteine 
requests 
  All samples   Routine homocysteine 
requests 
  
Female and 
male 
  Female and 
male 
  Female 
 
Male   Female Male 
ADMA       
age 0.067* 0.077* 0.140 0.025** 0.897 0.055* 
Na 0.006*** <0.001*** 0.020** 0.052* 0.000*** 0.005*** 
total protein 0.002*** 0.003*** 0.003*** 0.166 0.033** 0.019** 
fT4 0.001*** 0.453 0.001*** 0.273 0.637 0.044** 
log thcy 0.115 0.299 0.084* 0.255 0.494 0.230 
Tr creatinine 0.563 0.461 0.638 0.111 0.202 0.423 
Tr uric <0.001*** <0.001*** 0.003*** 0.016** 0.002*** 0.155 
       
SDMA       
age <0.001*** <0.001*** <0.001*** 0.048** <0.001*** 0.172 
Na 0.882 0.096* 0.570 0.938 0.072* 0.696 
total protein 0.007*** 0.020*** 0.152 0.010*** 0.456 0.002*** 
fT4 0.132 0.143 0.536 0.147 0.341 0.062* 
log thcy 0.177 0.291 0.627 0.060* 0.849 0.062* 
Tr creatinine <0.001*** <0.001*** <0.001*** <0.001*** <0.001*** <0.001*** 
Tr uric 0.002*** 0.003*** 0.688*** 0.001*** 0.194 0.014** 
       
MMA       
age 0.171 0.389 0.118 0.118 0.291 0.729 
Na 0.948 0.856 0.722 0.722 0.516 0.229 
total protein 0.046** 0.001*** 0.019 0.019 0.001*** 0.202 
fT4 0.014** 0.114 0.008*** 0.008*** 0.332 0.455 
log thcy 0.382 0.446 0.382 0.382 0.598 0.768 
Tr creatinine 0.199 0.007*** 0.153 0.153 0.041** 0.106 
Tr uric 0.092* 0.615 0.075* 0.075* 0.306 0.594 
Table 5.5. Predictors of ADMA, SDMA and MMA as determined by linear modelling. The table 
gives the significance (probability) of variables being predictors of ADMA, SDMA or MMA. The 
results for all samples combined and selected subgroups are given for comparison. 
* significant at p < 0.1 
** significant at p < 0.5 
*** significant at p < 0.01 
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5.1.5. Discussion of Individual Predictors 
 
5.1.5.1. Age and Gender 
ADMA, SDMA and  MMA show a significant association with age and this, sub-divided 
by gender, is shown in figure 5.7. ADMA concentrations initially decrease with age, then 
begin to rise from age 20-30 years before finally reaching a plateau at approximately 70 
years of age. In figure 5.7 the data presented is for the results from all samples but the same 
changes in methylated arginines and age were seen when results from patients with low 
TSH and high TSH were excluded (not shown). The initial decrease in ADMA 
concentrations is consistent with the findings of Lücke et al203 who examined 34 healthy 
volunteers aged 2 days to 24 years of age and demonstrated that ADMA decreased from 
approximately 0.8 µmol/L to 0.5 µmol/L over this age range.   
 
 
 
 
 ADMA log SDMA MMA 
age  +  +++ 
 − 
Na  +++ 
 −  − 
total protein  +++  +++  ++ 
T4  +++ 
 − 
 ++ 
log thcy 
 −  −  − 
Tcreat 
 − 
 +++ 
 − 
Turic  +++  +++  + 
Table 5.6. Classification of variables as 
predictors of ADMA, SDMA and MMA. 
+ = minor predictor (p<0.1) 
++ = moderate predictor (p<0.5) 
+++ = significant predictor (p≤0.01) 
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Figure 5.8. Variation of ADMA, SDMA and MMA with age. 
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In a study of 500 volunteers aged 19 - 75 years Schulze et al also noted an association 
between plasma ADMA and age204, however, they concluded that whilst plasma ADMA 
increases consistently across the age range for men it only shows an increase with age for 
women post-menopause (greater than 50 years of age). The data from that study is 
reproduced in figure 5.8 and close inspection would suggest that for women plasma ADMA 
actually begins to increase before the 50 year age cut-off that had been used, and is in 
keeping with the data shown in figure 5.7. Schulze et al also concluded that pre-menopausal 
women had lower plasma ADMA concentrations than men of a similar age, but that 
following menopause plasma ADMA concentrations in women were higher than men204. 
Figure 5.7 (above) does not substantiate their claim: plasma ADMA concentrations being 
higher for women compared with men for all age groups. It would seem likely that the 
single age division used by Schulze et al is inappropriate has led to mis-interpretation of 
their data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Variation of ADMA with age as presented by Schulze et al (2005). 
Redrawn from reference 204. 
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MMA possibly shows the same association with age as does ADMA, but it is difficult to 
draw robust conclusions as there is a higher degree of variability for MMA within each age 
division compared with ADMA. 
 
SDMA increases with age across the whole age range examined, and it would seem likely 
that this is a reflection of a decrease in renal function with age, as the renal excretion of 
SDMA is its only known route of elimination from the body. 
 
5.1.5.2. Sodium 
Figure 5.9 shows the relationship between plasma ADMA and sodium and although 
considerable scatter is present (in part due to associations with other variables) the 
relationship is highly significant (from step-wise regression model p = 0.006). An 
association between ADMA and sodium has been noted previously205,206,207,208. In studies 
on healthy volunteers Kielstein205,206 et al noted that infusion of ADMA increased urinary 
retention of sodium, whereas there were no effects on plasma renin or noradrenaline. 
Plasma sodium was not measured in these studies and it should be noted that, following 
infusion, plasma ADMA concentrations were greatly increased over normal and 
pathophysiological values (to approximately 40 µmol/L). In a study of hypertensive 
subjects, patients followed a low sodium diet for seven days, then a high sodium diet for 
seven days and finally another low sodium diet for a further seven days. During the periods 
of low sodium intake plasma concentrations decreased and plasma nitrate increased whilst 
the reverse was observed during the high sodium diet207. The changes in ADMA and nitrate 
were more pronounced for those subjects deemed to be salt-sensitive (blood pressure 
increased by >5% by salt loading). In a similar study of normotensive subjects plasma 
ADMA was again found to increase following sodium-loading and was associated with a 
decrease in plasma nitrate208. When the same subjects followed a high sodium diet but with 
additional potassium supplementation (60 mmol KCl per day) no changes in either ADMA 
or nitrate were detected. Although the studies described above confirm the observation of 
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an association between plasma ADMA and sodium they offer contradictory information as 
regards to cause and effect. In the present work the strength of association seen between 
sodium and ADMA is somewhat surprising given that the samples came from an essentially 
random selection of patients who were not deliberately stressed with either salt or ADMA 
loading. The effect of sodium on blood pressure in the general population remains 
debatable209, but patients with end-stage renal failure are particular susceptible to the 
adverse effects of salt loading which can lead to severe hypertension and left ventricular 
hypertrophy209. It has been suggested that these adverse effects due to the increased plasma 
sodium itself and not due to the associated hypervolaemia209 and, given this, further 
research into the link between plasma ADMA and sodium is warranted. 
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Figure 5.10. The variation of plasma ADMA with plasma sodium. The Pearson 
correlation coefficient (r = 0.277) is highly significant at p = 0.01. 
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5.1.5.3. Thyroid Function 
The associations between ADMA, MMA, log SDMA and TSH and fT4 are shown in figure 
5.11. ADMA was significantly increased for patients with decreased TSH as compared with 
patients with TSH values within the reference range (Mann-Whitney, p = 0.001),  no 
difference was detected for patients with an increased TSH compared with those with 
normal TSH (Mann-Whitney, p = 0.904). ADMA concentrations showed a significant 
association with fT4 (p = 0.004). Similar results were observed for MMA, being increased 
for decreased TSH as compared to normals (Mann-Whitney, p = 0.001), no difference 
between patients with high TSH as compared with normals (Mann-Whitney, p = 0.816) and 
a significant association with fT4 (p =0.024). No statistically significant differences were 
detected for log SDMA for low vs normal TSH (Mann-Whitney, p = 0.142) or high vs 
normal TSH (Mann-Whitney, p = 0.730), however a statistically significant association was 
present for  log SDMA and fT4 (p = 0.004); this latter finding was inconsistent with the 
results obtained with linear modelling in which no association was detected between log 
SDMA and fT4.  Further analysis of the data showed a significant association between 
creatinine and fT4 (Trcreatinine vs fT4, Pearson correlation = 0.027), and when linear 
modelling for log SDMA was repeated, with the exclusion of creatinine as a variable, fT4 
became a significant predictor of log SDMA (p = 0.019). A possible explanation of these 
findings is that there are changes in GFR, associated with thyroid status, with an associated 
change in the renal excretion of SDMA, and that SDMA concentrations are therefore 
indirectly linked with thyroid status. To further investigate this possibility results from 
routine requests for creatinine and thyroid function for a one month period were extracted 
from the laboratory computer  system. The creatinine results were divided into seven 
groups according to TSH, with five groups being used to cover the TSH reference range 
(0.3 - 4.2 mu/L); results were only used for patients with a normal eGFR (>60 ml/min) and 
males and females were analysed separately. The results of the analysis are shown in table 
5.6 and the confidence intervals for the mean creatinine of each group in figure 5.11. 
Absolute differences between the groups are small but statistically highly significant (one-
way ANOVA, females: p < 0.001, males: p = 0.001). When log SDMA was grouped in a 
similar fashion according to TSH (figure 5.12) one-way ANOVA showed a statistically 
significant association between the two (p = 0.031). 
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Figure 5.11. The variation of plasma ADMA, MMA and SDMA with TSH and with fT4. For patients with 
low vs normal TSH a statistically significant increase for both ADMA and MMA was observed (Mann-Whitney: p = 
0.001 for both).  No significant difference was detected for patients with a high vs normal TSH for either ADMA or 
MMA (Mann-Whitney: p = 0.904 and p = 0.816 respectively). For log SDMA no significant difference was observed 
for either patients with low vs normal TSH or high vs normal TSH (Mann:Whitney: p = 0.142 and p = 0.730 
respectively). ADMA, MMA and log SDMA were all highly correlated with fT4 (Pearson’s rho, p =0.247, p = 0.024 
and p = 0.004 respectively). 
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  Females   Males 
 TSH (mU/L) n mean plasma creatinine 
(µmol/L) 
n mean plasma creatinine 
(µmol/L) 
<0.30  121 64.5 45 78.7 
0.30 -  1.08 413 64.1 280 83.0 
1.09 -  1.86 728 66.0 656 84.3 
1.87 -  2.64 587 67.1 545 85.3 
2.65 -  3.42 344 67.4 274 84.9 
3.43 -  4.20 192 68.6 160 85.7 
> 4.20  353 68.2 193 86.6 
total  2738  2153  
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Table 5.7. The variation of plasma creatinine with TSH. The results of routine requests 
for plasma creatinine and TSH for a one month period were extracted from the 
laboratory computer system and grouped according to TSH such that the TSH reference 
range (0.3 - 4.2 mU/L) has been divided into five equally spaced groups. 
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Figure 5.12. The confidence interval of the mean for plasma creatinine. The results were  
grouped by TSH, such that the TSH reference range (0.3 - 4.2 mU/L) has been divided 
into five equally spaced groups. One way ANOVA showed a highly significant variation 
of mean plasma creatinine with TSH, for both females (p < 0.001) and males (p = 0.01) 
using data for routine requests extracted from the laboratory computer system for a one 
month period. 
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Two studies on the association between ADMA, SDMA and thyroid function been 
published210,211 and the findings, with comparison with the present work, are summarised in 
table 5.7. ADMA is consistently shown to be increased in hyperthyroidism, however a 
difference in ADMA between hypothyroid and euthyroid patients (increased ADMA in 
hypothyroidism) was only observed by Arikan et al. There is a complete lack of 
consistency regarding observations between SDMA and thyroid status, however, as noted 
above, associations between SDMA and TSH appear to depend greatly upon the way in 
which results have been subdivided; Hermenegildo et al having used TSH concentrations 
> 15 mU/L to classify patients as hypothyroid and Ariken et al using a threshold of 
10 mU/L. It should also be noted that in the present work, patients in the hyperthyroid 
group did not have primary hyperthyroidism, unlike the patients included by 
Hermenegildo et al and Ariken et al, but instead had a hyperthyroid pattern of results due to 
being over-treated hypothyroid patients. 
 
 
The reason for the association between ADMA and thyroid status has not been determined 
but a possible explanation comes from cell culture studies in which it has been 
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Figure 5.13. Confidence of the mean for log SDMA. The results have been grouped 
according to TSH such that the TSH reference range (0.3 - 4.2 mU/L) has been divided 
into five equally spaced groups. One way ANOVA showed a significant variation of mean 
log SDMA with TSH (p = 0.031). 
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demonstrated that the activity of PRMT I (and therefore production of ADMA) is regulated 
by T3 concentration212. 
 
 
Status   ADMA    SDMA  
  current work Hermenegildo 
et al210 
Arikan 
et al211 
 current work Hermenegildo 
et al210 
Arikan et al211 
hyperthyroid  0.60 ± 0.12 ↑ a) 
(n = 16) 
1.30 ± 0.12 ↑ a) 
(n = 19) 
0.89 ± 0.28 ↑ a) 
(n = 25) 
0.50 ± 0.12 
(n = 16) 
0.54 ± 0.07 ↑ a) 
(n = 19) 
0.35 ± 0.11 
(n = 25) 
euthyroid  0.49 ± 0.08 
(n =104) 
0.58 ± 0.06 
(n = 31) 
0.40 ± 0.08 
(n = 25) 
 0.56 ± 0.14 
(n = 104) 
0.27 ± 0.04 
(n = 31) 
 0.41 ± 0.11 
(n = 25) 
hypothyroid  0.49 ± 0.07 
(n = 14) 
0.57 ± 0.07 
(n = 12) 
0.69 ± 0.45 ↑ a) 
(n = 23) 
0.58 ± 0.15 
(n = 14) 
not given 0.28 ± 0.11 ↑ a) 
(n = 23) 
 
 
 
 
 
 
5.1.5.4. Uric Acid 
The associations between methylated arginines and transformed uric acid are shown in 
figure 5.13. ADMA and log SDMA both showed highly significant associations with 
transformed uric acid when both correlation coefficients were examined (p = 0.001 and 
p < 0.001 respectively) and linear modelling was used (p <0.001 and p = 0.002 
respectively. An association between MMA and transformed uric acid was only noted when 
linear modelling was used and was only of slight significance (p = 0.092). The association 
between ADMA, SDMA and uric acid is most probably due to the fact that they share a 
similar origin; ADMA and SDMA resulting from the breakdown of nuclear proteins and 
the bulk of uric acid being formed from the metabolism of endogenous nucleic acids213. 
 
 
Table 5.8. Comparison of  findings regarding thyroid status and methylated arginines with published 
studies. ADMA is consistently shown to be increased in hyperthyroidism, however there are 
inconsistencies as to findings in patients with hypothyroidism. There is no consistency with regard to the 
findings for SDMA, however it should be noted that in the current work, when SDMA is further 
subdivided according to TSH, it shows a significant increase with TSH. 
a)
 ↑ significant increase (p ≤ 0.01) 
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Figure 5.14. The association between uric acid and methylated arginines. 
The methylated arginines are plotted against transformed uric acid. ADMA 
and log SDMA both showed statistically significant correlations with 
transformed uric acid (Pearson: p = 0.001 and p 0.001 respectively. No 
significant association was detected between MMA and transformed uric 
acid (p = 0.200). 
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5.2. The ACADEMIC Study 
 
The ACADEMIC (arterial compliance and oxidant stress as predictors of rate of decline of 
renal function, morbidity and mortality in chronic kidney disease) study is an ongoing 
prospective investigation of cardiovascular risk in CKD stages 3 and 4 designed to evaluate 
the relationship between changes in arterial stiffness and renal function over time. The 
clinical aspects of this study were conducted by Dr Laurie Tomlinson (LT; Research 
Fellow, Brighton & Sussex University Hospitals NHS Trust). 
 
5.2.1. Subjects and Investigations 
 
Subjects 
All participants enrolled in the study were classified as having CKD stages 3 or 4 (staged 
according to the 2005 UK CKD guidelines). Exclusion criteria were previous diagnosis of 
left ventricular failure, aortic stenosis with gradient >30 mmHg and uncontrolled atrial 
fibrillation. All participants were treated with the aim of achieving United Kingdom Renal 
Association targets for management of BP in CKD; a target BP of 130/80 mmHg or less for 
patients with a urine protein:creatinine ratio <100 mg/mmol and 125/75 mmHg for those 
with a protein:creatinine ratio >100 mg/mmol. The choice of antihypertensive medication 
was at the discretion of the patient’s clinician but followed Renal Association and British 
Hypertension Society guidelines. The study was approved by the West Sussex Research 
Ethics Committee, and the patients gave written informed consent. The study was 
conducted in accordance with the Declaration of Helsinki. 
 
Patients who gave written informed consent for participation were included and had 
baseline clinical assessment, laboratory and PWV measurements and follow-up at 6 and 12 
months. A full history of renal disease, cardiovascular disease and associated risk factors 
was obtained. All measurements were conducted in a quiet, temperature controlled room by 
the same two researchers throughout the study. Cardiovascular disease was defined as a 
history of myocardial infarction, angina, coronary artery bypass grafting, stroke, transient 
ischaemic attack or peripheral vascular disease given by the patient and confirmed from the 
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medical notes. The cause of renal disease was determined by review of the medical notes, 
including biopsy results, imaging and blood tests, by the renal medical team. Hypertension 
was defined as a blood pressure ≥140 mmHg systolic and/or ≥90 mmHg diastolic and/or 
the current use of antihypertensive medication. 
 
 
PWV recordings 
Aortic stiffness was assessed by automatic carotid-femoral PWV measurement using the 
Complior device (Artech-Medical, Paris, France); the technical characteristics of this 
device have been described previously214, and indicate intra-observer within-session 
coefficients of variation for aortic PWV of 3.8 ±1.3% (n=25) In-house assessment of 
analytical reproducibility suggested an intra-observer imprecision of less than 4%. 
 
 
“Briefly, common carotid artery and femoral artery pressure waveforms were recorded 
noninvasively with a pressure-sensitive transducer. The pressure waveforms were digitised 
at a sample acquisition frequency of 800 Hz. The two pressure waveforms were then stored 
in a memory bank. A preprocessing system automatically analysed the gain in each 
waveform and adjusted it to equalise the two signals. Details of this procedure have been 
published previously (Asmar et al., 1995214). When the operator observed a pulse 
waveform of sufficient quality on the computer screen, digitisation was suspended and 
calculation of the time delay between the two pressure upstrokes was initiated. 
Measurement was repeated over 10 different cardiac cycles, and the mean was used for the 
final analysis. The distance travelled by the pulse wave was measured over the body 
surface as the distance between the two recording sites (D), whereas pulse transit time (t) 
was determined by the Complior. PWV was automatically calculated as PWV = D/t.”  
(Provided by Dr Laurie Tomlinson) 
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Blood pressure measurements 
Oscillometric BP was measured twice on the right arm using an appropriate cuff size with 
the patient supine after 5 and 10 min of rest (Omron 705 CP, Tokyo, Japan), and the mean 
of the two recordings of SBP and DBP was recorded. The mean blood pressure (MBP) was 
calculated by MBP = (SBP − DBP)/3 + DBP. 
 
Biochemical analysis 
At baseline, fasting lithium heparinised plasma samples were taken to measure creatinine, 
albumin, total cholesterol and uric acid. Plain random urine samples were also obtained and 
used to estimate proteinuria (total protein:creatinine ratio where > 30 mg/mmol was 
considered significant). 
 
Plasma cystatin-C concentrations were measured using a BNProSpec nephelometer (Dade 
Behring, Inc., UK) with a particle-enhanced immunonephelometric assay (N Latex 
Cystatin-C, Dade Behring, Inc.) 
 
Estimated glomerular filtration rate (eGFR), ml/min/1.73m2  body surface area, was 
calculated using the four-variable modified MDRD formula: 
 
 eGFR = 186 x ([Creatinine] (µmol/l)) / 88.4)-1.154 x (Age (years))-0.203 
 x (0.742 if female) x (1.210 if black) 
 
 
 
 
 
Study Population 
Baseline characteristics are summarised in table 5.8. None of the participants were 
receiving dialysis at baseline. The etiology of kidney disease was due to polycystic kidney 
disease in 23%, glomerular disease in 38%, and other causes in 39%.  
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Parameter Mean ± sd   or 
median (IQR) 
Reference range (at 
Royal Sussex County 
Hospital, Brighton) 
Demographics   
 age (years) 69.1±11.5  
 Male (%) 77  
   
Medical History   
 History of vascular disease (%) 42.9  
 History of hypertension (%) 78  
 History of diabetes (%) 23  
 History of smoking (%) 65  
 Body mass index (kg/m2) 29.4 ± 5.8  
   
Clinical Parameters   
 Systolic Blood Pressure (mmHg) 154.7 ± 20.9  
 Diastolic BP (mmHg) 82.7 ± 11.4  
 Pulse Pressure (mmHg) 71.8 ± 19.6  
 MAP (mmHg) 106.6 ±12.3  
 CF-PWV (m/s) 12.6 ± 2.8  
   
Plasma biochemistry   
 eGFR (mL/min/1.73m2) 32.1 ± 10.9 ≥ 60 
 creatinine (F) (µmol/L) 169.4 ± 56.3 44 - 80 
 creatinine (M) (µmol/L) 210.8 ± 69.5 62 - 106 
 Transformed creatinine 11.62 ±5.96  
 cystatin C (mg/L) 1.86  ± 0.58 0.49 - 0.98 
 albumin (g/L) 42.5 ± 3.1 34 - 48 
 cholesterol (mmol/L) 4.37 ± 0.98 < 5.0 
 uric acid (F) (mmol/L) 0.423 ± 0.118 0.14 - 0.34 
 uric acid (M) (mmol/L) 0.468 ± 0.096 0.20 - 0.42 
 Transformed uric acid 2.98 ± 1.92  
 ADMA (µmol/L) 0.554 ± 0.102  
 SDMA (µmol/L) 0.997 (0.821 - 1.310)  
 MMA (µmol/L) 0.171 (0.147 - 0.204)  
 arginine (µmol/L) 88 (72 - 121)  
 total homocysteine (µmol/L) 22.2 (18.8 - 27.3) 5 - 15 
   
Urine biochemistry   
 protein:creatinine ratio (mg/mmol) 28 (14 - 70)  
   
Medication use   
 anti-hypertensives (%) 90  
 diuretics (%) 60  
 statins (%) 60  
Table 5.9. Baseline characteristics of 133 patients in the ACADEMIC study. 
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5.2.2. Results 
 
SDMA, MMA, arginine and total homocysteine were not normally distributed 
(Kolmogorov-Smirnov: p = 0.044, 0.009, 0.021 and 0.47 respectively) but following 
logarithmic transform each variable passed the test for normality (Kolmogorov-Smirnov: 
p = 0.754, 0.791, 0.564 and 0.831 respectively). 
 
No association was found between any biochemical parameter and age, history of smoking, 
BMI, CF-PWV or any of the various measures of blood pressure. 
 
Biochemical parameters which showed an association with ADMA, log SDMA, log MMA 
and/or log total homocysteine are shown in table 5.9, no other significant associations 
(p ≤ 0.05) were noted. 
 
Log total homocysteine and log SDMA both showed strong associations with all measures 
of renal function (Trcreat, eGFR and cystatin C), consistent with previous findings53,117. 
ADMA, however, showed a very significant association with cystatin C, but not with 
Trcreat or eGFR (significance of Pearson correlation coefficient: p <0.001, p = 0.247, 
p = 0.403, respectively). The association between ADMA and cystatin C is most probably 
due to the fact that both are derived from the degradation of nucleic proteins103,215. No 
statistically significant association was found between ADMA and log homocysteine. 
 
To investigate which biochemical parameters might be determinants of CF-PWV a 
multivariate stepwise model was constructed using age, ADMA, log SDMA, log arginine, 
log MMA, log (arginine/ADMA), log total homocysteine, Truric acid, Trcreat, and cystatin 
C as variables. Log (arginine/ADMA) was included as it has been suggested that the ratio 
of  arginine to ADMA is a determinant of  vascular function216; the ratio of arginine to 
ADMA did not passed the Kolmogorov-Smirnov test for normality (p = 0.006) whereas the 
logarithm of the ratio did (p = 0.719). 
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The only significant determinants of CF-PWV were age and cystatin C (p <0.001, p = 0.04 
respectively). 
 
 
Pearson correlation 
analysis 
log hcy ADMA log SDMA log MMA log arginine 
log thcy Correlation Coefficient  0.153 0.253 0.061 0.118 
  Significance 
 0.078 0.003** 0.484 0.177 
ADMA Correlation Coefficient 0.153  0.355 0.482 0.146 
  Significance 0.078  <0.001** <0.001** 0.094 
log SDMA Correlation Coefficient 0.253 0.355  0.210 0.169 
  Significance 0.003** <0.001**  0.015* 0.052 
log MMA Correlation Coefficient 0.061 0.482 0.210  0.320 
  Significance 0.484 <0.001** 0.015*  <0.001** 
log arginine Correlation Coefficient 0.118 0.146 0.169 0.320  
  Significance 0.177 0.094 0.052 <0.001**  
albumin Correlation Coefficient 0.155 -0.182 -0.162 -0.067 -0.037 
  Significance 0.075 0.036* 0.062 0.441 0.674 
eGFR Correlation Coefficient -0.344 -0.073 -0.716 -0.093 -0.060 
  Significance <0.001** 0.403 <0.001** 0.284 0.495 
Transformed 
creatinine 
Correlation Coefficient 0.288 0.101 0.746 0.082 0.136 
  Significance <0.001** 0.247 <0.001** 0.348 0.119 
cystatin C Correlation Coefficient 0.319 0.309 0.727 0.071 0.104 
  Significance <0.001** <0.001** <0.001** 0.415 0.233 
Transformed 
uric acid 
Correlation Coefficient 0.236 -0.019 0.152 0.047 0.010 
  Significance 0.006** 0.829 0.081 0.594 0.913 
 
 
 
 
 
 
 
 
 
Table 5.10. Correlations between plasma results for participants in the ACADEMIC study. 
** significant at p < 0.5 
*** significant at p < 0.01 
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5.2.3. Discussion 
 
Plasma ADMA showed no association with log total homocysteine for either samples that 
had been received for routine clinical investigation or for samples that had been taken as 
part of the ACADEMIC study. For the samples received routinely, effort had been made to 
ensure that plasma had been promptly separated from red-cells, however possible delays in 
the receipt of these samples meant that this could not be guaranteed. Erythrocytes continue 
to produce homocysteine after blood samples have been taken53, and delays in sample 
processing could be a confounding factor in the analysis, however this would not apply to 
the results from the ACADEMIC study, in which samples had been processed immediately. 
If plasma total homocysteine concentrations are a determinant of plasma ADMA 
concentrations then, the fact that no association has been found between the two in this 
work, it would appear that it is a much weaker determinant than other factors such as 
plasma sodium concentrations and thyroid status. 
 
For patients in the ACADEMIC study no association was found between CF-PWV and 
total homocysteine concentrations; results from other studies (section 1.4.3) have reported 
both negative and positive associations. A large percentage of patients in the ACADEMIC 
study were taking statins (60%), diuretics (60%) and/or anti-hypertensive agents (90%) and 
the use of these medications may have been a confounding factor in the investigation. 
There was not sufficient data for patients taking no medication to perform a sub-group 
analysis. 
 
In conclusion, the results of this work do not support the hypothesis that elevated plasma 
homocysteine concentrations cause vascular dysfunction by increasing plasma ADMA. 
 
 
 
 
 
  
130 
 
 
Publications 
 
Simultaneous quantitation of homocysteine, cysteine and methionine in plasma and urine 
by liquid chromatography-tandem mass spectrometry. G Weaving, BF Rocks, SA Iversen, 
MA Titheradge. Ann Clin Biochem (2006) 43, 474-480. 
 
 
Behavioural and psychological symptoms of Alzheimer type dementia are not correlated 
with plasma homocysteine concentration. N Tabet, H Rafi, G Weaving, B Lyons, 
SA Iversen. Dementia and geriatric cognitive disorders. (2006) 22, 432-438. 
 
 
Arginine and methylated arginines in human plasma and urine measured by tandem mass 
spectrometry without the need for chromatography or sample derivatisation. G Weaving, 
BF Rocks, MP Bailey, MA Titheradge. J Chrom B (2008) 874. 27-32. 
 
 
Liquid chromatography: is it essential for the determination of arginine and methylated 
arginines by tandem mass spectrometry? G Weaving, BF Rocks, MP Bailey, MA 
Titheradge. J Chrom B (2009) 877, 3267-3269. 
 
 
 
 
 
 
 
 
  
131 
REFERENCES 
 
                                                 
1  CHD UK Mortality. British Heart Foundation Statistics Database. 
 www.heartstats.org accessed  3/04/2010. 
 
2  Ross R. (1999) Atherosclerosis - an inflammatory disease. New Engl J Med 340, 
 115-126. 
 
3  Wang TJ, (2008) New cardiovascular risk factors exist, but are they clinically 
 useful? Eur Heart J 29, 441-444. 
 
4  Shishehbor MH, Oliveira LPJ, Lauer MS, Sprecher DL, Wolski K, Cho L, 
 Hoogwerf BJ, Hazen, SL. (2008) Emerging cardiovascular risk factors that account 
 for a significant portion of attributable mortality risk in chronic kidney disease. Am 
 J Cardiol 101, 1741-1746. 
 
5  Myers GL, Christenson RHM, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer 
 CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PWF. (2009) National 
 Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: 
 emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 
 55, 378-384. 
 
6  Mansoor MA, Svardal AM, Ueland PM. (1992) Determination of the in vivo redux 
 status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma. 
 Anal Biochem 200, 218-229. 
 
7  Carson NAJ, Cusworth DC, Dent CE, Field, CMB, Neill DW, Westall, RG. (1963) 
 Homomocystinuria: a new inborn error of metabolism associated with mental 
 deficiency. Arch Dis Childh 38, 425-436. 
 
8 Mudd SH, Finkelstein JD, Irreverre F, Laster L. (1964) Homocystinuria: an 
 enzymatic defect. Science 143, 1443-1445. 
  
9  Mudd SH, Harvey L, Abeles RH. (1969) A derangement in B12 metabolism leading 
 to homocystinemia, cystathioninemia and methylmalonic aciduria. Biochem 
 Biophys Res Commun 35, 121-126. 
 
10  McCully KS. (1969) Vascular pathology of homocysteinemia: implications for the 
 pathogenesis of arteriosclerosis. Am J Pathol 56, 111-128. 
 
11  Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz, RE, Andria G, 
 Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. 
 (1985) The natural history of homocystinuria due to cystathionine-B-synthase 
 deficiency. Am J Hum Genet 37, 1-31. 
 
12  Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ, Walter JH, 
 Howard PM, Naughten ER. (2001) Vascular outcome in patients with 
  
132 
                                                                                                                                                     
 homocystinuria due to cystahionine β-synthase deficiency treated chronically: a 
 multicenter observational study. Arterioscler Thromb Vasc Biol 21, 2080-2085. 
 
13  Naughten ER, Yap S, Mayne PD. (1998) Newborn screening for homocystinuria: 
 Irish and world experience. Eur J Pediatr 157 (Suppl 2) S84-S87. 
 
14  Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. (1991) 
 Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for 
 coronary artery disease. Am J Hum Genet 48, 536-545. 
 
15  Blom HJ. (2001) Diseases and drugs associated with hyperhomocysteinemia. In 
 Homocysteine in Health and Disease.  (Carmel R, Jacobsen DW, ed) pp 331-340, 
 Cambrdge University Press, Cambridge. 
 
16  Refsum H, Ueland PM, Nygård O, Vollset SE. (1998) Homocysteine and 
 cardiovascular disease. Annu Rev Medicine 49, 31-62. 
 
17  Desouza C, Keebler M, McNamara DB, Fonseca V. (2002) Drugs affecting 
 homocysteine metabolism: impact on cardiovascular risk. Drugs 62, 605-616. 
 
18  Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. (1995) A quantitative 
 assessment of plasma homocysteine as a risk factor for vascular disease: probable 
 benefits of increasing folic acid intake. JAMA 274, 1049-1057. 
 
19  Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, 
 Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, 
 McMaster D, Verhoef P, Witterman J, Rubba P, Bellet H, Wautrecht JC, 
 de Valk HW, Sales Lúis AC, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon D, 
 Medrano MJ, Candito M, Evans AE, Andria G. (1997) Plasma homocysteine as a 
 risk factor for vascular disease: the European Concerted Action Project. JAMA 277, 
 1775-1781. 
 
20  Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. (2002) 
 Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence 
 with special emphasis on case-controlled studies and nested case controlled studies. 
 Int J Epidemiol 31, 59-70. 
 
21  The Homocysteine Studies Collaboration. (2002) Homocysteine and risk of 
 ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022 
 
22  Møller J, Rasmussen K, Christensen L. (1999) External quality assessment of 
 methylmalonic acid and total homocysteine. Clin Chem 45, 1536-1542. 
 
23  Ogino S, Wilson RB. (2003) Genotype and haplotype distributions of MTHFR 
 677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum 
 Genetics 48, 1-7. 
 
  
133 
                                                                                                                                                     
24  Wald DS, Law M, Morris JK. (2002) Homocysteine and cardiovascular disease: 
 evidence on causality from a meta-analysis. BMJ 325, 1202-1208. 
 
25  Brattström L, Wilcken DEL, Öhrvik J, Brudin L. (1998) Common 
 methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia 
 but not to vascular disease: the result of a meta-analysis. Circulation 98, 2520-2526. 
 
26  Klerk M, Verhoef P, Clarke R, Blom HJ, Kok KJ, Schouten and the MTHFR 
 Collaboration Group. (2002) MTHFR 677C→T polymorphism and risk of coronary 
 heart disease: a meta-analysis. JAMA 288, 2023-2031. 
 
27  Den Heijer M, Lewington S, Clarke R. (2005) Homocysteine, MTHFR and risk of 
 venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb 
 Haemost 3, 292-299. 
 
28  Cronin S, Furie KL, Kelly PJ. (2005) Dose-related association of MTHFR 677T 
 allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. 
 Stroke 36, 1581-1587. 
 
29  Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. 
 (2002) Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic 
 stroke: results of a meta-analysis. Neurology 59, 529-536. 
 
30  Lewis SJ, Ebrahim S, Davey Smith G. (2005) Meta-analysis of MTHFR 677C→T 
 polymorphism and coronary heart disease: does totality of evidence support causal 
 role for homocysteine and preventive potential of folate? 
 doi:10.1136/bmj.38611.658947.55 (published 10 October 2005) 
 
31  Jacques PF, Bostom AG, Williams RR, Curtis Ellison R, Eckfeldt JH, 
 Rosenberg IH, Selhub J, Rozen R. (1996) Relation between folate status, a common 
 mutation in methylenetetrahydrofolate reductase, and plasma homocysteine 
 concentrations. Circulation 93, 7-9. 
 
32  Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. (1999) The effect 
 of folic acid fortification on plasma folate and total homocysteine concentrations. 
 NEJM 340, 1449-1454. 
 
33  Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, 
 Sides EG, Wang CH, Stampfer M. (2004) Lowering homocysteine in patients with 
 ischaemic stroke to prevent recurrent stroke, myocardial infarction, and death: the 
 Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. 
 JAMA 291, 565-575. 
 
34  Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, 
 Nordrehaug JE, Arnesen E, Rasmussen K. (2006) Homocysteine lowering and 
 cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578-
 1588. 
  
134 
                                                                                                                                                     
 
35  The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. (2006) 
 Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J 
 Med 354, 1567-1577. 
 
36  Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino, PD, 
 Gaziano JM. (2007) Effect on homocysteine lowering on mortality and vascular 
 disease in advanced chronic kidney disease and end-stage renal disease: a 
 randomized controlled trial. JAMA 298, 1163-1171. 
 
37  Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, 
 Refsum H, Pedersen EKR, Nygård O. (2008) Mortality and cardiovascular events in 
 patients treated with homocysteine-lowering B vitamins after coronary angiography: 
 a randomized controlled trial. JAMA 300, 795-804. 
 
38  Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring 
 JE, Manson JE. (2008) Effect of folic acid and B vitamins on risk of cardiovascular 
 events and total mortality among women at high risk for cardiovascular disease: a 
 randomized trial. JAMA 299, 2027-2036. 
 
39  Siliman EZ, Shalash OA. (2008) Homocysteine, vitamins, and vascular disease 
 prevention: more negaative results. Am J Clin Nutr 87, 1069-1070. 
 
40  Spence JD, Bang H, Chambless LE, Stampfer MJ. (2005) Vitamin Intervention for 
 Stroke Prevention trial: an efficacy analysis. Stroke 36, 2404-2409. 
 
41  Joseph J, Handy DE, Loscalzo J. (2009) Quo vadis: whither homocysteine research? 
 Cardiovasc Toxicol 9, 53-63. 
 
42  Mohan IV, Jagroop IA, Mikhailidis DP, Stansby G. (2008) Homocysteine activates 
 platelets in vitro. Clinical and Applied Thrombosis/Hemostasis. 14, 8-18 
 
43  Rikitake Y, Liao JK. (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97, 
 1232-1235. 
 
44  D'Angelo A, Selhub J. (1997) Homocysteine and thrombotic disease. Blood 90, 
 1-11. 
  
45  Perna AF, Ingrosso D, Lombardi C, Acanfora F, Satta E, Cesare M, Violetti E, 
 Romano M, De Santo NG. (2003) Kidney Int 63 (Suppl 84), S137-S140. 
 
46  Perla-Kaján J, Twardowski T, Jakubowski H. (2007) Mechanisms of homocysteine 
 toxicity in humans. Amino Acids 32,561-572. 
 
47  Signorello MG, Segantin A, Passalacqua M, Leoncini G. Homocysteine decreases 
 platelet NO level via protein kinase C activation. Nitic Oxide 20, 104-113. 
 
  
135 
                                                                                                                                                     
48  Khajuria A, Houston DS. (2000) Induction of monocyte tissue factor expression by 
 homocysteine: a possible mechanism for thrombosis. Blood 96, 966-972. 
  
49  Loscalzo J. (1996) The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98, 
 5-7. 
 
50  Jacobsen DW (2001) Cellular mechanisms of homocysteine pathogenesis in 
 atherosclerosis. In Homocysteine in Health and Disease.  (Carmel R, Jacobsen 
 DW, ed) pp 425-440, Cambrdge University Press, Cambridge. 
 
51  El-Khairy L, Vollset SE, Refsum H, Ueland PM. (2003) Plasma total cysteine, 
 mortality and cardiovascular disease hospitalizations: the Hordaland Homocysteine 
 Study. Clin Chem 49, 6. 
 
52  Poddar r, Sivasubramanian N, DiBello P, Robinson K, Jacobsen DW. (2001) 
 Homocysteine induces expression and secretion of monocyte chemoattractant 
 protein-1 and interleukin-8 in human aortic endothelial cells: implications for 
 vascular disease. Circulation 103, 2717-2723. 
 
53 Rasmussen K, Møller J. (2000) Total homocysteine measurement in clinical 
 practice. Ann Clin Biochem 37, 627-648. 
   
54  Ducros V, Demuth K, Sauvant MP, Quillard M, Caussé E, Candito M, Read MH, 
 Drai J, Garcia I, Gerhardt MF. (2002) Methods for homocysteine analysis and 
 biological relevance of the results. J Chrom B 781, 207-226. 
 
55  Nekrassova O, Lawrence NS, Compton RG. (2003) Analytical determination of 
 homocysteine: a review. Talanta 60, 1085-1095. 
 
56  Toyo'oka T. (2009) Recent advances in separation and detection methods for thiol 
 compounds in biological samples. J Chrom B 877, 3318-3330. 
  
57  McMenamin ME, Himmelfarb J, Nolin TD. (2009) Simultaneous analysis of 
 multiple aminothiols in human plasma by high performance liquid chromatography 
 with fluorescence detection. J Chrom B 877, 3274-3281. 
 
58  Rafii M, Elango R, Housed JD, Courtney-Martin G, Darling P, Fisher L, Pencharz 
 PB. (2009) Measurement of homocysteine and related metabolites in human plasma 
 and urine by liquid chromatography electrospray tandem mass spectrometry. J 
 Chrom B 877, 3282-3291. 
 
59  Tomaiuolo M, Vecchione G, Margaglione M, Pisanelli D, Grandone E. (2009) 
 Stable-isotope dilution LC-ESI-MS/MS techniques for the quantification of total 
 homocysteine in human plasma. J Chrom B 877, 3292-3299. 
 
60  Carlucci F, Tabucchi A. (2009) Capillary electrophoresis in the evaluation of 
 aminothiols in body fluids. J Chrom B 877, 3347-3357. 
 
  
136 
                                                                                                                                                     
61  Kredich NM, Kendall HE, Spence FJ. (1981) A sensitive radiochemical enzyme 
 assay for S-adenosyl-L-homocysteine and L-homocysteine. Anal Biochem 116, 
 503-510. 
 
62  Refsum H, Helland S, Ueland PM, (1985) Radioenzymic determination of 
 homocysteine in plasma and urine. Clin Chem 31, 624-628. 
 
63  Briddon A. (1998) Total plasma homocysteine as part of the routine aminogram by 
 ion-exchange chromatography. Amino Acids 15: 235-239. 
 
64  Toyo'oka T, Imai K. (1984) New Fluorogenic reagent having halogenbenzofurazan 
 structure for thiols: 4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole. Anal Chem 
 56, 2461-2464. 
 
65  Toyo'oka T, Suzuki T, Saito Y, Uzu, S, Imai K. (1989) Fluorogenic reagent for 
 thiols: 4-(N,N-dimethylaminosulphonyl)-7-fluoro-2,1,3-benzoxadiazole. Analyst 
 114, 413-419. 
 
66  Refsum H, Ueland PM, Svardal AM. (1989) Fully automated fluorescence assay for 
 determining total homocysteine in plasma. Clin Chem 35, 1921-1927. 
 
67  Fiskerstrand T, Refsum H, Kvalhelm G, Ueland PM. (1993) Homocysteine and 
 other thiols in plasma and urine: automated determination and sample stability. Clin 
 Chem 39, 263-271. 
 
68  Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic K, Ji J, Otto 
 JM, Taylor LM. (1994) Rapid HPLC determination of total homocysteine and other 
 thiols in serum and plasma: sex differences and correlation with cobalamin and 
 folate concentrations in healthy subjects. Clin Chem 40, 873-881. 
 
69  Pastore A, Massoud R, Motti C, Russo AL, Fucci G, Cortese C, Federici G. (1998) 
 Fully automated assay for total homocysteine, cysteine, cysteinylglycine, 
 glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine. Clin 
 Chem 44, 825-832. 
 
70  Araki A, Sako Y. (1987) Determination of free and total homocysteine in human 
 plasma by high-performance liquid chromatography with fluorescence detection. J 
 Chrom Biomedical Applications 422, 43-52. 
 
71  Ubbink JB, Vermaak WJ, Bissbort S. (1991) Rapid high-performance liquid 
 chromatographic assay for total homocysteine levels in human serum. J Chrom 
 Biomedical applications 565, 441-446. 
 
72  Pfeiffer CM, Huff DL, Gunter EW. (1999) Rapid and accurate HPLC assay for 
 plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 
 45, 290-292. 
 
  
137 
                                                                                                                                                     
73  Nolin TD, McMenamin ME, Himmelfarb J. (2007) Simultaneous determination of 
 total homocysteine, cysteine, cysteinylglycine and glutathione in human plasma by 
 high-performance liquid chromatography: application to studies of oxidative stress. 
 J Chrom B 852, 554-561. 
 
74  D'Eramo J, Finkelstein AE, Boccazzi FO, Fridman O. (1998) Total homocysteine 
 levels in plasma: high-performance liquid chromatographic determination with 
 electrochemical detection and glassy carbon electrode. J Chrom B 720, 205-210. 
 
75  Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF. (1999) Measurement of 
 plasma total homocysteine by HPLC with coulometric detection. Clin Chem 45, 
 150-152. 
 
76  Melnyk S, Pogribna M, Pogribny I, Hine RJ, James SJ. (1999) A new HPLC 
 method for the simultaneous determination of oxidized and reduced plasma 
 aminothiols using coulometric electrochemical detection. J Nutr Biochem 10, 490-
 497. 
 
77  Stabler SP, Marcell PD, Podell ER, Allen RH. (1987) Quantitation of total 
 homocysteine, total cysteine, and methionine in normal serum and urine using 
 capillary gas chromatography-mass spectrometry. Anal Biochem 162, 185-196. 
 
78  Pietzsch J, Julius U, Hanefeld M. (1997) Rapid determination of total homocysteine 
 in human plasma by using N(O,S)-ethoxycarbonyl ethyl ester derivatives and gas 
 chromatography-mass spectrometry. Clin Chem 43, 2001-2004. 
 
79  Shinohara Y, Hasegawa H, Tagoku K, Hashimoto T. (2001) Simultaneous 
 determination of methionine and total homocysteine in human plasma by gas 
 chromatography-mass spectrometry. J Chrom B 758, 283-288. 
 
80  Stamler JS, Loscalzo J. (1992) Capillary zone electrophoretic detection of biological 
 thiols and their S-nitrosated derivatives. Anal Chem 64, 779-785. 
 
81  Vecchione G, Margaglione M,Grandone E, Colaizzo D, Cappucci G, Fermo I, 
 D'Angelo A Di Minno G. (1999) Determining sulfur containing amino acids by 
 capillary electrophoresis: a fast novel method for total homocyst(e)ine human 
 plasma. Electrophoresis 20, 569-574. 
 
82  Caussé E, Siri N,Bellet H,Champagne S, Bayle C, Valdiguié P, Salvayre R, 
 Couderc F. (1999) Plasma homocysteine determined by capillary electrophoresis 
 with laser-induced fluorescence detection. Clin Chem 45, 412-414. 
 
83  Frantzen F, Faaren AL, Alfheim I, Nordhei AK. (1998) Enzyme conversion 
 immunoassay for determining total homocysteine in plasma or serum. Clin Chem 
 44, 311-316. 
 
  
138 
                                                                                                                                                     
84  Demuth K, Ducros V, Michelsohn, S, Paul JL. (2004) Evaluation of Advia 
 Ceantaur® automated chemiluminescence immunoassay for determining total 
 homocysteine in plasma. Clin Chim Acta 349, 113-120. 
 
85  Shipchandler MT, Moore EG. (1995) Rapid fully automated measurement of 
 plasma homocyst(e)ine with the Abbot IMx® analyzer. Clin Chem 41, 991-994. 
 
86  Tan Y, Tang L, Sun X, Zhang N, Han Q, Xu M, Baranov E, Tan X, Tan X, Rashidi 
 B, An Z, Perry A, Hoffman R. (2000) Total-homocysteine enzymatic assay. Clin 
 Chem 46, 1686-1688. 
 
87  Han Q, Lenz M, Tan Y, Xu M, Sun X, Tan X,Tan X, Tang L, Miljkovic D, 
 Hoffman RM. (1998) High expression and proprties of recombinant homocysteine 
 α,γ-lyase. Protein Expression and Purification 14, 267-274. 
 
88  Dou C, Xia D, Zhang L, Chen X, Flores P, Datta A, Yuan C. (2005) Development 
 of a novel enzymatic cycling assay for total homocysteine. Clin Chem 51, 1987-
 1989. 
 
89  Jin M, Wang F, Uthup M, Szydlowska M. (2009) Analytical performance of an 
 enzymatic cycling method for total homocysteine measurement. Clin Chim Acta 
 399, 119-120. 
 
90  Roberts R, Roberts W. (2004) Performance characteristics of a recombinant 
 enzymatic cycling assay for quantification of total homocysteine in serum and 
 plasma. Clin Chim Acta 344, 95-99. 
 
91  Zappacosta B, Persichilli S, Minucci A, Scribano D, Baroni S, Fasanella S, Neri P, 
 Daloiso PD, Giardina B, De Sole P. (2006) Evaluation of a new enzymatic method 
 for homocysteine measurement. Clin Biochem 39, 62-66. 
 
92  Magera MJ, Lacey JM, Casetta B, Rinaldo P. (1999) Method for the determination 
 of total homocysteine in plasma and urine by stable isotope dilution and 
 electrospray tandem mass spectrometry. Clin Chem 45, 1517-1522. 
 
93  Gempel K, Gerbitz KD, Casetta B, Bauer MF. (2000) Rapid determination of total 
 homocysteine in blood spots by liquid chromatography-electrospray ionization-
 tandem mass spectrometry. Clin Chem 46, 122-123. 
 
94  Nelson BC, Pfeiffer CM, Sniegoski LT, Satterfield MB. (2003) Development and 
 evaluation of an isotope dilution LC/MS method for the determination of total 
 homocysteine in human plasma. Anal Chem 75, 775-784. 
 
95  McCann SJ, Gillingwater S, Keevil BG, Cooper DP, Morris MR. (2003) 
 Measurement of total homocysteine in plasma and blood spots using liquid 
 chromatography-tandem mass spectrometry: comparison with the plasma Abbot 
 IMx method. Ann Clin Biochem 40, 161-165. 
 
  
139 
                                                                                                                                                     
96  Nelson BC, Satterfield MB, Sniegoski LT, Welch MJ. (2005) Simultaneous 
 quantification of homocysteine and folate in human serum or plasma using liquid 
 chromatography/tandem mass spectrometry. Anal Chem 77, 3586-3593. 
 
97  Tuschl K, Bodamer OA, Erwe W, Mühl A. (2005) Rapid analysis of total plasma 
 homocysteine by tandem mass spectrometry. Clin Chim Acta 351, 139-141. 
 
98  Kuhn J, Götting C, Kleesiek K. (2006) Rapid micro-scale assay for homocysteine 
 by liquid chromatography-tandem mass spectrometry. Clin Biochem 39, 164-166. 
 
99  Huang Y, Lu ZY, Brown KS, Whitehead AS, Blair IA. (2007) Quantification of 
 intracellular homocysteine by stable isotope dilution liquid chromatography/tandem 
 mass spectrometry. Biomed Chromatogr 21, 107-112. 
 
100  Rafii M, Elango R, Courtney-Martin G, House JD, Fisher L, Pencharz PB. (2007) 
 High-throughput and simultaneous measurement of homocysteine and cysteine in 
 human plasma and urine by liquid chromatography-electrospray tandem mass 
 spectrometry. Anal Biochem 371, 71-81. 
  
101  Li S, Jia J, Liu G, Wang W, Cai Y, Wang Y, Yu C. (2008) Improved and simplified 
 LC-ESI-MS/MS method for homocysteine determination in human plasma: 
 application to the study of cardiovascular diseases. J Chrom B 870, 63-67. 
  
102  Hempen C, Wanschers H, van der Sluijs Veer G. (2008) A fast liquid 
 chromatographic tandem mass spectrometric method for the simultaneous 
 determination of total homocysteine and methylmalonic acid. Anal Bioanal Chem 
 391, 263-270. 
 
103  Pahlich S, Zakaryan RP, Gehring H. (2006) Protein arginine methylation: cellular 
 functions and methods of analysis. Biochim Biophys Acta 1764, 1890-1903. 
 
104  Bogle RG, MacAllister RJ, Whitley JGS, Vallance P. (1995) Induction of NG-
 monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO 
 synthases? Am J Physiol 269, 750-756. 
 
105  Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. 
 (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction 
 in humans and is actively metabolised by dimethylarginine 
 dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23, 1455-1459. 
 
106  Tran CTL, Leiper JM, Vallance P. (2003) The DDAH/ADMA/NOS pathway. 
 Atheroscler Suppl 4, 33-40. 
 
107  Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, 
 Vallance P, McDonald N. (2001) Structural insights into the hydrolysis of cellular 
 nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat 
 Struct Biol 8, 679-683. 
 
  
140 
                                                                                                                                                     
108  Palm F, Onozato ML, Luo Z, Wilcox CS. (2007) Dimethylarginine 
 dimethylaminohydrolase (DDAH): expression, regulation, and function in the 
 cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293, 3227-3245. 
 
109  Leiper J, Vallance P. (1999) Biological significance of endogenous methylarginines 
 that inhibit nitric oxide synthases. Cardiovasc Res 43, 542-548. 
 
110  Böger RH. (2003) The emerging role of asymmetric dimethylarginine as a novel 
 cardiovascular risk factor. Cardiovas Res 59, 824-833. 
 
111  Leiper JM, Santa Maria J, Chubb A, Macallister RJ, Charles IG, Whitley JGS, 
 Vallance P. (1999) Identification of two human dimethylarginine 
 dimethylaminohydrolases with distinct tissue distributions and homology with 
 microbial arginine deiminases. Biochem J 343, 209-214. 
 
112  Tran CTL, Fox MF, Vallance P, Leiper JM. (2000) Chromosomal localization, gene 
 structure, and expression pattern of DDAH1: comparison with DDAH2 and 
 implications for evolutionary origins. Genomics 68, 101-105. 
 
113  Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, 
 Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, 
 Welch WJ, Wilcox CS. (2007) Isoform-specific regulation by NG,NG-
 dimethylarginine dimethylaminohydrolase of rat serum asymmetric 
 dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 
 101, 627-635. 
 
114  Nijveldt RJ, Teerlink T, Siroen MPC, van Lambalgen AA, Rauwerda JA, van 
 Leeuwen PAM. (2003) The liver is an important organ in the metabolism of 
 asymmetrical dimethylarginine (ADMA). Clin Nutr 22, 17-22. 
 
115  Sakurada M, Shichiri M, Imamura M, Azuma H, Hirata Y. (2008) Nitric oxide 
 upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction 
 in endothelial cells. Hypertension 52, 903-909. 
 
116  Knipp M, Braun O, Gehrig PM, Sack R, Vašák M. (2003) Zn(II)-free 
 dimethylargininase-1 (DDAH 1) is inhibited upon specific cys-S-nitrosylation. J 
 Biol Chem 278 3410-3416. 
 
117  Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer, Breithardt G, 
 Fobker M, Reinecke. (2006) Symmetrical dimethylarginine: a new combined 
 parameter for renal function and extent of coronary artery disease. J Am Son 
 Nephrol 17, 1128-1134. 
  
118  Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. (2001) 
 Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric 
 dimethylarginine. Circulation 104, 2569-2575. 
 
  
141 
                                                                                                                                                     
119  Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. (1999) Novel 
 mechanism for endothelial dysfunction: dysregulation of dimethylarginine 
 dimethylaminohydrolase. Circulation 99, 3092-3095. 
 
120  Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. (2006) Adverse effects of 
 cigarette smoke on NO bioavailabilty: role of arginine metabolism and oxidative 
 stress. Hypertens 48, 278-285. 
 
121  Lin KY, Ito A, Asagami T, Tsao P, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, 
 Cooke JP. (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role 
 of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. 
 Circulation 106, 987-992. 
 
122  Vallance P, Leone A, Calver A, Collier J, Moncada S. (1992) Accumulation of an 
 endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 
 339, 572-575. 
 
123  Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper 
 MM, Haller H, Fliser D. (2004) Cardiovascular effects of systemic nitric oxide 
 synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109, 
 172-177. 
 
124  Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H, Haller H, 
 Fliser D. (2004) Subpressor dose asymmetric dimethylarginine modulates renal 
 function in humans through nitric oxide synthase inhibition. Kidney Blood Press 
 Res 27, 143-147. 
 
125  Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser 
 D, Hoeper MM. (2005) Asymmetrical dimethylarginine in idiopathic pulmonary 
 arterial hypertension. Arterioscler Thromb Vasc Biol 25, 1414-1418. 
 
126  Kielstein JT, Tsikas D, Fliser D. (2006) Effects of asymmetric dimethylarginine 
 (ADMA) infusion in humans. Eur J Clin Pharmacol 62, 39-44. 
 
127  Blackwell S. (2010) The biochemistry, measurement and current clinical 
 significance of asymmetric dimethylarginine. Ann Clin Biochem 47,17-28. 
 
128  Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, 
 Zweier JL. (2007) Evidence for the pathological role of endogenous 
 methylarginines in regulation of endothelial NO production and vascular function. J 
 Biol Chem 282, 879-887. 
 
129  Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, 
 Stuehlinger M, Tsao PS. (2001) Plasma concentrations of asymmetric 
 dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J 
 Cardiol 88, 1201-1203. 
 
  
142 
                                                                                                                                                     
130  Anderson JL, Carlquist JF, Roberts WL, Horne BD, May HT, Schwarz EL, Pasquali 
 M, Nielson R, Kushnir MM, Rockwood AL, Bair TL, Muhlestein JB. (2007) 
 Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for 
 diabetes and cardiovascular risk? Am Heart J 153, 67-73. 
 
131  Stühlinger MC, Fahim A, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, 
 Reaven GM, Tsao PS. (2002) Relationship between insulin resistance and an 
 endogenous nitric oxide synthase inhibitor. JAMA 287, 1420-1426. 
 
132  Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, 
 Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. (2005) 
 Asymmetric dimethylarginine and the risk of cardiovascular events and death in 
 patients with coronary artery disease. Results from the AtheroGene study. Circ Res 
 97 e53-e59. 
 
133  Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, 
 Minar E, Müller M, Wolzt M, Schillinger M. (2006) Asymmetric dimethylarginine 
 predicts major adverse events in patients with advanced peripheral artery disease. 
 Arterioscler Thromb Vasc Biol 26, 2536-2540. 
 
134  Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-
 Lucke C, Kusus M, Maas R, Schwedhelm E, Strödter D, Simon BC, Mügge A, 
 Daniel WG, Tillmanns H, Maisch B, Streichert T, Böger RH. (2006) Asymmetric 
 dimethylarginine is an independent risk factor for coronary heart disease: results 
 from the multicentre Coronary Artery Risk Determination investigating the 
 influence of ADMA Concentration (CARDIAC) study. Am Heart J 152, 493e1-
 493e8. 
 
135  Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, 
 Winkelmann BR, März W. (2007) Asymmetrical dimethylarginine independently 
 predicts total and cardiovascular mortality in individuals with angiographic 
 coronary artery disease (the Ludwigshafen risk and cardiovascular health study). 
 Clin Chem 53, 273-283. 
 
136  Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, 
 Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH. (2001) Plasma 
 concentration of asymmetrical dimethylarginine and mortality in patients with end-
 stage renal disease: a prospective study. Lancet 358, 2113-2117. 
 
137  Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. (2005) 
 Asymmetric dimethylarginine predicts progression to dialysis and death in patients 
 with chronic kidney disease: a competing risks modeling approach. J Am Soc 
 Nephrol 16, 2449-2455. 
 
138  Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E. 
 (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the 
 Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 16, 2456-2461. 
  
143 
                                                                                                                                                     
 
139  Selley ML. (2003) Increased concentrations of homocysteine and asymmetric 
 dimethylarginine and decreased concentrations of nitric oxide in the plasma of 
 patients with Alzheimer's disease. Neurobiology of Aging 24, 903-907. 
 
140  Yoo HJ, Lee SC. (2001) Elevated levels of plasma homocyst(e)ine and asymmetric 
 dimethylarginine in elderly patients with stroke. Atherosclerosis 158, 425-430. 
 
141  Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DEL. (2006) 
 Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors 
 for coronary disease. Atherosclerosis 184, 383-388. 
 
142  Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. (2003) Plasma levels of asymmetrical 
 dimethylarginine and adverse cardiovascular events after percutaneous coronary 
 intervention. Eur Heart J 24, 1912-1919. 
 
143  Martens-Lobenhoffer J, Bode-Böger SM. (2007) Chromatographic-mass 
 spectrometric methods for the quantitation of L-arginine and its methylated 
 metabolites in biological fluids. J Chrom B 851, 30-41. 
 
144  Teerlink T. 2007) HPLC analysis of ADMA and other methylated L-arginine 
 analogs in biological fluids. J Chrom B 851, 21-29. 
 
145  Horowitz JD, Heresztyn T. (2007) An overview of plasma concentrations of 
 asymmetric dimethylarginine (ADMA) in health and disease and clinical studies: 
 methodological considerations. J Chrom B 851, 42-50. 
 
146  Tsikas D. (2008) A critical review and discussion of analytical methods in the L-
 arginine/nitric oxide area of basic and clinical research. Anal Biochem 379, 139-
 163. 
 
147  Pettersson A, Uggla L, Backman V. (1997) Determination of dimethylated arginines 
 in human plasma by high-performance liquid chromatography. J Chrom B 692, 257-
 262. 
 
148  Chen BM, Xia LW, Zhao RQ. (1997) Determination of NG,NG-dimethylarginine in 
 human plasma by high-performance liquid chromatography. J Chrom B 692, 467-
 471. 
 
149  Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM. (2002) Determination of 
 arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human 
 plasma and other biological samples by high-performance liquid chromatography. 
 Anal Biochem 303, 131-137 
 
150  Zhang W, Kaye DM. (2004) Simultaneous determination of arginine and seven 
 metabolites in plasma by reversed-phase liquid chromatography with a time-
 controlled ortho-phthaldialdehyde precolumn derivatisation. Anal Biochem 326, 87-
 92. 
  
144 
                                                                                                                                                     
 
151  Blackwell S, St J O'Reilly D, Talwar DK. (2009) HPLC analysis of asymmetric 
 dimethylarginine (ADMA) and related arginine metabolites in human plasma using 
 a novel non-endogenous internal standard. Clin Chim Acta 401, 14-19. 
 
152  Marra M, Bonfigli AR, Testa R, Testa I, Gambini A, Coppa G. (2003) High-
 performance liquid chromatographic assay of asymmetric dimethylarginine, 
 symmetric dimethylarginine, and arginine in human plasma by derivatization with 
 naphthalene-2,3-dicarboxaldehyde. Anal Biochem 318, 13-17. 
  
153  Heresztyn T, Worthley MI, Horowitz JD. (2004) Determination of L-arginine and 
 NG,NG- and NG,NG'-dimethyl-L-arginine in plasma by liquid chromatography as 
 AccQ-FluorTM fluorescent derivatives. J Chrom B 805, 325-329. 
 
154  Sotgia S, Zinellu A, Pinna GA, Deiana L, Carru C. (2008) A new selective pre-
 column ninhydrin-based derivatization for a RP-HPLC determination of plasma 
 asymmetric dimethy-L-arginine (ADMA) by fluorescence detection. Amino Acids 
 34, 677-682. 
 
155  Huang LF, Guo FQ, Liang YZ, Hu QN, Cheng BM. (2003) Rapid simultaneous 
 determination of arginine and methylated arginines in human urine by high-
 performance liquid chromatography-mass spectrometry. Analytica Chimica Acta 
 487, 145-153. 
 
156  Martens-Lobenhoffer J, Krug, Bode-Böger SM. (2004) Determination of arginine 
 and asymmetric dimethylarginine (ADMA0 in human plasma by liquid 
 chromatography/mass spectrometry with the isotope dilution technique. J Mass 
 Spectrom 39, 1287-1294. 
 
157  Kirchherr H, Kühn-Velten WN (2005) HPLC-tandem mass spectrometric method 
 for rapid quantification of dimethylarginines in human plasma. Clin Chem 51, 249-
 252. 
 
158  Martens-Lobenhoffer J, Bode-Böger SM. (2006) Measurement of asymmetric 
 dimethylarginine (ADMA) in human plasma: from liquid chromatography 
 estimation to liquid chromatography-mass spectrometry quantitation. (2006) Eur J 
 Clin Pharmacol 62, 61-68. 
 
159  Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frölich JC. (2003) Quantitative 
 determination of circulating and urinary asymmetric dimethylarginine (ADMA) in 
 humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-
 pentafluoropropionyl) derivative. J Chrom B 798, 87-99. 
 
160  Albsmeier J, Schwedhelm E, Schulze F, Kastner M, Böger RH. (2004) 
 Determination of NG,NG-dimethyl-L-arginine, and endogenous NO synthase 
 inhibitor, by gas chromatography-mass spectrometry. J Chrom B 809, 59-65. 
 
  
145 
                                                                                                                                                     
161  Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. (2000) Determination of 
 arginine and methylated arginines in human plasma by liquid chromatography-
 tandem mass spectrometry. J Chrom B 748, 157-166. 
 
162  Martens-Lobenhoffer J, Bode-Böger SM. (2006) Fast and efficient determination of 
 arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in 
 biological fluids by hydrophilic-interaction liquid chromatography-electrospray 
 tandem mass spectrometry. Clin Chem 52,488-493. 
 
163  Bishop MJ, Crow B, Norton D, Paliakov E, George J, Bralley JA. (2007) Direct 
 analysis of un-derivatized asymmetric dimethylarginine (ADMA) and L-arginine 
 from plasma using mixed-mode ion-exchange liquid chromatography-tandem mass 
 spectrometry. J Chrom B 859, 164-169 
 
164  Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. (2005) 
 Liquid chromatography-tandem mass spectrometry method for the analysis of 
 asymmetric dimethylarginine in human plasma. Clin Chem 51, 1268-1271. 
 
165  Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer, Böger RH. (2007) 
 High-throughput liquid chromatographic-tandem mass spectrometric determination 
 of arginine and dimethylated arginine derivatives in human and mouse plasma. J 
 Chrom B 851, 211-219. 
 
166  Caussé E, Siri N, Arnal JF, Bayle C, Malatray P, Valdiguié P, Salvayre R, 
 Couderc F. (2000) Determination of asymmetrical dimethylarginine by capillary 
 electrophoresis-laser-induced fluorescence. J Chrom B 741, 77-83. 
 
167  Valtonen P, Karppi J, Nyyssönen K, Valkonen VP, Halonen T, Punnonen K. (2005) 
 Comparison of HPLC method and commercial ELISA assay for asymmetric 
 dimethylarginine (ADMA) determination in human serum. J Chrom B 828, 97-102. 
 
168  Široká R, Trefil L, Rajdl D, Racek J, Cibulka R. (2007) Asymmetric 
 dimethylarginine - comparison of HPLC and ELISA methods. J Chrom B 850, 586-
 587. 
 
169  Martens-Lobenhoffer J, Westphal S, Awiszus R, Bode-Böger S, Luley C. (2005) 
 Determination of asymmetric dimethylarginine: liquid chromatography-mass 
 spectrometry or ELISA? Clin Chem 51,2188-2189. 
 
170  Pundak S, Wilchek M. (1981) Synthesis of guanidino-N-alkylarginines by the use of 
 polymeric pseudoureas. J Org Chem 46, 808-809. 
 
171  Safar ME. (2004) Peripheral pulse pressure, large arteries, and microvessels. 
 Hypertension 44, 121-122. 
 
172  Bramwell JC, Hill AV. (1922) The velocity of the pulse wave in man. Proc Soc 
 Lond (Biol) 93, 298-306. 
 
  
146 
                                                                                                                                                     
173  Laurent S, Boutouyrie P, Lacolley P. (2005) Structural and genetic bases of arterial 
 stiffness. Hypertension 45, 1050-1055. 
  
174  Learoyd BM, Taylor M. (1966) Alterations with age in the viscoelastic properties of 
 human arterial walls. Circ Res 18, 278-292. 
 
175  O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. (2002) Clinical 
 applications of arterial stiffness; definitions and reference values. Am J Hypertens  
 15, 426-444. 
 
176  McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. (2005) 
 Normal vascular aging: differential effects on wave reflection and aortic pulse wave 
 velocity: the Anglo Cardiff Collaborative Triall (ACCT). J Am Coll Cardiol 
 46, 1753-1760. 
 
177  Boutouyrie P, Tropeano  AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. 
 (2002) Aortic stiffness is an independent predictor of primary coronary events in 
 hypertensive patients: a longitudinal study. Hypertension 39, 10-15. 
 
178  Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, 
 Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. 
 (2006)  Arterial stiffness and the risk of coronary heart disease and stroke: the 
 Rotterdam Study. Circulation 113, 657-663. 
 
179  Laurent S, Katsahlan S, Fassot C, Tropeano AI, Laloux B, Boutouyrie P. (2003) 
 Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. 
 Stroke 34, 1203-1206. 
 
180  Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. (2002) 
 Aortic  pulse-wave velocity and its relationship to mortality in diabetes and glucose 
 intolerance: an integrated index of vascular function? Circulation 106, 2085-
 2090. 
 
181  Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. (2003) 
 Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney 
 Int 63,  1852-1860. 
 
182  Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, 
 Cockcroft J, Kaiser DR, Thuillez C. (2002) Applications of arterial stiffness, Task 
 Force  III: recommendations for user procedures. Am J Hypertension 15, 445-452. 
 
183  Laurent S, Cockcroft J, van Bortel J, Boutouyrie P, Giannattasio C, Hayoz D, 
 Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H on behalf of the 
 European Network for non-invasive investigation of large arteries. (2006) Expert 
 consensus document on arterial stiffness: methodological issues and clinical 
 applications. Eur Heart J 27, 2588-2605. 
 
  
147 
                                                                                                                                                     
184  Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent S. (2006) Carotid 
 and aortic stiffness: determinants of discrepancies. Hypertension 47, 371-376. 
 
185  London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. (2001) 
 Arterial wave reflections and survival in end-stage renal failure. Hypertension 38, 
 434-438. 
 
186  Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Lamm G, Stark N, Rammer M, 
 Eber B. (2005) Increased arterial wave reflections predict severe cardiovascular 
 events in patients undergoing percutaneous coronary interventions. Eur Heart J 26, 
 2657-2663. 
 
187  Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J. 
 (1999)  Plasma homocysteine, aortic stiffness, and renal function in hypertensive 
 patients. Hypertension 34 (part 2), 837-842. 
 
188  Woodside JV, McMahon R, Gallagher AM, Cran GW, Boreham CA, Murray LJ, 
 Strain JJ, McNulty H, Robson PJ, Brown KS, Whitehead AS, Savage M, Young IS. 
 (2004) Total homocysteine is not a determinant of arterial pulse wave velocity in 
 young healthy adults. Atherosclerosis 177, 337-344. 
 
189  Tso TK, Huang HY, Chang CK, Huang WN. (2006) A positive correlation between 
 homocysteine and brachial-ankle pulse wave velocity in patients with systemic 
 lupus erythematosus. Clin Rheumatol 25, 285-290. 
 
190  Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H, Larson MG, 
 Wang TJ, Selhub J, Jacques PF, Vita JA, Keyes MJ, Mitchell GF. (2007) 
 Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine 
 levels with alterations in arterial stiffness. The Framingham Heart Study. 
 Circulation 115, 3079-3085. 
 
191  Ertek S, Torun AN, Ates K. (2009) The factors that affect plasma homocysteine 
 levels,  pulse wave velocity and their relationship with cardiovascular disease 
 indicators in peritoneal dialysis patients. Int Urol Nephrol DOI 10.1007/s11255-
 009-9625-y 
 
192  Vyssoulis G, Karpanou E, Kyvelou S-M, Adamopoulos D, Gialernios T, 
 Gymnopouloy E, Cokkinos D, Stefanadis C. (2010) Associations between plasma 
 homocysteine levels, aortic stiffness and wave reflection in patients with arterial 
 hypertension, isolated office hypertension and normotensive controls. Journal of 
 Human Hypertension 24, 183-189. 
 
193  Sherwood RA, Titheradge AC, Richards DA. (1990) Measurement of plasma and 
 urine amino acids by high-performance liquid chromatography with electrochemical 
 detection using phenylisothiocyanate derivatization. J Chromatogr 528, 293-303 
 
  
148 
                                                                                                                                                     
194  Kakimoto Y, Akazawa, S. (1970) Isolation and identification of NG,NG- and NG,N'G-
 dimethylarginine, Nε-mono,di-, and trimethyllysine, and glucosylgalactosyl- and 
 galactosyl-δ-hydroxylysine from human urine. J Biol Chem 245, 5751-5758. 
 
195  Corbin JL, Reporter M. (1974) NG-methylated arginines; a convenient preparation 
 of NG-methylarginine. Anal Biochem 57, 310-312. 
 
196  Li, S, Jia J, Liu G, Wang W, Cai Y, Wang Y, Yu C. (2008) Improved and simplified 
 LC-ESI-MS/MS method for homocysteine determination in human plasma: 
 application to the study of cardiovascular diseases. J Chrom B 870, 63-67. 
 
197  Weaving G, Rocks BF, Iversen SA, Titheradge MA. (2006) Simultaneous 
 quantitation of homocysteine, cysteine and methionine in plasma and urine by 
 liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 43, 474-480. 
 
198  Mengerink, Y, Kutlán D, Tóth F, Csámpai A, Molnár-Perl I, (2002) Advances in the 
 evaluation of the stability and characteristics of the amino acid and amine 
 derivatives obtained with the o-phthaldialdehyde/3-mercaptopropionic acid and o-
 phthaldialdehyde/N-acetyl-L-cysteine reagents: high-performance liquid 
 chromatography-mass spectrometry study. J Chrom A 949, 99-124. 
 
199  Junk G, Svec H. (1963) The mass spectra of the a-amino acids. J Am Chem Soc 85, 
 839-845. 
 
200  Letellier S, Garnier JP, Spy J, Bousquet B. (1997) Determination of the L-DOPA/L-
 tyrosine ratio in human plasma by high-performance liquid chromatography: 
 usefulness as a marker in metastatic malignant melanoma. J Chrom B 696, 9-17. 
 
201  The Merck Index, 12th Edition, 1996, Merck & Co., Inc Whitehouse Station , NJ 
 
202  Williams JA, Phang JM (1982) Production of ornithine by intact human 
 erythrocytes, Am J Physiol, Cell Physiol 242, C393-C397. 
 
203  Lücke T, Kanzelmeyer N, Kemper MJ, Tsikas D, Das AM. (2007) Developmental 
 changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma 
 asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 45, 
 1525-1530. 
 
204  Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. (2005) 
 Determination of a reference value for NG,NG-dimethyl-L-arginine in 500 subjects. 
 Eur J Clin Invest 35, 622-626. onlinelibrary.wiley.com/doi/10.1111/j.1365-
 2362.2005.01561.x 
 
205  Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, 
 Hoeper MM, Haller H, Fliser D. (2004) Cardiovascular effects of systemic nitric 
 oxide synthase inhibition with asymmetrical dimethylarginine in humans. 
 Circulation 109, 172-177. 
  
149 
                                                                                                                                                     
 
206  Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H, Haller H, 
 Fliser D. (2004) Subpressor dose asymmetric dimethylarginine modulates renal 
 function in humans through nitric oxide synthase inhibition. Kidney Blood Press 
 Res 27, 143-147. 
 
207  Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. (2000) Study 
 on the relationship between plasma nitrite and nitrate level and salt sensitivity in 
 human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 
 101, 856-861. 
 
208  Fang Y, Mu JJ, He, LC, Wang SC, Liu ZQ. (2006) Salt loading on plasma 
 asymmetrical dimethylarginine and the protective role of potassium supplement in 
 normotensive salt-sensitive asians. Hypertension 48, 724-729. 
 
209  Kooman JP, van der Sande FM, Leunissen ML. (2004) Sodium, blood presure and 
 cardiovascular pathology: is it all volaemia? Nephrol Dial Transplant 19, 1046-
 1049. 
  
210  Hemenegildo C, Medina P, Segarra, Vila J, Ortega J, Lluch. (2002) Plasma 
 concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric 
 oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metb 87, 
 5636-5640. 
 
211  Arikan E, Karadag CH, Guldiken S. (2007) Asymmetric dimethylarginine levels in 
 thyroid disease. J Endocrinol Invest 30, 186-191. 
 
212  Amur SG, Shanker G, Pieringer RA. (1984) Regulation of myelin basic protein 
 (arginine) methyltransferase by thyroid hormone in myelogenic cultures of cells 
 dissociated from embryonic mouse brain. J Neurochem 494-498. 
 
213  Lamb E, Newman J, Price CP. Kidney Function Tests. In Tietz Textbook of Clinical 
 Chemistry and Molecular Diagnostics 4th edition (Burtis CA, Ashwood ER, 
 Bruns DE, ed) pp 797-835, Elsevier Saunders, USA. 
 
214 Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, 
 Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave 
 velocity measurement. Validation and clinical application. Hypertension. 26, 485-
 490 
 
215  Newman DJ. (2002) Cystatin C. Ann Clin Biochem 39, 89-104. 
 
216  Walker HA, McGing E, Fisjer I, Bode-Böger SM, Jackson G, Ritter JM, 
 Chowienczyk. (2001) Endothelium-dependent vasodilation is independent of the 
 plasma L-arginine/ADMA ratio in men with stable angins: lack of effect of oral L-
 arginine on endothelial function, oxidative stress and exercise performance. J Am 
 Coll Cardiol 38, 499-505. 
